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Due to the high attrition rates in drug development and lengthy and resource 
intensive animal pharmacology studies, there is a need for expedited cost-
effective selection of the leading drug candidates to progress into 
development. This objective could be accomplished by establishing in silico – 
in vitro – in vivo correlations (ISIVIVC) and pharmacokinetic-
pharmacodynamic (PK-PD) relationships for the drug candidates as early as 
possible during the discovery phase.  
The ISIVIVC have been extensively studied and empirical rules 
established for a diverse set of compounds from different therapeutic areas. 
Further, PK-PD relationships have been established for several classes of 
therapeutic compounds, particularly for the anti-infective agents. However, the 
corresponding ISIVIVC analysis is lacking for anti-mycobacterial compounds 
and PK-PD relationship analysis is limited to individual anti-mycobacterial 
and anti-malarial drugs. Hence, to fill up the information gap in these areas, 
ISIVIVC for the standard anti-mycobacterial compounds was investigated in 
this thesis; further, the PK-PD relationships for the compound classes of 
nitroimidazoles and spiroindolones, respectively from tuberculosis and malaria 
programs, were examined. 
The objectives of the research work presented in this thesis can be 
broadly divided into two categories: tuberculosis (under Part 1 and 2) and 
malaria (under Part 3). In Part 1, the ISIVIVC of anti-mycobacterials are 
described. Tuberculosis (TB) drug discovery and development have met 
limited success with only two new drugs approved over the last 40 years. The 
problem is partly due to the lack of well-established relationship between in 
ix 
 
vitro physicochemical properties and pharmacokinetic parameters of anti-
tuberculosis (anti-TB) drugs. In an attempt to benchmark and compare such 
physicochemical properties for anti-TB agents, these parameters derived from 
standard assays were compiled for 36 anti-TB compounds, thus ensuring 
direct comparability across drugs and drug classes. Correlations between the 
in vitro physicochemical properties and the in vivo pharmacokinetic 
parameters were then evaluated. Such correlations will be useful for guiding 
the drug development of future drugs. In our study, it was found that most of 
the current anti-TB drugs exhibited favorable solubility, permeability and 
metabolic stability. Analysis of human PK parameters revealed associations 
between lipophilicity and volume of distribution, clearance, plasma protein 
binding and oral bioavailability. Not surprisingly, most compounds with 
favorable pharmacokinetic properties complied with various empirical rules. 
This work will provide a reference dataset for the TB drug discovery 
community with a focus on comparative in vitro properties and 
pharmacokinetics. 
The second part of this thesis describes the PK-PD relationship for 
nitroimidazoles. PA-824 is a bicyclic 4-nitroimidazole, currently in phase II 
clinical trials for the treatment of tuberculosis. Dose fractionation PK-PD 
studies in mice indicated that the driver of PA-824 in vivo efficacy is the time 
during which the free plasma drug concentrations are above the MIC (fT>MIC).  
In this study, a panel of closely related potent bicyclic 4-nitroimidazoles was 
profiled in both in vivo PK and efficacy studies. A retrospective analysis was 
performed for a set of seven nitroimidazole analogs to identify the PK 
parameters that correlate with the in vivo efficacy. It was found that the in vivo 
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efficacy of bicyclic 4-nitroimidazoles correlated better with the lung PK than 
with the plasma PK. Further, moderate-to-high volumes of distribution and 
lung to plasma ratios of > 2 related to good efficacy. Among all the PK-PD 
indices, total lung T>MIC correlated the best with the in vivo efficacy (rs = 0.88) 
followed by lung Cmax/MIC and AUC/MIC. Thus, lung drug distribution 
studies could potentially be exploited to guide the selection of new 
nitroimidazole analogs for efficacy studies. 
Limited information is available on PK-PD parameters driving the 
efficacy of antimalarial class of compounds. The third part of this thesis 
describes the PK-PD relationship for compounds belonging to the class of 
spiroindolones analogs. The objective in this study was to determine dose-
response relationships for a panel of related spiroindolone analogs and further 
identify the PK-PD index that correlates best with the efficacy of KAE609 
using a dose fractionation approach. All spiroindolone analogs studied 
displayed a maximum reduction in parasitemia, with 90% effective dose 
(ED90) values ranging between 6 and 38 mg/kg of body weight. KAE609 was 
identified as the most potent analog. Further, the dose fractionation study 
revealed that the percentage of the time in which KAE609 plasma 
concentrations remained above 2*IC99 (TRE) within 48 h (%T>TRE) and the 
AUC0-48/TRE correlated well with parasite reduction (R
2
=0.97 and 0.95, 
respectively), but less so for the Cmax/TRE (R
2
=0.88). For KAE609, (and 
supposedly for its analogs) the dosing regimens covering T>TRE of 100%, 
AUC0-48/TRE of 587 and a Cmax/TRE of 30 result in maximum reduction in 
parasitemia in the P. berghei malaria mouse model. 
xi 
 
The outcome of this work could serve as guidance to prioritize new 
drug candidates against tuberculosis and malaria, thereby facilitating the lead 
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Chapter 1. Introduction 
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1.1 Infectious diseases 
Infectious diseases are caused by pathogenic microorganisms, such as 
bacteria, viruses, parasites or fungi; the diseases can spread directly or 
indirectly from one person to another. Three major infectious diseases namely 
acquired immune deficiency syndrome (AIDS), tuberculosis (TB) and malaria 
are related to increased number of deaths every year. Hence there is an urgent 
need to develop effective medicines to treat successfully such diseases (WHO, 
2014a). 
The Novartis Institute for Tropical Diseases (NITD) is dedicated to the 
discovery and development of new drugs to treat neglected infectious diseases 
and efforts are ongoing in the fields of Dengue fever, Human African 
Trypanosomiasis, Malaria and Tuberculosis (NITD, 2014). The research work 
presented in this thesis is focused on two infectious diseases namely, 
tuberculosis (Part 1 - In silico – in vitro – in vivo correlations for standard anti-
TB drugs and Part 2 - Pharmacokinetic-Pharmacodynamic relationships for 
nitroimidazoles) and malaria (Part 3 - Pharmacokinetic-Pharmacodynamic 
relationships for spiroindolones).  
 
1.2 Tuberculosis 
TB is a contagious disease affecting about one third of the world population. It 
is caused by the bacteria, mycobacterium tuberculosis (Mtb) and is spread 
through the air by coughing, sneezing, or even talking. Due to its unique lipid 
cell wall, the bacillus can remain in dormant state for many years. Some 
people with the latent form of infection will never develop active TB, 
however, 5 to 10 percent of carriers may develop active TB and will become 
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sick in their lifetime (Dye and Williams, 2010). Every year nearly 8 million 
new cases of TB are reported globally resulting in 1.4 million deaths. In 2012, 
around 8.6 million people developed TB, [including ~450,000 multi drug 
resistant (MDR) TB cases] resulting in 1.3 million deaths (WHO, 2012a). 
Approximately 80% of reported TB cases are from 22 different countries with 
the largest number of new TB cases occurring in Asia and the greatest 
proportion of new cases per population are from sub-Saharan Africa (Figure 
1). 
Common symptoms of active lung TB are cough with sputum and 
blood at times, chest pains, weakness, weight loss, fever and night sweats. 
Treatment for active, drug-sensitive TB consists of 4 medicines known as 
first-line drugs and is administered for a period of 6 months [a combination of 
4 drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) for 2 months, 
followed by rifampicin and isoniazid for 4 months]. The long duration and 
complex regimen is burdensome for patients. World Health Organization 
(WHO) recommended Directly Observed Therapy Short Course (DOTS), 
aiding TB patients to take medicines under direct observation by healthcare 
worker. Poor treatment compliance as well as the use of inadequate regimens 
has led to the emergence of multi-drug-resistant and extensively-drug-resistant 
(MDR-TB and XDR-TB) TB strains. Today, treatment for drug-resistant TB 
relies on the second-line drugs [aminoglycosides (kanamycin and amikacin), 
cycloserine, ethionamide, protionamide, capreomycin, aminosalicylic acid, 
and fluoroquinolones (including ofloxacin, levofloxacin, gatifloxacin and 
moxifloxacin)], and is commonly administered for 2 years or longer including 
daily injections for six months. This treatment is complex, expensive, and 
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often causes severe side effects. MDR-TB is resistant to at least isoniazid and 
rifampicin, and XDR-TB is resistant to isoniazid, rifampicin, fluoroquinolones 
and at least one of the three injectable second-line drugs (capreomycin, 
kanamycin and amikacin) (WHO, 2012b). Currently, drug-resistant TB is 
quite common in India and China — the two countries with the highest MDR-
TB burdens. 
One-third of the more than 33 million people living with AIDS are also 
infected with tuberculosis. TB is a serious threat for people with human 
immuno deficiency virus (HIV), especially in sub-Saharan Africa, where it 
causes up to half of all AIDS deaths. TB-HIV co-infections are also on the rise 
in other areas of the world, particularly Western Asia, including China, and 
Eastern Europe. TB control programs are further complicated in settings 
where the incidence of co-infection with HIV is high, because drug-drug 
interactions with anti-retroviral therapy are difficult to avoid (Balganesh et al., 
2008; WHO, 2012b). To make the landscape even more complex, there are 
recent reports of totally drug resistant TB cases (Udwadia et al., 2012). 
Needless to say, there is an urgent need to discover new TB drugs active 
against all drug-resistant forms of TB and compatible with treatment against 




Figure 1. Estimated TB incidence rates during 2012. Data Source from WHO 
(2013) 
 
1.2.1 Discovery of anti-mycobacterial drugs 
In 1946 streptomycin was discovered to be active against Mtb and since then it 
has been extensively used as monotherapy, as a consequence, arising 
undesired resistance to the treatment. The need for multidrug therapy of TB to 
prevent the rapid development of drug resistance was then widely recognized. 
Later on, para aminosalicylic acid (PAS) and isoniazid were found to be active 
against TB. The first combination regimen was given in 1952 and consisted of 
streptomycin, aminosalicylic acid and isoniazid for a period of 24 months. 
Several other drugs were discovered to be active against Mtb (e.g. 
pyrazinamide, cycloserine, kanamycin, ethionamide and ethambutol) in the 
following years. During 1960’s, streptomycin, isoniazid and ethambutol were 
given for a period of 18 months (Figure 2).  
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The discovery of rifampicin in 1963 and its addition to the 
combination therapy during 1970’s led to a significant reduction of the 
treatment duration from 18 months to 9-12 months. In 1980’s streptomycin 
was replaced with pyrazinamide and the new four drug combination (i.e. 
pyrazinamide, rifampicin, isoniazid and ethambutol) led to further reduction of 
the treatment to 6-8 months. Since then this combination has been used to treat 
TB (Ma et al., 2010). Although rifampicin is a cornerstone of the current TB 
regimen, it induces the enzyme cytochrome P450. These enzymes cause some 
antiretroviral drugs to be metabolized rapidly, inhibiting effective anti-retro 
viral therapy. Hence, drug-drug interactions are a major concern with 
combination of drug treatment for therapeutic area like anti-HIV or other 
chronic disease medications such as those used in diabetics (Koul et al., 2011). 
All four 1
st
-line anti-TB agents in use today were launched in the 50’s 
and 60’s before the era of pharmacokinetics (PK) and pharmacodynamics 
(PD). In the case of rifampicin, financial considerations came before clinical 
pharmacology evaluation to support dose selection (van et al., 2011). Since 
there is a rapid emergence of resistance against standard TB drug regimen, 





Figure 2. History of drug discovery and development of treatment regimens 
for TB.  Reprinted from Ma et al. (2010), with permission from Elsevier.  
 
1.2.2 Ideal drug candidates 
An ideal drug combination should consist of at least three drugs that are active 
against drug susceptible and drug resistant (MDR and XDR) tuberculosis and 
produce stable cure in a shorter period compared to the standard treatment. 
Such combination(s) should have potent, synergistic, and complementary 
activities against various subpopulations of Mtb (Dartois and Barry, 2010). In 
addition, it should also be suitable to treat patients co-infected with Mtb and 
HIV; which could be achieved by replacing rifampicin (drug interactions with 
anti-retroviral drugs) in the combination therapy (Ma et al., 2010).  
1.2.3 Drug development pipeline 
There are several new classes of compounds in various phases of drug 
discovery, preclinical and clinical development (Figure 3) (Ginsberg, 2010; 
Lienhardt et al., 2012). Among others, the following candidates are presently 
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being evaluated as potential TB drugs: rifapentine (a semisynthetic rifamycin) 
having longer half-life than rifampicin; SQ-109, a highly modified derivative 
of ethambutol; oxazolidinones (linezolid, PNU-100480 and AZD5847); 
fluoroquinolones (ofloxacin, gatifloxacin and moxifloxacin); nitroimidazoles 
(PA-824 and OPC-67683) and TMC207. Interestingly, OPC-67683 
(delamanid) and TMC207 (bedaquiline) demonstrated activity against drug-
resistant strains of Mtb in patients (Cox and Laessig, 2014; Diacon et al., 
2014; Gler et al., 2012). The mechanisms of action of the current drug 
candidates are summarized in Figure 4. Drugs with novel mechanisms of 
action are needed to create new combination regimens active against all drug-
resistant strains of TB and compatible with HIV treatment.  
 
Figure 3. Global tuberculosis drug pipeline. With permission  of Oxford 
University Press Lienhardt et al. (2012).  
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Figure 4. Mechanism of action of new compounds in clinical development for 
tuberculosis.  Reprinted from Ma et al. (2010), with permission from Elsevier. 
 
1.2.4 Combination therapy 
Few phase III clinical trials were initiated to evaluate the possibility of 
shortening TB treatment by replacing one of the standard TB drugs (either 
isoniazid or ethambutol) by fluoroquinolones (either moxifloxacin or 
gatifloxacin). Surprisingly, recent reports demonstrated that none of the 
regimens was able to reduce TB treatment from 6 months to 4 months (Warner 
and Mizrahi, 2014).  Although these new regimens displayed more rapid 
initial decline in bacterial load as compared to the control group, none of them 
showed superior activity compared to the standard regimen (Gillespie et al., 
2014; Jindani et al., 2014; Merle et al., 2014). In addition, clinical trials with 
different combinations of moxifloxacin (fluoroquinolone), PA-824 
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(nitroimidazole), TMC-207 (bedaquiline) and other drugs (clofazimine) have 
been reported to be ongoing (TB Alliance, 2014) (Table 1).  
Table 1. Tuberculosis clinical development pipeline. Data Source from TB 
Alliance  (2014) 
 
Phase 1 Phase 2 Phase 3 Phase 4 
PK of first-line 




line drugs in 






























1.2.5 Challenges in TB drug discovery programs  
Mtb is a slow growing pathogen that multiplies once in 22- 24 h and has a 
unique thick lipid cell wall which is a waxy coating primarily composed of 
mycolic acids. The in vitro potency of test compounds is determined in broth 
where their minimum inhibitory concentration (MIC) to the growth of Mtb is 
measured. MIC is determined in an extracellular environment, but Mtb resides 
inside the macrophages; hence an intracellular macrophage MIC (ex vivo) 
measurement is performed. In this case, compounds have to penetrate the cells 
to reach the bacterium and then exert their activity. The assay requires 
approximately 4 to 5 weeks and the final read out is the number of colony 
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forming units (CFU). The cell line of choice for this assay [such as human 
acute monocytic leukemia cell line (THP1) or bone marrow-derived 
macrophage (BMDM), activated or resting macrophages] is rather 
controversial and the sensitivity is generally not very good. Due to slow turn-
around time, lack of sensitivity and controversy about the usage of different 
cells lines, this is considered a profiling assay and is run preferentially during 
the late drug discovery phase (Franzblau et al., 2012). In reality (in vivo 
situation), the site of infection is in the lungs and Mtb resides inside the 
macrophages. The compounds, dosed orally, need to overcome absorption and 
metabolism hurdles to reach systemic circulation and distribute into lungs to 
be available at the site of infection. In TB patients, the lungs also present 
granulomas, calcified granulomas, necrotic lesions, caseous lesions and this 
complexity has triggered a lot of discussion on which is the best representative 
animal model to mimic the human disease (Dartois and Barry, III, 2013).   
The use of mice as animal model in drug discovery is widespread. 
They are relatively small, cost effective and well characterized as 
pharmacological models for screening purpose. They have been used as tool to 
assess the bactericidal and sterilizing potencies of individual drugs and drug 
combinations (Andries et al., 2010). Hall marks of pulmonary TB in humans 
are granulomas, caseous necrosis and/or cavitation and hypoxia (Barry, III et 
al., 2009; Rhoades et al., 1997) which are not reproduced in mice. Moreover, 
during the chronic phase of the disease, unlike humans, the lungs and spleen 
of mice contain high numbers of persisting bacteria (Boshoff and Barry, III, 
2005). Alternative animals such as guinea pigs, rabbits (Kjellsson et al., 2012; 
Prideaux et al., 2011) and even cynomolgus monkeys have been used as 
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preclinical models as they mimic the pathogenesis of TB better than mice with 
features such as hypoxic lesions and solid necrotic granulomas (Via et al., 
2008). Non-human primate models of TB that recapitulate the human disease 
are ideal for identifying the clinically relevant PK-PD predictors of 
sterilization efficacy of anti-TB agents. However, these models are very 
expensive and their accessibility limited due to ethical issues making them not 
suitable for screening purposes in the early stages of drug discovery. 
In spite of the already mentioned limitations, most of the standard TB 
drugs have shown to be efficacious in the murine TB models, suggesting a 
certain translational relevance to the human situation. For this reason, the anti-
TB activity of new drug candidates is generally tested in mice. There are two 
types of TB model in mouse: (a) acute and (b) established model. In the acute 
model the drug treatment starts one week post infection, which corresponds to 
rapidly growing Mtb (Pethe et al., 2010). In the chronic model the treatment 
starts 3-4 weeks post infection, when Mtb growth has reached a plateau (Rao 
et al., 2013). TB in vivo pharmacological studies are lengthy and resource 
intensive. Depending on the model, it takes 8 to 12 weeks to get one efficacy 
read out and high containment facilities are required to perform these 
experiments. In light of these, fast and simple assays, instead of the lengthy 
and resource intensive animal pharmacology studies would be much desirable 








Malaria is the most prevalent infectious disease worldwide affecting about 3.3 
billion people - half of the world’s population is at risk of the infection 
(Greenwood and Mutabingwa, 2002). It is caused by parasites of the 
Plasmodium species. The disease is transmitted to people by the bite of an 
infected Anopheles mosquito. About 250 million people are infected each year 
resulting in approximately 1 million deaths annually. In 2012, there were 
approximately 207 million malaria cases and estimated 627 000 deaths 
(Murray et al., 2012; WHO, 2012c). It is common in parts of Africa, Asia and 
Latin America (Figure 5). Most deaths occur among children living in sub-
Saharan Africa where a child dies every minute from malaria (WHO, 2014b). 
There are five parasite species that cause malaria in humans. 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium 
malariae and Plasmodium knowlesi. P. falciparum, most prevalent in sub-
Saharan Africa, is responsible for the majority of malaria deaths globally. P. 
vivax is the second most significant species prevalent in Southeast Asia and 
Latin America. P. vivax and P. ovale cause additional complication of dormant 
liver stage that can reactivate anytime leading to clinical symptoms. P. ovale 
and P. malariae represents only a small percentage of infections. The fifth 
species P. knowlesi generally infects primates but has also led to human 




Figure 5. Estimated malaria incidence rates during 2000 – 2012. Data Source 
from WHO (2014b) 
 
1.3.1 Discovery of antimalarial drugs  
The standard antimalarial drugs are summarized in Table 2. They are 
classified by chemical class such as arylaminoalcohol, 4-aminoquinolines, 8-
amionquinolines, sesquiterpene lactone (artemisinin), biguanides, 
diaminopyrimidines, sulfonamides, hydroxynaphthoquinone, and antibiotics. 
Quinine and quinidine are the first antimalarials extracted from cinchona 
alkaloids during the seventeenth century. Various other compounds active 
against Plasmodia were discovered later in the twentieth century. Artemisinin, 
isolated from the leaves of Artemisia annua by Chinese scientists in 1972, is 
one of the most important antimalarial principle (Warrell et al., 1993). The 
treatment for uncomplicated malaria requires 3 days of dosing. 
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Primaquine, is the only registered drug for the treatment of 
hypnozoites, a dormant form of the parasites (P. vivax and P. ovale) residing 
in the liver (latency) and responsible for recurring clinical symptoms (relapse). 
The drug needs to be dosed daily for 14 days and it is associated with gastro-
intestinal side effects, risk of haemolytic anaemia for patients with low activity 
of glucose-6-phosphate dehydrogenase (G6PD) and is not safe in pregnant 
women. Tefenoquine, another 8-aminoquinoline derivative with better in vitro 
activity and wider therapeutic index compared to primaquine, is currently 
being evaluated for the treatment of P. vivax malaria (Burrows et al., 2014; 
Held et al., 2013). 
It is noteworthy that emergence of resistance to traditional 
antimalarials has been reported within a few years of their introduction 
(Talisuna et al., 2004). This is mostly related to the extensive use of single 
drug based treatments. Additional contribution to drug resistance might be the 
sub-optimal doses administered to children or pregnant women (Barnes et al., 
2008; Na-Bangchang and Karbwang, 2009; White et al., 2009). Widespread 
resistance against common antimalarials is responsible for the recent increase 
in malaria-related mortality (White, 2004). In order to reduce the risk of 
selecting drug resistance, WHO’s recommendation is to combine artemisinin 
with other antimalarials. Currently the treatment of choice for uncomplicated 
falciparum malaria is a combination of two or more antimalarial drugs with 
different mechanism of action.  
Table 2 and Figure 6 summarize the mode of action of antimalarial 
drugs together with the emergence of the corresponding drug resistance. Many 
of the antimalarials prevent haeme detoxification within the digestive vacuole. 
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Cell lysis and autodigestion are triggered by blocking the polymerization of 
the toxic byproduct of the haemoglobin degradation, the haem, into insoluble 
and non-toxic pigment granules (Olliaro and Yuthavong, 1999). Genetic 
changes in transporters chloroquine resistance transporter (PfCRT) and 
multidrug resistance protein-1 (PfMDR1) have led to the resistance of 
chloroquine and mefloquine. Likewise mutations in dihydropteroate 
synthetase (PfDHPS), dihydrofolate reductase (PfDHFR), and cytochrome bc1 
complex (PfCYTB) have steered resistance to sulfadoxine (SDX), 
pyrimethamine (PYR) and atovaquone (ATO), respectively (Ding et al., 
2012). Ideally new drug candidates should display different mechanisms of 
action to be considered as treatment against drug-resistant strains of malarial 
parasites.  
The advantages of combination therapy should be balanced against the 
increased chance of drug interactions. Cytochrome P450’s are frequently 
involved in the metabolism of antimalarial agents (Navaratnam et al., 2000) 
and due attention should be given when combinations are used (Giao and de 
Vries, 2001). Moreover, some artemisinin derivatives autoinduce their first-




Table 2. Antimalarial drugs and their mode of action. Data Source from Warrell et al. (1993); Wongsrichanalai et al. (2002) 
 








Interferes with parasite haem 
detoxification with in the 
digestive vacuole 
1632 1910 278 
Quinidine    
Mefloquine 1977 1982 5 
Halofantrine    
Benflumetol (Lumefantrine)    
4-aminoquinolines 
Chloroquine 1945 1957 12 
Amodiaquine    
Pyronaridine    
8-aminoquinolines 
Primaquine Competitive inhibition of 
dihydro-orotate dehydrogenase 
involved in pyrimidine synthesis 
   





Breakdown of peroxide bridge 
generates free radicals that 
undergo alkylating reaction. 
Inhibit calcium adenosine 
triphosphatase, PfATPase 
1972 2008-2013 ~36 
Dihyroartemisinin    
Artetmether    
Arteether    
Artesunate    
Biguanides 
Proguanil Inhibits dihydrofolate reductase 
(block the synthesis of nucleic 
acids) (PfDHFR) 
1948 1949 1 
Chlorproguanil    
Diaminopyrimidines Pyrimethamine    
 Trimethoprim     
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Competitive inhibitors of 
dihydropteroate synthase 
(PfDHPS) 




 1967 1967 0 
Hydroxynaphthoquinone Atovaquone 
Interferes with cytochrome 
electron transport (PfCYTB) 
causing inhibition of nucleic acid 
and adenosine triphosphate 
synthesis 
1996 1996 0 
Lincosamide antibiotic Clindamycin 
Inhibits early stages of protein 
synthesis similar to macrolides 
   
Antibiotics Tetracyclines Inhibitors of aminoacyl-tRNA 
binding during protein synthesis 
   
Tetracycline derivative Doxycycline    
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1.3.2 Ideal drug candidates 
The ideal treatment for uncomplicated malaria should be highly efficacious 
(possibly as single oral dose to avoid compliance issues) and well tolerated 
with a very good safety profile. The requirements for drugs against severe 
malaria are slightly different, as parenteral administration is preferred to 
achieve rapid parasite clearance. If the goal is a malarial causal prophylactic 
agent, the drug should be active against the liver stage of the parasites (Wells 
et al., 2009) and be exquisitely safe. Furthermore, the new selected candidate 
should be reasonably cheap to produce and effective against drug resistant 
strains. Combination of two or more agents is a common and successful 
strategy in the field of antimalarial therapy. The combination partners should 
have synergistic action to minimize drug-related adverse effects and further 
reduce the risk of selecting resistant mutants of the parasites (Held et al., 
2013).  
 
1.3.3 Drug development pipeline 
There are several new classes of compounds in various phases of preclinical 
and clinical development (Figure 7). Different approaches have been pursued 
to identify new drug candidates. Ferroquine (SR97193), a chloroquine 
derivative acting against chloroquine-resistant parasites in vitro and arterolane 
(OZ277), an endoperoxide, designed based on the active pharmacophore of 
artemisinins are two examples of traditional drug discovery (Held et al., 2013). 
OZ439, a second generation endoperoxide known to have improved PK, has 
demonstrated clinical efficacy in humans and is currently being tested in 
combination efficacy studies (Charman et al., 2011; Moehrle et al., 2013). 
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Figure 6. Known genetic determinants of naturally occurring resistant 
mechanisms; mutations (red dot). Ding et al. (2012), with permission of 
Biomed Central Ltd. 
 
Rational drug design has successfully led to DSM265 and P218 that are 
currently evaluated in preclinical and clinical phase (Baldwin et al., 2005; 
Coteron et al., 2011; Yuthavong et al., 2012). 
Finally, phenotypic high throughput screening successfully identified 
two clinical candidates (KAE609 and KAF156) (Smith et al., 2014). KAE609 
(formerly called NITD609) represents a new chemotype. It belongs to the 
spiroindolone class and is not only active against blood stage but also against 
liver and transmission stages (Rottmann et al., 2010; Yeung et al., 2010). The 
compound inhibits the P-type sodium transporter ATPase 4 (PfATP4) 
resulting in an increased (toxic) sodium concentration in the parasite (Spillman 
et al., 2013). This compound has demonstrated safety and clinical efficacy in 
phase I and II trials (Leong et al., 2014a; White et al., 2014). The second 
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compound KAF156 from the imidazolopiperazine class showed good in vitro 
activity against all stages of parasites including liver and transmission stages. 
It is currently undergoing phase II clinical trials (Kuhen et al., 2014; Leong et 
al., 2014b; Nagle et al., 2012). This class of compounds acts via a novel 
mechanism, involving a previously unannotated gene now called P. 
falciparum cyclic amine resistance locus (Pfcarl) (Meister et al., 2011). 
 
1.3.4 Combination therapy 
The following are the artemisinin-based combination therapies (ACTs) 
recommended for the treatment of uncomplicated falciparum malaria: 
artemether plus lumefantrine, artesunate plus amodiaquine or mefloquine or 
sulfadoxine-pyrimethamine, dihydroartemisinin plus piperaquine. These 
combinations must be given for at least three days for an optimum effect. 
ACTs are currently the most effective treatment for malaria, with a 95% cure 
rate against falciparum malaria (German and Aweeka, 2008). There are reports 
of artemisinin resistance at the Cambodia–Thai border and recently ACTs 
exhibited delayed parasite clearance in patients emphasizing the need for new 
medicines with novel mechanisms of action (Dondorp et al., 2009; Ferreira et 
al., 2013; Miotto et al., 2013; Noedl et al., 2008). Second-line treatments 
(alternative ACT) against resistant malaria are also available and consist of, 
for example, artesunate plus tetracycline or doxycycline or clindamycin, 
quinine plus tetracycline or doxycycline or clindamycin. These combinations 





Figure 7. Global antimalarial drug pipeline. Data Source from MMV (2014) 
 
1.3.5 Challenges in Malaria drug discovery programs  
Plasmodium species has a complex lifecycle (Figure 8). Infected female 
Anopheles mosquitos transmit the parasites to humans. The mosquitos inject 
sporozoites into the bloodstream of the human host. These sporozoites reach to 
the liver and rapidly invade the liver cells. In all species of Plasmodium, 
sporozoites develop into schizonts, which in turn mature to form several 
thousand merozoites. In P. vivax and P. ovale, but not in P. falciparum, a 
proportion of the liver-stage parasites (known as hypnozoites) remain dormant 
in the hepatocytes. This stage of the parasite can remain dormant for months 
or several years and eventually can lead to relapsing malaria. When the liver 
cells rupture, the merozoites are released into the bloodstream where they 
rapidly invade the red blood cells. These blood-stage parasites replicate 
asexually - through ring, trophozoite and schizont - rapidly attaining a high 
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parasite burden and destroying the infected red blood cells, leading to the 
clinical symptoms of malaria (fever, chills, headache, muscle aches, tiredness, 
nausea, vomiting and diarrhea). The disease is considered uncomplicated 
when clinical or laboratory signs of vital organ dysfunction are absent.  P. 
falciparum infections, if not promptly treated, can quickly progress to severe 
malaria (leading to coma, severe breathing difficulties, low blood sugar, and 
low blood haemoglobin) and lead to death. Children are particularly 
vulnerable since they have little or no immunity to the parasite. A small 
percentage of merozoites, differentiate into male and female gametocytes, 
which are taken up by the mosquito in her blood meal. Male and female 
gametocytes fuse within the mosquito forming diploid zygotes, which in turn 
become ookinetes, migrate to the midgut of the insect, pass through the gut 
wall and form the oocysts. Meiotic division of the oocysts occurs and 
sporozoites are formed, which then migrate to the salivary glands of the 
female Anopheles mosquitos ready to continue the cycle of transmission back 
to man. 
Ideally, drugs should be active against all stages of the parasites. 
Antimalarial activity will be assessed on the basis of in vitro activity against P. 
falciparum and in vivo efficacy in animal models following oral dose 
administration of test compounds (Charman et al., 2011; Fidock et al., 2004). 
Plasmodium species that cause human disease (P. falciparum – blood stage, P. 
vivax – liver stage) are essentially unable to infect common laboratory 
animals. Humanized mice have been developed that sustain P. falciparum 
infection of human erythrocytes in vivo (Jimenez-Diaz et al., 2013; Moreno et 
al., 2001). This model is complex and expensive as it requires daily infusions 
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of human erythrocytes in severe immunodeficient mice. In addition, the 
relevance and the value of such model remain controversial (Held et al., 
2013). 
Plasmodium berghei is a species that infects rodents and is extensively 
used in preclinical drug testing. It has been validated through the identification 
of several antimalarials, such as mefloquine (Peters et al., 1977), halofantrine 
(Peters et al., 1987) and artemisinin derivatives (Posner et al., 2003; 
Vennerstrom et al., 2000). Screening test compounds in the P. berghei murine 
model is standard practice in malaria drug discovery and development (Fidock 
et al., 2004). Such studies can also generate robust PK-PD data that could be 
further used for dose optimization as reported for DHA (Gibbons et al., 2007), 
chloroquine (Moore et al., 2011) and piperaquine (Moore et al., 2008). 
Additionally, they are a useful tool for the comparison of single-dose and 
combination therapies not easily feasible in the clinical setting (Moore et al., 
2008).  
For decades, the efficacy of test compounds against the dormant liver 
stage (hypnozoites) has been studied in rhesus monkeys infected with P. 
cynomolgi, a simian parasite that unlike P. berghei develops hypnozoites 
(Deye et al., 2012). Primaquine has been the only available hypnozoitocidal 
drug for half a century. 
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Figure 8. Plasmodium life cycle. Data Source from MMV (2014) 
 
A recent report suggested that low dose primaquine regimens retain 
adequate efficacy in some areas, but not uniformly. The efficacy and safety of 
high dose primaquine regimens need to be assessed in a range of endemic and 
geographical locations (John et al., 2012). Tefanoquine, like primaquine, 
belongs to the class of 8-aminoquinolines and is being developed for radical 
cure (blood and liver stage elimination) of P. vivax malaria. Recent reports in 
P. cynomolgi-infected rhesus monkeys, demonstrated ten-fold lower doses 
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(1.8 mg/kg vs 18 mg/kg) may be effective against P. vivax hypnozoites if the 
drug is deployed in combination with a blood-schizonticidal drugs than as 
monotherapy (Dow et al., 2011).  
Although murine and monkey malaria models are useful tools to screen 
and characterize drug candidates, they also present limitations. Firstly, the 
plasmodia species can differ significantly in their degree of infection, lethality 
and synchronicity which could affect the results compared to human 
plasmodia species (Fidock et al., 2004). Secondly, species differences might 
make the extrapolation from one to another Plasmodium not accurate 
(Langhorne et al., 2011). However, all the standard antimalarial drugs 
available have demonstrated efficacy in both mouse and monkey model for 
blood stage and liver stage malaria, respectively. Hence, it is reasonable to 
expect new chemical entities to do the same as a filter before entering into 
clinical trials. Ideally, since these animal models are resource and time 
intensive, it would be very valuable to identify assays and readouts to screen 
and prioritize promising candidates before moving into lengthy animal 
pharmacology studies. 
 
1.4 Drug Discovery Strategies 
Drug discovery and development is risky, expensive and lengthy (Dickson and 
Gagnon, 2004b). The high attrition rate for new chemical entities is largely 
responsible for the high cost of bringing drugs to market. Most drug 
candidates fail before they reach the clinic, and only one in nine compounds 
makes it through development and gets approval by the regulatory authorities 
and finally reaches the market (Nwaka and Ridley, 2003). In 2001, the average 
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cost of discovering and developing a new drug was in the order of US $800 
million; current estimates are closer to approximately US $900 million 
(Alanine et al., 2003; Rawlins, 2004). Further, drug development is a lengthy 
process. As an example, it took in average 12 years and 10 months for the 
drugs approved in 2002 to be developed (Figure 9) (Dickson and Gagnon, 
2004a). Rigorous “go/no-go” decision criteria are important early in drug 
discovery and development (Alanine et al., 2003) to select and progress the 
most promising candidates.  
 
 
Figure 9. Drug development process and time involvement. Reprinted by 
permission from Macmillan Publishers Ltd: Dickson and Gagnon (2004a) 
  
Drug discovery is an articulated process that consists of following 
phases: target selection, target validation, hit identification, lead identification, 
lead optimization and candidate selection (Figure 10). It is integrative in 
nature, based on close interactions, communication and collaboration between 
scientists with different core expertise (e.g. chemistry, biology, pharmacology 
and pharmacokinetics) and involves iterative cycles (Alanine et al., 2003; 
Bleicher et al., 2003). The challenge of any drug discovery effort is to identify 
and develop compounds that will be efficacious and safe in humans (Fidock et 
al., 2004). During the early drug discovery phase, it is important to define the 
ideal Target Product Profile (TPP) for a particular indication. The progression 
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criteria (i.e., potency, efficacy, physicochemical properties, pharmacokinetics 
and toxicological properties) are specified based on the standard of care 
(Gabrielsson et al., 2009). 
Drug discovery starts conventionally with the screening of chemical 
libraries against a specific drug target (biochemical assay) or in whole cell 
(phenotypic assay). They result typically in a large number of compounds 
(hits) that need to be followed up on. As a consequence, the corresponding 
assays must be high throughput, conservative in sample use, inexpensive and 
rapid (Kerns and Di, 2003). Promising hits from a screening campaign can be 
developed into lead series following a comprehensive assessment of chemical 
integrity, synthetic robustness, structure-activity relationships (SAR), as well 
as bio-physicochemical properties (Fidock et al., 2004).  
 
Figure 10. Drug discovery process. Reprinted by permission from Macmillan 
Publishers Ltd: Bleicher et al. (2003) 
  
Lead identification can be driven through chemical modification of the 
hits to achieve improved potency, safety or ease of synthesis (Alanine et al., 
2003). SAR is explored to derive the relationship between molecular 
properties of drugs and their activity. Structure-pharmacokinetic relationship 
(SPR) is investigated to identify which structural modifications lead to 
improved absorption, distribution, metabolism and elimination (ADME) 
properties (Figure 11). These relationships once established could be useful to 
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predict the properties of new compounds. Promising lead series are progressed 
to lead optimization (Kerns and Di, 2003).  
 
Figure 11. Parallel optimization of SAR and SPR. Reprinted from Di and 
Kerns (2003), with permission from Elsevier. 
  
Lead optimization (LO) is labor intensive and perhaps the most 
important phase in drug discovery, as many compounds fail at this stage.  It is 
imperative that each LO project has multiple leads or lead series, since the 
dropout rate is typically ~ 25-50% (Alanine et al., 2003). The overall 
properties of the lead compounds are optimized by structural modifications 
and the most promising drug candidates are selected for further evaluation. 
Applying ISIVIVC to predict PK properties at this stage is useful and reduces 
the turnaround time. Balancing all properties is challenging. The goal is to 
identify compounds that meet the proposed target product profile. Further PK 
and toxicological assessments in rodents and non-rodents follow not only 
because of regulatory requirements, but also more importantly to predict the 
clinical outcome. Pharmacokinetic-pharmacodynamic relationships 
established in relevant preclinical models can be a useful guide for human 
dose predictions (Gabrielsson and Weiner, 2006). Development candidates 
also need to be easy to manufacture, stable, readily formulated, bioavailable, 
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have an acceptable half-life and be well tolerated (Fidock et al., 2004). Early 
understanding of the liabilities of a compound class, in silico - in vitro - in vivo 
correlations, dose-response relationship and early integration of PK-PD 
analysis are important to reduce attrition and maximize success of drug 
discovery and development (Gabrielsson et al., 2009). 
In summary, there is a need for new drugs with novel mechanism of 
actions against tuberculosis and malaria. Given the various challenges, it is 
imperative early on in the drug discovery programs to identify surrogate 
readouts and assays for screening and selecting the most promising candidates 
to progress into lengthy animal pharmacology studies and later into clinical 
studies. In this context, we have undertaken the effort to evaluate in silico - in 
vitro - in vivo correlations for standard TB drugs (chapter 3) and PK-PD 
relationships for a class of nitroimidazoles (chapter 4) and spiroindolones 
(chapter 5) for the treatment of tuberculosis and malaria, respectively. 
 
1.4.1 In silico – in vitro – in vivo correlations  
It is widely recognized that, apart from in vitro potency at the desired target, 
physicochemical as well as absorption, distribution, metabolism and 
elimination properties need to be considered for the selection of drug 
candidates. Studies in the late 1990s pointed out poor PK and toxicity as 
important causes of costly late-stage failures in drug development. Following 
such studies, a battery of tests to assess ADME properties as well as potential 
toxicity of test compounds were integrated in the early stages of drug 
discovery and resulted in a dramatic reduction of attrition associated with poor 




Figure 12. Reasons for attrition (1991 - 2000). Reprinted by permission from 
Macmillan Publishers Ltd: Kola and Landis (2004). 
  
Although clinical trials are indispensable to ultimately demonstrate 
efficacy and safety of novel therapeutic agents, in the early phases of drug 
discovery when dealing with large numbers of compounds an efficient multi-
dimensional approach is necessary. There are three categories of experiments: 
in vitro (Latin for within the glass), in vivo (Latin for within the living) and in 
silico (performed on computer) studies. Each of them has pros and cons. 
Understanding the limitation of each approach is the key to apply them 
effectively to accomplish the objective. Establishing ISIVIVC is particularly 
valuable when such correlations can be used to predict certain properties (e.g. 
clearance, half-life or bioavailability), thus decreasing cost and turnaround 
time (Figure 13). An additional advantage offered by the predictive approach 
is the decreased animal usage (Durairaj et al., 2009). The relationship between 
physicochemical properties and PK has been investigated for drugs in various 
indications: neuromuscular blocking agents (Proost et al., 1997), 
bisphosphonates (Hirabayashi et al., 2001), beta adrenergic antagonists and 
dihydropyridine calcium channel antagonists (van de Waterbeemd et al., 2001; 
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van De et al., 2001). The outcome suggests that PK can be optimized by 
modulating physicochemical properties. 
             
Figure 13. In silico - in vitro - in vivo relationship. Reprinted from Di and 
Kerns (2003), with permission from Elsevier.  
 
Lipophilicity appears to be one of the key physicochemical parameters 
with an impact on various PK properties. It is often computed in silico or 
determined experimentally and has been widely used to build structure 
property relationships. The ability of molecules to partition into biological 
membranes is governed by molecular size and lipophilicity and hence they are 
the major factors in determining drug disposition. Increasing molecular weight 
often leads to higher lipophilicity resulting in higher potency, but also 
contributes to decreased dissolution/solubility limiting oral absorption (van de 
Waterbeemd et al., 2001). Increasing lipophilicity influences permeability, 
plasma protein binding (PPB) and volume of distribution (Vd). Further, highly 
lipophilic compounds also become more prone to P450 metabolism, resulting 
in increased clearance (Davis et al., 2000; Proost et al., 1997; Smith et al., 
1996; van de Waterbeemd et al., 2001; van De et al., 2001). Activity, 
physicochemical parameters and developability of a compound need to be 
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balanced against each other. For this reason early understanding of the in 
silico - in vitro - in vivo relationship for a compound class is important and can 
lead to the identification of candidates with optimal properties in a more 
efficient and faster way.  
In this context, we have undertaken the effort to evaluate and 
understand the in silico - in vitro - in vivo correlations for standard TB drugs 
(chapter 3). 
 
1.4.2 Pharmacokinetic-Pharmacodynamic (PK-PD) relationships  
In vitro potency, physicochemical and PK properties are the critical 
determinants of in vivo efficacy. Understanding PK-PD relationships in drug 
discovery is important to select the best compound among many, guide lead 
optimization, design optimal pharmacology experiments, minimize attrition 
rate and eventually guide human dose prediction and or support clinical trial 
preparation. 
In modern antibiotic drug development, PK-PD principles are applied 
to select doses and dosing regimens. The PK profiles obtained in animal 
models and human volunteers are combined with values of drug potency in 
vitro and efficacy in animal models to calculate PK-PD indices that inform 
rational trial design (Craig, 1998; Craig, 2001; Scaglione and Paraboni, 2006). 
Based on this approach, antibiotics have been classified as exerting 
concentration-dependent or time-dependent killing. PK-PD parameters such as 
AUC/MIC (area under the curve/minimum inhibitory concentration) and 
Cmax/MIC (maximum concentration/minimum inhibitory concentration) 
correlate to the efficacy of concentration dependent killing agents while time 
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during which serum levels remain above MIC (T>MIC) correlate to the efficacy 
of time dependent killing agents (Figure 14) (Craig, 1998; Schuck and 
Derendorf, 2005). Regardless of the specific efficacy driver, this information 
has enabled the selection of dosing regimens that optimize clinical efficacy 
while suppressing the emergence of resistant organisms, and has supported the 
determination of clinically relevant susceptibility breakpoints (Drusano, 
2007). 
                
          




























Figure 14. PK-PD indices used in anti-infectives.  Redrawn from Schuck and 
Derendorf (2005)  
 
1.4.2.1 PK-PD for antibacterials 
PK-PD principles are well established for some antibacterial drugs but are not 
universally understood for all antibiotic classes. Fluoroquinolones, for 
example, display concentration dependent killing and bactericidal effect 
against gram-negative bacilli was observed at a Cmax/MIC of >12 or 
AUC/MIC of > 100-125. Maximum activity of fluoroquinolones is achieved 
when the AUC/MIC exceeds 250 (Figure 15) (Craig, 2001; Wright et al., 
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2000). Penicillins and cephalosporins show time dependent killing. 
Bacteriostatic effect is observed with 30-40% of T>MIC, maximum effect is 
observed with 60-70% of T>MIC (Figure 16).   
      
Figure 15. PK-PD relationship for levofloxacin in a thigh infection model of S. 
pneumonia. Reprinted from Andes and Craig (2002), with permission from 
Elsevier. 
 
     
Figure 16. PK-PD relationship for ceftazidime in a lung infection model of K. 
pneumonia. Reprinted from Andes and Craig (2002), with permission from 
Elsevier. 
 
Generally, the correlation between antibacterial effect and PK-PD 
indices is similar for compounds belonging to the same class. Examples are 
fluoroquinolones (Figure 17A), penicillins, cephalosporins and carbapenems 
against various pathogens in the lungs and thighs of neutropenic mice (Figure 
17B). As a consequence, the magnitude of the effect shown by a compound 
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can be predicted using in vitro potency and in vivo PK (Cmax/MIC, AUC/MIC 
and T>MIC) (Andes and Craig, 2002). 
A      B 
        
Figure 17. PK-PD relationship of various fluoroquinolones (A); penicillins, 
cephalosporins and carbapenems (B) in different models of infection. 
Reprinted from Andes and Craig (2002), with permission from Elsevier. 
 
Which PK-PD index best correlates with efficacy depends on several 
factors, including mechanism of action and kill kinetics. As a general rule, 
antimicrobial agents that act via the inhibition of an enzyme or the bacterial 
growth display concentration dependent killing and their efficacy correlate 
well with the AUC/MIC or Cmax/MIC. Conversely, antimicrobials that act on 
the cell wall display time-dependent killing and their efficacy correlate with 
fT>MIC (Barbour et al., 2010). Once the relationship is established for a 
compound class, it can be applied to new compounds of the same class to 
predict their efficacy and prioritize the most promising ones. Overall, 
understanding the PK-PD relationship of a class of compounds early on is 
important for lead optimization and for optimal study design and certainly 




1.4.2.2 PK-PD for Tuberculosis 
In the last decade PK-PD relationships for standard TB drugs in preclinical 
murine models were established. AUC/MIC is the PK-PD parameter that best 
correlated with the in vivo efficacy for rifampicin (Jayaram et al., 2003), 
isoniazid (Jayaram et al., 2004), fluoroquinolones (moxifloxacin, ofloxacin 
and sparfloxacin) (Shandil et al., 2007) and TMC207 (Rouan et al., 2012).   % 
T>MIC is the PK-PD parameter that best described the in vivo efficacy for PA-
824 (Ahmad et al., 2011). Based on the results obtained for rifampicin, further 
clinical studies have been initiated to optimize the clinical dose (Burman et al., 
2011; Rosenthal et al., 2012; Steingart et al., 2011; van et al., 2011). This 
illustrates the importance and the potential impact of a thorough understanding 
of the relationship between drug exposure and antibacterial effect for new and 
existing TB drugs. 
In this context, we have undertaken the effort to evaluate the PK-PD 
relationship for a class of nitroimidazoles (chapter 4) currently under 
preclinical evaluation as potential treatment against TB. 
 
1.4.2.3 PK-PD for Malaria 
PK-PD relationships are not well understood for antimalarial drugs and 
therapeutic strategies are largely based on empirical clinical evidence. Many 
antimalarials in use today were developed and clinically tested before the 
modern era of rational dose selection. The doses and dose regimens in initial 
clinical trials, including those for the newer and most effective artemisinin 
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derivatives (Gautam et al., 2009), were derived empirically (Newton et al., 
2006).  
In recent years, numerous drug monitoring programs have been 
launched to assess the adequacy of doses and to model dose-response in 
uncomplicated and severe malaria (Hoshen et al., 2001; Svensson et al., 2002; 
White et al., 2008). Quantitative PD read-outs, such as parasitemia, parasite 
clearance rates, and parasite clearance time, have been used to assess 
parasitological response to treatment in relation to clinical outcome (Ashley et 
al., 2008; White, 2002). Based on these more precise definition of clinical and 
parasitological responses (Price et al., 2007), new drug combinations have 
been proposed (D'Alessandro, 2009; Hoshen et al., 2002), and doses have been 
revised when required (Newton et al., 2006). Although a standardized 
relationship between parasitological responses in vitro and clinical outcome 
remains to be fully established (White, 1997), progress has been made in 
understanding the PK-PD relationship for standard antimalarial drugs such as 
chloroquine and artimisinin (Bakshi et al., 2013). The field is clearly moving 
towards the rational selection of dose, dosing frequency and duration of 
antimalarial treatment (White, 2013).  
In this context, we have undertaken the effort to evaluate the PK-PD 
relationship for a class of spiroindolones (chapter 5) currently in clinical 















Hypotheses and Objectives 
 
Two working hypotheses are proposed in this thesis. The first hypothesis 
addresses the relationship between the physicochemical properties and the 
pharmacokinetic parameters of the anti-mycobacterial compounds. The second 
hypothesis, addresses the complex nature of the PK-PD relationship with 
specific emphasis on two classes of anti-mycobacterial and anti-malarial 
compounds, respectively. 
In recent years there has been an increase in the understanding of the 
relationship between several parameters during early drug discovery. The in 
silico – in vitro – in vivo relationship between various physicochemical and 
pharmacokinetic parameters of drug molecules have been established in other 
therapeutic areas (Section 1.4.1). However, this kind of analysis is lacking for 
the anti-mycobacterial compounds.  
Hypothesis 1: The pharmacokinetic properties of anti-mycobacterial 
candidates are dependent on their physicochemical properties and once a 
relationship is established between these two parameters; it can be used to 
predict the PK parameters of a new compound from its physicochemical 
properties. This hypothesis will be tested in Part 1 with the standard anti-
mycobacterial compounds. 
The first part of the research project is to profile the standard anti-
mycobacterial drugs currently available in the market or undergoing 
preclinical and clinical development. These drugs belong to different chemical 
class and display different mechanism of action. Nevertheless, the 
pharmacokinetic properties of all drugs are dependent on their 
physicochemical properties but not on their mechanism of action. Hence, the 
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objective of the part I study is to identify physicochemical properties of anti-
mycobacterial candidates and their influence on the pharmacokinetic profiles. 
Specific objectives were:  
 Systematic compilation of in silico physicochemical properties for a 
set of 36 anti-mycobacterial compounds. 
 Evaluate in vitro PK parameters.  
 Systematic compilation of the in vivo pharmacokinetic parameters. 
 Establish the correlations between the in silico, in vitro and in vivo 
parameters. 
Secondly, there is an increased awareness in understanding the relationship 
between pharmacokinetic and pharmacodynamics properties to facilitate the 
early drug discovery programs. These relationships have been established for 
several classes of anti-infective agents (Section 1.4.2). However, this kind of 
analysis is lacking for the anti-mycobacterial and anti-malarial compounds.  
Hypothesis 2: The PK-PD correlation established from the lead 
compounds in the anti-mycobacterial and anti-malarial agents can be 
applied for analogs from the same classes of compounds, provided they 
share the same mechanism of action. This hypothesis will be tested in Part 
2 (the nitroimidazole analogs of the anti-mycobacterial compounds) and 
Part 3 (the spiroindolone analogs of the anti-malarial compounds) of this 
thesis. 
The second part of the research project is to evaluate the PK-PD 
relationships for compounds belonging to the chemical class of the 
nitroimidazoles. Dose fractionation PK-PD studies in mice indicate that the 
efficacy of PA-824 is driven by the time during which its free plasma 
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concentration is above its minimum inhibitory concentration. To test our 
hypothesis, we evaluated whether the same PK-PD relationship holds true for 
nitroimidazole analogs sharing the same mechanism of action. Specific 
objectives were:  
 A panel of closely related bicyclic 4-nitroimidazoles was profiled in in-
vitro potency and physicochemical assays. 
 Evaluation of the in vivo pharmacokinetic parameters. 
 Evaluation of the in vivo efficacy. 
 Systematic PK-PD analysis was done to identify the efficacy driver. 
The third part of the research project was to evaluate the PK-PD 
relationships for compounds belonging to the chemical class of the 
spiroindolones. KAE609, a spiroindolone analog, is currently in phase II 
clinical development and represents a promising potential treatment for 
malaria. The objective of this third part of the study was to assess dose-
response relationship for a class of compounds and PK-PD relationship for the 
lead compound KAE609 in mice to determine whether the efficacy is 
concentration dependent or time dependent. Specific objectives were:  
 A panel of closely related spiroindolones was profiled in both in vitro 
potency and in vitro pharmacokinetic assays. 
 Evaluation of the in vivo pharmacokinetic parameters.  
 Establish dose-response relationship for a class of spiroindolone 
analogs. 
 Pharmacokinetic modeling for KAE609. 
 Dose fractionation studies for KAE609. 















Chapter 3. Comprehensive physicochemical, 






Studies in the late 1990s indicated that poor PK and toxicity were the common 
causes of many costly late-stage failures in drug development. In light of these 
situations, a battery of tests to assess ADME properties as well as potential 
toxicity of new drug candidates, were integrated in the early stages of drug 
discovery and resulted in a dramatic reduction of attrition associated with PK- 
and toxicity-related factors (Kola and Landis, 2004). Physicochemical 
parameters affect absorption, oral bioavailability and other ADME parameters. 
Experimental and computational analyses of very large sets of small molecule 
drugs resulted in various empirical rules such as, Lipinski’s Rule of Five, 
whereby poor absorption or permeation is more likely if a compound exhibits 
one or more of the following properties:  molecular weight (MW)  >500, 
cLogP  >5, hydrogen bond donors (HBD)  >5 or acceptors (HBA) >10 
(Lipinski et al., 2001). Veber’s rule added that compounds with less than 10 
rotatable bonds and a polar surface area (PSA) <140 Å
2
 are more likely to 
have good oral bioavailability (Veber et al., 2002).  Further Gleeson’s analysis 
revealed that almost all ADME parameters (solubility, permeability, 
bioavailability, volume of distribution, plasma protein binding and clearance) 
are compromised with either increasing molecular weight, logP, or both. In 
general, as the MW and/or logP increases, the solubility, permeability and 
bioavailability decreases while the in vivo clearance increases, thus 
recommending MW <400, and cLogP  <4 to improve ADME parameters 
(Gleeson, 2008). In addition, Egan showed that cLogP and PSA could be used 
as a tool (Egan Egg model) for predicting good passive gut absorption (Egan 
et al., 2000). 
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In the early drug discovery, emphasis is most often placed on the in 
vitro potency, while desirable physicochemical and PK parameters are 
considered as secondary attributes in the decision making process. To be 
efficacious, anti-infectives have to (i) effectively penetrate the microbe and 
inhibit an essential cellular process and (ii) reach the site of infection – lung 
tissue and lesions for pulmonary TB. Hence, the chemical space occupied by 
antibacterials (O'Shea and Moser, 2008) and anti-mycobacterials (Koul et al., 
2011) is distinct from that of drugs targeting non-infectious diseases. 
Recently, a comprehensive analysis (Franzblau et al., 2012) of various 
microbiological and animal study protocols used by different TB research 
groups was carried out. A guide for medicinal chemist to optimize compounds 
against TB has also been discussed (Cooper, 2013; Dartois and Barry, III, 
2013). Further, physicochemical, biopharmaceutical and clinical PK-PD 
properties of selected anti-TB compounds and novel agents under 
development have been reviewed (Brennan and Young, 2008; Budha et al., 
2008; Dartois and Barry, 2010; Davies and Nuermberger, 2008; Holdiness, 
1984; Nuermberger and Grosset, 2004; Vaddady et al., 2010). These reviews 
do not include comparative analyses and correlation between in silico 
parameters, including the in vitro potency, in vitro PK and in vivo PK 
properties. Hence, in this chapter, we have collated the in vitro potency and in 
vitro PK parameters for a set of 36 compounds generated using the 
standardized procedures. In silico physicochemical and in vivo 
pharmacological parameters were also compiled. We have used computational 
approaches to seek relationships between in silico properties, in vitro potency, 
in vitro PK and human in vivo PK parameters, with the objective to develop a 
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correlation that will help guiding early drug discovery efforts against TB. Not 
surprisingly, lipophilicity emerged as a major factor driving in vitro and in 
vivo PK properties.  
 
3.2 Materials and Methods 
 
3.2.1 Chemicals 
All the standard compounds were obtained from commercial sources (Sigma-
Aldrich, Sequoia research products and Cayman chemicals) except 
bedaquiline (TMC-207), PA-824, delamanid (OPC-67683), valnemulin and 
PNU-100480 which were synthesized at Novartis (Table 3).  Stock solutions 
of the compounds were prepared using 90% DMSO. The 36 compounds used 
in the study were isoniazid, rifampicin, pyrazinamide, ethambutol, 
streptomycin, kanamycin, amikacin, p-aminosalicylic acid, cycloserine, 
ethionamide, rifabutin, rifapentine, moxifloxacin, levofloxacin, gatifloxacin, 
ciprofloxacin, ofloxacin, sparfloxacin, capreomycin, thioacetazone, linezolid, 
prothionamide, clarithromycin, amoxicillin, clavulanate, meropenem, 
clofazimine, metronidazole, thioridazine, mefloquine, vancomycin, 
valnemulin, PNU-100480, PA-824, bedaquiline and delamanid. 
 
3.2.2 Physicochemical parameters 
Molecular weight, cLogP (calculated octanol:water partitioning coefficient), 
PSA (which measures the surface sum of overall polar atoms), rotatable 
bonds, HBD and HBA were generated using proprietary software based on 





3.2.3 In vitro potency and cytotoxicity 
Minimum inhibitory concentration (MIC50) was determined using the lab 
strain Mtb H37Rv by turbidimetric assay as described previously 
(Kurabachew et al., 2008; Pethe et al., 2010) (Appendix 1). Cytotoxicity was 
tested in hepatocyte cell line (HepG2) (ATCC, #HB-8065) for hepatotoxicity 
and baby hamster kidney cell line (BHK21) (ATCC, #CCL-10) for renal 
toxicity, in 96-well microplates as described elsewhere (Pethe et al., 2010). 
Briefly, the cells were seeded at a density of 10
5
 cells per mL, incubated at 37 
 C for 24 h and exposed to twofold serial diluted compounds for 3 days. Cell 
viability was monitored using the Cell Proliferation Kit II (Invitrogen). 
Relative fluorescence units were measured at OD450, using a Tecan Safire
2
, 
and CC50 curves were plotted using Graph Pad Prism 5 software. 
 
3.2.4 In vitro PK studies  
In vitro PK parameters such as solubility, permeability [parallel artificial 
membrane permeability assay (PAMPA) and colon carcinoma cell line (Caco-
2) assay], metabolic stability in mouse and human liver microsomes were 
measured at Cyprotex using standard protocols as described at 
www.cyprotex.com/admepk/ (Obach, 1999; Wohnsland and Faller, 2001). 
Thirty two compounds were profiled in various assays. Thermodynamic 
solubility was determined in phosphate buffer saline (PBS) buffer at pH 7.4 
using high performance liquid chromatography (HPLC). For solubility 
(mg/mL) mean values from two independent replicates are given.  Mean 
apparent permeability (Papp with units being 10
-6
 cm/sec) values from four 
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replicates are given for PAMPA permeability. Caco-2 permeability was 
provided as mean Papp (10
-6
 cm/sec) (1) from apical to basolateral (A-B), and 
(2) from basolateral to apical (B-A), as well as the ratio between the two 
values, from two independent replicates. In vitro metabolic stability in both 
mouse and human liver microsomes was determined and their intrinsic 
clearance (CLint, µL/min/mg protein) values are given. PAMPA, Caco-2 
permeability and metabolic stability sample analysis was carried out using 
optimized LC-MS/MS methods (Appendix 2). Plasma protein binding data 
were obtained either from published literature (section 3.2.6) or in silico 
methods using GastroplusTM 8.5, simulations Plus, Inc. (www.simulations-
plus.com).  
 
3.2.5 Mouse in vivo PK and efficacy studies 
All procedures involving mice were reviewed and approved by the 
institutional animal care and use committee of the Novartis Institute for 
Tropical Diseases. Animal studies were carried out in accordance with the 
Guide for the Care and Use of Laboratory Animals. All animals were kept 
under specific pathogen-free conditions and fed water and chow ad libitum, 
and all efforts were made to minimize suffering or discomfort.  
In vivo PK data for ethambutol, cycloserine, ethionamide, mefloquine, 
clofazimine, valnemulin and PA-824 were obtained in CD-1 female mice. For 
isoniazid, rifampicin, pyrazinamide, moxifloxacin, linezolid, and bedaquiline, 
PK parameters were compiled from the literature (Table 6). The compounds 
were formulated either in 0.5% carboxy methyl cellulose or 10% 
hydroxypropyl-beta-D-cyclodextrin; 10% lecithin (PA-824) (Stover et al., 
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2000) suspension and administered orally at doses ranging from 10 to 200 
mg/kg. Blood samples were collected by retro-orbital bleeding at various time 
points (0.08 to 24 h) post-dose. All procedures during pharmacokinetic 
experiments were performed under isoflurane anesthesia (Diehl et al., 2001). 
Groups of three mice were used for each time point. Blood was centrifuged at 
13,000 rpm for 7 min at 4 ºC, and plasma was harvested and stored at –20 ºC 
until analysis. Plasma samples were analyzed using optimized LC-MS/MS 
conditions and PK parameters were calculated using WinNonLin software 
version 5.1.  
In vivo acute mouse efficacy studies were carried out as described 
earlier (Pethe et al., 2010). Briefly, animals were infected intranasally with 10
3
 
Mtb H37Rv bacilli. One week post-infection animals were treated for one 
month with the appropriate dose. At 2 and 4 weeks post dosing, the lungs were 
aseptically removed, homogenized and the bacterial load were estimated by 
plating serial dilutions on 7H11 agar plates. Mean log cfu reductions (mean 
value ± SD) were calculated from five animals at each time point and 
compared to untreated controls.  
 
3.2.6 Human in vivo PK properties 
Human PK data were obtained from published literature: isoniazid (Brennan et 
al., 2008; Brunton et al., 2010; Nuermberger and Grosset, 2004; Vaddady et 
al., 2010), rifampicin (Brennan et al., 2008; Brunton et al., 2010; Nuermberger 
and Grosset, 2004; Vaddady et al., 2010), pyrazinamide (Brennan et al., 2008; 
Brunton et al., 2010; Nuermberger and Grosset, 2004), ethambutol (Brennan et 
al., 2008; Brunton et al., 2010; Vaddady et al., 2010), streptomycin (Brennan 
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et al., 2008; Dartois and Barry, 2010; Obach et al., 2008), kanamycin 
(Brennan et al., 2008; Dartois and Barry, 2010; Obach et al., 2008), amikacin 
(Brennan et al., 2008; Brunton et al., 2010; Dartois and Barry, 2010), p-
aminosalicylic acid (Brennan et al., 2008; Dartois and Barry, 2010), 
cycloserine (Brennan et al., 2008; Dartois and Barry, 2010), ethionamide 
(Brennan et al., 2008; Dartois and Barry, 2010), rifabutin (Brennan et al., 
2008; Dartois and Barry, 2010; Obach et al., 2008), rifapentine (Brennan et al., 
2008; Nuermberger and Grosset, 2004), moxifloxacin (Brennan et al., 2008; 
Brunton et al., 2010; Dartois and Barry, 2010; Nuermberger and Grosset, 
2004), levofloxacin (Brunton et al., 2010; Dartois and Barry, 2010; 
Nuermberger and Grosset, 2004), gatifloxacin (Brennan et al., 2008; Brunton 
et al., 2010; Dartois and Barry, 2010; Nuermberger and Grosset, 2004; Obach 
et al., 2008), ciprofloxacin (Brunton et al., 2010; Dartois and Barry, 2010; 
Nuermberger and Grosset, 2004), ofloxacin (Brunton et al., 2010; Dartois and 
Barry, 2010; Nuermberger and Grosset, 2004), sparfloxacin (Nuermberger and 
Grosset, 2004; Obach et al., 2008), capreomycin (Brennan et al., 2008; Dartois 
and Barry, 2010), thioacetazone (Vaddady et al., 2010), linezolid (Brennan et 
al., 2008; Dartois and Barry, 2010; Obach et al., 2008), prothionamide 
(Dartois and Barry, 2010), clarithromycin (Brennan et al., 2008; Obach et al., 
2008), amoxicillin (Dartois and Barry, 2010; Obach et al., 2008), clavulanate 
(Dartois and Barry, 2010; Obach et al., 2008), meropenem (Obach et al., 
2008), clofazimine (Dartois and Barry, 2010), metronidazole (Dartois and 
Barry, 2010; Obach et al., 2008), thioridazine (Brennan et al., 2008), 
mefloquine (Brunton et al., 2010; Karbwang et al., 1994), vancomycin (Healy 
et al., 1987; Obach et al., 2008), PNU-100480 (Wallis et al., 2010), PA-824 
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(Ginsberg et al., 2009), bedaquiline (Brennan et al., 2008; Dartois and Barry, 
2010) and delamanid (Diacon et al., 2011). No human PK data was available 
in the published literature for valnemulin. 
 
 
3.2.7 Statistical analysis 
Correlations were tested using TIBCO Spotfire version 4.0.2 
(http://spotfire.tibco.com). Statistical analysis was carried out using Prism 
software (GraphPad Prism, version 5.02, San Diego, California USA, 
www.graphpad.com). A Spearman’s correlation analysis was performed to 
determine the relationship between various parameters.   
 
3.3 Results and Discussion 
To benchmark and compare physicochemical, potency and 
pharmacokinetic properties of available anti-TB agents, we experimentally 
determined and compiled these parameters for 36 anti-TB compounds, using 
standardized and centralized assays, thus ensuring direct comparability across 
drugs and drug classes. The compound set included first and
 
second line anti-
TB agents, clinical candidates as well as drugs that exhibited in vitro activity 
against Mtb (Table 3). Of the 36 compounds selected, 15 were natural 
products (compounds of natural origin and semi-synthetic derivatives) and the 
remaining 21 were fully synthetic molecules. The majority of these drugs are 
administered orally, with a few injectables. Half of the compounds were 
initially developed as either Gram-positive or Gram-negative antibacterials. 
These were introduced as part of combination regimens for the treatment of 
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MDR-TB, due to the emergence of resistance to first line anti-TB drugs (Table 
3 and Figure 18). 









Route Activity Chemical class Source 
1 Isoniazid* SM Oral TB Pyridines Sigma 
2 Rifampicin NP Oral TB/Gm+ Rifamycins Sigma 
3 Pyrazinamide* SM Oral TB Pyrazines Sigma 
4 Ethambutol SM Oral TB Ethylenediamine Sigma 
5 Streptomycin NP Injectable TB/Gm+/Gm- Aminoglycosides Sigma 
6 Kanamycin NP Injectable Gm+/Gm- Aminoglycosides Sigma 





SM Oral TB Salicylates Sigma 
9 Cycloserine NP Oral TB - Sigma 




11 Rifabutin NP Oral TB Rifamycins Sequoia 
12 Rifapentine NP Oral TB Rifamycins Sequoia 
13 Moxifloxacin SM Oral Gm+/Gm- Fluoroquinolones Sequoia 
14 Levofloxacin SM Oral Gm+/Gm- Fluoroquinolones Sigma 
15 Gatifloxacin SM Oral Gm+/Gm- Fluoroquinolones Sequoia 
16 Ciprofloxacin SM Oral Gm+/Gm- Fluoroquinolones Sigma 
17 Ofloxacin SM Oral Gm+/Gm- Fluoroquinolones Sigma 
18 Sparfloxacin SM Oral Gm+/Gm- Fluoroquinolones Sigma 
19 Capreomycin NP Injectable TB Aminoglycosides Sigma 
20 Thioacetazone* SM Oral TB - Sigma 
21 Linezolid SM Oral Gm+ Oxazolidinones Sigma 
22 Prothionamide* SM Oral TB Thiomides Cayman 
23 Clarithromycin NP Oral Gm+ Macrolides Sequoia 
24 Amoxicillin NP Oral Gm+/Gm- Penicillins Sigma 
25 Clavulanate NP Oral Gm+/Gm- Beta Lactams Sigma 
26 Meropenem NP Injectable Gm+/Gm- Carbapenem Sigma 
27 Clofazimine NP Oral Leprosy/TB Riminophenazine Sigma 
28 Metronidazole* SM Oral Anaerobic Nitroimidazole Sigma 
29 Thioridazine SM Oral Antipsychotic Phenothiazine Sigma 
30 Mefloquine SM Oral Antimalarial Isoquinolines Sigma 
31 Vancomycin NP Injectable Gm+ Polypeptides Sigma 
32 Valnemulin NP Oral Gm- Pleuromutilins Novartis 
33 PNU-100480* SM Oral TB Oxazolidinone Novartis 
34 PA-824* SM Oral TB Nitroimidazole Novartis 
35 Bedaquiline SM Oral TB Diarylquinoline Novartis 
36 Delamanid* SM Oral TB Nitroimidazole Novartis 
#
SM, synthetic molecule; NP, natural product (including compounds of natural 
origin and semi-synthetic derivatives); Gm+, Gram-positive bacteria; Gm-, 













(6) Kanamycin (7) Amikacin
(9) Cycloserine
(10) Ethionamide
(11) Rifabutin (12) Rifapentine
(13) Moxifloxacin (14) Levofloxacin





(21) Linezolid (22) Prothionamide
(23) Clarithromycin
(24) Amoxicillin
(31) Vancomycin (32) Valnemulin
(28) Metronidazole(25) Clavulanate (26) Meropenem (27) Clofazimine
(29) Thioridazine
(30) Mefloquine
Clinical candidates Recently approved drugs
(33) PNU-100480 (34) PA-824 (35) TMC-207 (36) OPC-67683  
Figure 18. Chemical structures of 36 anti-TB compounds: the numbering 





3.3.1 Physicochemical properties 
Physicochemical parameters and Lipinski rule violations are presented in 
Table 4. Most compounds follow Lipinski’s rule of five and Veber’s rule with 
MW <500 (n=25), cLogP <5 (n=30), HBD <5 (n=29), HBA <10 (n=27), have 
PSA <140 Å
2 
(n=27) and rotatable bonds <10 (n=34), which is predictive of 
good oral bioavailability (Table 4) (Lipinski et al., 2001; Veber et al., 2002). 
The majority of the compounds display acceptable drug-like properties with 
cLogP <5, the exception being natural product derivatives such as 
aminoglycosides and rifamycins (Figure 19A-E).  
All compounds were subjected to the ‘Egan egg’ analysis (Figure 20) 
(Egan et al., 2000). Twenty-four compounds were within the inner ellipsoid 
and are therefore predicted to exhibit good passive absorption through the 
gastro-intestinal tract, in agreement with acceptable oral bioavailability (Table 
9). Compounds falling outside the ellipsoid are natural products (Table 3). 
Interestingly, both rifampicin and rifapentine have good oral bioavailability in 
humans, suggesting that they may be actively transported (Egan et al., 2000). 
Amoxicillin, located on the borderline of the ellipsoid, is known to be 







Table 4. Physicochemical parameters 
 









Isoniazid 137.14 -0.67 2 4 0 68.01 2 
Rifampicin 822.96 3.71 6 16 3 220.15 5 
Pyrazinamide 123.12 -0.68 1 4 0 68.87 1 
Ethambutol 204.31 0.12 4 4 0 64.52 9 
Streptomycin 581.58 -4.26 14 19 3 331.43 11 
Kanamycin 484.51 -5.17 11 15 2 282.61 6 
Amikacin 586.60 -6.36 13 18 3 326.15 10 
p-aminosalicyclic 
acid 
153.14 1.06 3 4 0 83.55 1 
Cycloserine 102.09 -1.19 2 4 0 64.35 0 
Ethionamide 166.25 1.73 1 2 0 38.91 2 
Rifabutin 847.03 4.73 5 15 2 205.55 5 
Rifapentine 877.05 5.09 6 16 4 220.15 6 
Moxifloxacin 401.44 -0.08 2 7 0 86.27 4 
Levofloxacin 361.38 -0.51 1 7 0 77.48 2 
Gatifloxacin 374.42 3.40 1 6 0 74.24 4 
Ciprofloxacin 331.35 -0.73 2 6 0 77.04 3 
Ofloxacin 361.38 -0.51 1 7 0 77.48 2 
Sparfloxacin 392.41 -0.61 3 7 0 103.06 3 
Capreomycin 668.72 -7.06 15 22 4 375.92 10 
Thioacetazone 236.30 0.88 3 5 0 79.51 4 
Linezolid 337.35 0.17 1 7 0 71.11 4 
Prothionamide 180.27 2.26 1 2 0 38.91 3 
Clarithromycin 747.97 2.37 4 14 2 182.91 8 
Amoxicillin 365.41 -1.87 4 8 0 132.96 4 
Clavulanate 199.16 -1.07 2 6 0 87.07 2 
Meropenem 383.47 -3.28 3 8 0 110.18 5 
Clofazimine 473.41 7.70 1 4 1 44.68 4 
Metronidazole 171.16 -0.46 1 6 0 86.34 3 
Thioridazine 370.58 6.00 0 2 1 6.48 4 
Mefloquine 378.32 3.67 2 3 0 45.15 4 
Vancomycin 1449.29 -1.14 19 33  530.49 
 
Valnemulin 564.83 5.57 3 7 2 118.72 10 
PNU-100480 353.42 1.00 1 6 0 61.88 4 
PA-824 359.26 2.79 0 8 0 93.8 6 
Bedaquiline 555.52 7.25 1 4 2 45.59 8 
Delamanid 534.50 5.25 0 10 2 106.27 9 
Anti-TB compounds 
n=36 
428.31    
(102 to 
1449) 
0.86           
(-7.1 to 
7.7) 
3.78                     
(0 to 
19) 










gram + ve activity) 
n=33 
813          
(290 to 
1880) 
2.1             
(-5.1 to 
6.4) 
7.1               
(1 to 
29) 









gram –ve activity) 
n=113 
414 (138 to 
1203) 
-0.1           
(-5.0 to 
3.3) 
5.1                    
(1 to 
23) 











MW, molecular weight; cLogP, calculated logP or octanol:water partition 
coefficient; HBD: hydrogen bond donors; HBA: hydrogen bond acceptors; 
Lipinski violations, number of Lipinski rule violations (referring to Lipinski’s 
rule of five), PSA: polar surface area; RB, rotatable bond. Mean values and 
ranges (in parentheses) are provided for the summary parameters. Gram-
positive and Gram-negative antibacterial physicochemical parameters were 
obtained from O’Shea and Moser (O'Shea and Moser, 2008).   
 
3.3.2 In vitro potency and cytotoxicity 
Compounds displayed a wide range of MIC50 values from 0.01 to 11 mg/L 
(Table 5). Pyrazinamide, metronidazole, meropenem and amoxicillin were 
found to be inactive (MIC50 >30 mg/L). Pyrazinamide, known to be inactive in 
standard neutral pH medium, and require acidic pH to exert its growth 
inhibitory activity, showed an MIC50 of 25 mg/L at pH 5.5. Although 
metronidazole was inactive against growing Mtb, it was active against hypoxic 
non-growing Mtb (Wayne and Hayes, 1996). Meropenem in combination with 
clavulanate has shown good inhibitory activity both in vitro and in vivo 
(England et al., 2012; Hugonnet et al., 2009), but when tested individually 
neither drug showed any in vitro inhibitory activity. The MIC50 data presented 
in the current study are comparable to the data obtained by Franzblau and co-






             
































































Figure 19. Physicochemical properties of anti-TB compounds and their relationship with cLogP 
(A) molecular weight (B) hydrogen bond donors (HBD) (C) hydrogen bond acceptors (HBA) (D) polar surface area (PSA) and (E) rotatable 
bonds. The horizontal and vertical lines are the cut-offs from Lipinski’s rule of five (A, B and C) and Veber’s rule (D and E). The majority of the 
compounds lie within Lipinski’s space (lower left quadrant). The compounds are categorized as synthetic molecules (blue open squares) and 





Figure 20. Egan egg analysis of 36 anti-TB compounds 
The numbering of compounds is the same as in Table 3. Compounds within 
the ellipsoid are known to have good passive absorption and those outside 
have poor absorption. Compounds within the red and blue dotted circles are 
injectables and rifamycins, respectively. 
 
A cytotoxicity (CC50) measurement was carried out using two common 
cell lines, namely BHK21 (kidney cell line) and HepG2 (liver cell line). Most 
compounds tested were non-cytotoxic up to a maximum concentration tested 
(2.5 to 29 mg/L), with CC50 to MIC50 ratios of >7-800. Mefloquine was the 
only exception, with CC50 values of 4.2 and 2.8 mg/L and an MIC50 of 3.8 
mg/L (Table 5).  It is important to note here that many anti-TB agents are pro-
drugs that are primarily activated inside Mtb. Cytotoxicity assays in human 
cell lines do not capture the potential toxicity of these active metabolites if 
bioconversion does not take place within host cells. 
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3.3.3 In vitro pharmacokinetics  
In vitro solubility, permeability and liver microsomal metabolic stability are 
key predictors of oral bioavailability. These properties were determined using 
standardized assays and are summarized in Table 5. Ninety percent of the 
compounds showed moderate-to-high solubility, except clofazimine, PA-824 
and bedaquiline which are poorly soluble. For predicting permeability, 
PAMPA is employed as a simple in vitro model of passive diffusion through 
an artificial membrane. The Caco-2 cell layer permeability assay is widely 
used as a more predictive in vitro model of absorption through the intestinal 
epithelium. While PAMPA only measures passive diffusion, the Caco-2 
permeability assay integrates active uptake, efflux and permeation via the 
paracellular route. Most of the compounds (62%) exhibited low PAMPA 
permeability while 90% of the compounds showed moderate to high Caco-2 
permeability and no or low active efflux except for rifampicin, thioacetazone 
and clarithromycin. Exceptions were streptomycin and clofazimine displaying 
low Caco-2 permeability. More than 90% of the compounds displayed low-to-
medium intrinsic clearance in both mouse and human liver microsomes. There 
was a good correlation between the two species, except for ethionamide and 
prothionamide with high and medium clearance in mouse and human 
microsomes, respectively (Table 5). Anti-TB compounds displayed wide range 










Caco-2 permeability Caco-2 efflux 







 mg/L mg/L mg/L (Papp 10
-6
 cm/s)  (µL/min/mg protein) % 
Isoniazid 0.04 >2.74 4.93 ND ND ND - 21.7 13.9 1 
Rifampicin 0.02 >16.46 1.79 1.6 1.52 18.4 12.1 3.04 2.84 90 (60-90) 
Pyrazinamide >9.85 >2.46 2.72 1.73 70.4 37.1 0.5 Low Low 10 
Ethambutol 0.60 >4.09 0.79 ND ND ND - Low Low 30 (6-30) 
Streptomycin 0.09 >11.63 2.04 ND 0.78 0.57 0.7 9.76 Low 35 
Kanamycin 0.76 >9.69 ND 6.32 ND ND - 14.6 2.97 1 
Amikacin 0.22 >11.73 2.94 ND ND ND - 32.8 16.8 4 ± 8 
p-aminosalicyclic acid 0.09 >3.06 0.97 ND ND ND - Low 41.9 75 (50-75) 
Cycloserine 2.14 >2.04 2.94 ND ND ND - ND ND 0 
Ethionamide 0.34 >3.33 0.70 14.6 57.3 29.6 0.5 210 77.1 30 
Rifabutin 0.01 >16.94 0.21 63.2 12.4 17.4 1.4 16.2 27.4 85 
Rifapentine 0.02 >17.54 0.11 19.3 7.68 15 1.95 9.1 11.2 97
#
 
Moxifloxacin 0.11 >8.03 2.76 0.22 17.2 29.1 1.7 Low 0.78 50 
Levofloxacin 0.30 >7.23 3.1 0.02 8.23 17.3 2.1 Low 4.32 30 (24-38) 
Gatifloxacin 0.07 >7.49 2.8 0.06 8.65 19.4 2.2 0.94 4.01 20 
Ciprofloxacin 0.31 - - - - - - - - 40 
Ofloxacin 0.56 >7.23 2.11 0.02 9.25 20.1 2.2 2.77 5.8 25 ± 6 
Sparfloxacin 0.08 >7.85 0.99 0.59 28.8 31.2 1.1 0.14 2.63 45 
Capreomycin 0.67 >13.37 ND 0.09 ND ND  8.24 0.80 - 
Thioacetazone 0.05 - 0.16 ND 3.87 57.2 14.8 5.78 4.75 95 
Linezolid 0.51 >6.75 1.97 0.05 18.1 31.2 1.7 2.98 0.89 30 





Clarithromycin - - 0.57 19.5 1.31 54.3 41.4 7.82 41.1 77 (70-80) 
Amoxicillin >29.23 >7.31 2.22 ND ND ND - Low 6.48 25 
Clavulanate >15.93 >3.98 >5 0.46 37.5 21.4 0.6 3.8 1.46 9 
Meropenem >30.68 >7.67 >5 ND ND ND - ND ND 13 
Clofazimine 0.12 >9.47 <0.005 2.58 0.17 0.18 1.0 Low Low 70 
Metronidazole >136.93 >3.42 1.34 0.59 39.8 27.6 0.7 3.98 Low 4 
Thioridazine 5.21 >7.41 2.57 91 3.8 5.0 1.3 107 44.6 96.6
#
 
Mefloquine 3.78 4.20 / 2.80 - - - - - - - 98.2 
Vancomycin 11.01 >28.99 - - - - - - - 30 
Valnemulin 0.68 - >5 ND ND ND - Low 0.62 94
#
 
PNU-100480 0.18 - 0.45 92.8 5.54 5.9 1.1 0.91 1.41 78
#
 
PA-824 0.3 >7.19 0.03 16.8 47.6 30.2 0.6 1.3 5.78 56
#
 
Bedaquiline 0.18 >11.11 <0.005 ND ND ND - Low 2.33 99.9
#
 





   10% (3) 62% (13) 10% (2)   90% (27) 93.3% (28) 66% (23) 
Moderate
$
   33% (10) - 19% (4)   3.3% (1) 6.7% (2) 20% (7) 
High
$
   47% (14) 38% (8) 71% (15)   6.7% (2) - 9% (3) 
Very high
$
   10% (3) - -   - - 6% (2) 
MIC50, minimum inhibitory concentration; *CC50, Cytotoxicity was measured in HepG2 (human hepatocellular carcinoma) and BHK21 (baby hamster 
kidney) cell lines. The highest concentration tested was equivalent to 20 µM, with all compounds having a CC50 >20 µM in both cell lines apart from 
mefloquine. For comparison purpose, CC50 values in the table are expressed in mg/L; -, Not tested; ND, not detected or data not available due to 
analytical/technical issues; 
$
Compounds were grouped into various categories based on the following cut-offs. Solubility: low, <0.05 mg/mL; moderate, 0.05-
1 mg/mL; high, 1-5 mg/mL and very high, >5 mg/mL. PAMPA (Parallel artificial membrane permeability assay): low, <10 Papp 10
-6
 cm/s; and high >10 Papp 
10
-6
 cm/s. Caco-2 permeability: low, <1 Papp 10
-6
 cm/s; moderate, 1-5 Papp 10
-6
 cm/s; and high >5 Papp 10
-6
 cm/s. Clint (intrinsic clearance): low, <50 
µL/min/mg of protein; moderate, 50-150 µL/min/mg of protein; and high >150 µL/min/mg of protein. PPB, human plasma protein binding obtained from 
published literature (Section 3.2.6); 
#
human PPB predicted using Gastroplus
TM
 8.5, simulations Plus, Inc. (www.simulations-plus.com); PPB: low <70; 
moderate 70-95, high 95-99, very high >99%. Numbers in parentheses indicate the number of compounds in each group. 
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3.3.4 Mouse in vivo PK and in vivo efficacy 
Mouse in vivo PK and efficacy data were either retrieved from the literature or 
generated as part of this study (Table 6). 14 compounds were chosen having 
good anti-mycobacterial activity (MIC < 10 mg/L) and that are administered 
orally. Doses were selected based on the efficacious exposure observed in 
humans. Based on the MIC50 and PK parameters, plasma PK-PD indices 
(fCmax/MIC, fAUC/MIC and fT>MIC) were calculated and corrected for plasma 
protein binding to reflect the free drug fraction (indicated by “f”). Anti-TB 
compounds studied displayed wide range of fCmax/MIC, fAUC/MIC and fT>MIC 
(Table 6). Overall, unbound peak concentrations (Cmax) were above the MIC at 
some point during the dosing interval, except for compounds with high plasma 
protein binding such as mefloquine, clofazimine and bedaquiline (Table 6 and 
9).  
The mean log CFU reduction at 2- and 4-weeks post dosing ranged 
between 0.5 and 6.7 (Table 6). Cycloserine displayed very poor efficacy in 
murine model of TB. The current clinical candidates, moxifloxacin, PA-824, 
bedaquiline and PNU-100480 showed good efficacy with 3.3 to 6.7 log CFU 
reductions. Among the four first line anti-TB compounds, isoniazid showed 
good efficacy (4.5 to 5 log reductions) compared to other three drugs i.e., 
rifampicin, ethambutol and pyrazinamide (0.5 to 2.5 log CFU reductions). 
Except for PA-824 – for which efficacy is driven by the fraction of the dosing 
interval during which free plasma concentration exceeds the MIC or fT>MIC 
(Ahmad et al., 2011) – the efficacy of all compounds tested (rifampicin, 
isoniazid, moxifloxacin, PA-824 and bedaquiline) was concentration-
dependent, i.e. either fAUC/MIC and/or Cmax/MIC best correlated with lung 
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cfu reduction (Jayaram et al., 2003; Jayaram et al., 2004; Rouan et al., 2012; 
Shandil et al., 2007). 
However, no clear trend in correlations between PK-PD indices across 
compounds and mean log cfu reduction was observed. This is an important 
observation and clearly shows that simple PK-PD rules of thumb cannot be 
used to guide the discovery and development of novel TB drugs (Dartois and 
Barry, III, 2013). This feature is specific of TB drugs, which are in stark 
contrast with many other antibacterials for which plasma PK-PD indices 
usually fall within relatively narrow and reasonably predictive windows 
(Scaglione and Paraboni, 2006). The complexity of the TB pathology, where 
the pathogen resides in remote lesion compartments, likely contributes to the 
lack of correlation between plasma PK and efficacy (Dartois, 2014).  
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Mean  Δlog cfu reduction ± SD 
        
   2 weeks 4 weeks 
Isoniazid* 25 28.2 52.2 0.25 1.7 42 0.04 408.9 756.9 62 4.53 ± 0 5.2 ± 0 
Rifampicin* 10 10.58 139.7 1.33 7.61 83 0.02 89.9 1187.5 100 0.98 ± 0.40 2.37 ± 0.37 
Pyrazinamide* 150 146.1 303.8 0.42 1.05 42 9.85 8.6 17.9 15 0.46 ± 0.25 1.29 ± 0.2 
Ethambutol
#
 100 6.44 19.79 1.5 1.49 25 0.6 8.1 24.7 25 1.4 ± 0.34 1.9 ± 0.31 
Cycloserine
#@
 175 214.28 209.73 0.25 0.67 0 2.14 100.1 98.0 20 -0.19 ± 0.73 ND 
Ethionamide
#
 12.5 0.57 0.21 0.08 0.28 30 0.34 1.2 0.4 0.6 1.58 ± 0.36 2.56 ± 0.52 
Moxifloxacin* 200 4.53 23.58 0.5 4.03 60 0.11 16.5 85.7 70 3.28 ± 0.24 4.44 ± 0 
Linezolid*
@
 100 65 73.4 0.33 0.65 31 0.51 87.9 99.3 19 1.35 ± 0.90 2.13 ± 0.70 
PA-824
#
 100 16.25 276.11 4 3.28 89 0.3 6.0 101.2 52 5.94 ± 0 6.74 ± 0 
Bedaquiline*
@
 12.5 0.55 9.7 2 58.6 99 0.18 0.03 0.5 0 4.33 ± 0 4.64 ± 0 
Mefloquine
#
 25 1.8 30.84 4 23.18 80 3.78 0.1 1.6 0 0.64 ± 0.58 1.2 ± 0.35 
PNU-100480 100 ND ND ND ND ND ND ND ND ND 5.32 ± 0.16 6.65 ± 0.40 
Clofazimine
#
 25 0.94 37.6 8 32 99.8 0.12 0.02 0.6 0 2.05 ± 0.28 3.96 ± 0.32 
Valnemulin
#
 25 0.92 5.0 1 5.3 80 0.68 0.3 1.5 0 0.47± 0.28 0.91 ± 0.34 







0.46 – 5.94 0.91 – 6.74 
Cmax, maximum concentration reached in plasma; AUC, area under curve representing the exposure; Tmax, time to reach maximum concentration; t1/2, elimination half-life; 
PPB: plasma protein binding; MIC, minimum inhibitory concentration; fCmax/MIC, ratio of peak plasma concentration (Cmax) to the minimum inhibitory concentration (MIC); 
fAUC/MIC, ratio of area under curve to MIC; fT>MIC, 24 h period during which the compound concentration exceeded the MIC. “f” refers to free fraction. Mean Δlog cfu 
reduction: log10 of cfu reduction compared to untreated controls. Mean value ± SD from 5 animals are provided. *PK data from published literature (section 3.2.5). Isoniazid 
(Brennan and Young, 2008; Grosset and Ji, 1998), Rifampicin (Brennan and Young, 2008; Grosset and Ji, 1998), Pyrazinamide (Brennan and Young, 2008; Grosset and Ji, 
1998), Moxifloxacin (Gaonkar et al., 2006), Linezolid (Brennan and Young, 2008; Slatter et al., 2002), Bedaquiline (Andries et al., 2005). 
#





estimated based on dose linearity; ND: Not determined 
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3.3.5 Correlations between in silico parameters and in vitro potency and 
in vitro PK parameters 
Mycobacterium tuberculosis possesses a notoriously impermeable cell wall. 
Thus we tested the hypothesis that lipophilicity and permeability could be a 
determinant of in vitro potency. Across all drug classes included in this study, 
no apparent trend or significant correlation was observed between anti-
mycobacterial activity and cLogP, PAMPA or Caco-2 permeability, indicating 
that permeability and/or lipophilicity is not a predictor of activity inside the 
mycobacterium, at least not across this large set of compound classes (Table 
7). Examination of potential correlations within sub-groups of compounds 
(natural products, synthetic molecules, injectables and oral drugs) did not 
reveal any apparent association either (not shown). Within a given series 
however, a positive correlation is often detected between cLogP and potency, 
as recently published for indolcarboxamide and tetrahydropyrazolopyrimidine 
carboxamide series (Kondreddi et al., 2013; Yokokawa et al., 2013). 
 
Table 7. Correlation between MIC and in silico /in vitro parameters 
 
Parameters MIC (mg/L) 
 Spearman r P value significance 
Number of 
compounds 
cLogP -0.23 0.22  ns  30 
PAMPA -0.12 0.63  ns  17 
Caco-2 
permeability 
0.21 0.41  ns  17 
 
ns, not significant (P>0.05).  
 
As expected, some level of correlation was observed between in vitro 
PK and in silico properties. Generally, compounds with MWs lower than 400 
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and cLogP of <4 showed better solubility, Caco-2 permeability and plasma 
protein binding (Figure 21A-F). This is in agreement with Gleeson’s findings. 
Most of the outliers were natural products either belonging to the rifamycin 
class or aminoglycoside injectables.  A significant negative correlation was 
observed between cLogP and solubility, MW and Caco-2 permeability. 
Furthermore, both MW and cLogP showed to be positively correlated with 
PPB . Interestingly, RB seemed to relate to Caco-2 permeability and PPB 
(Table 8). In addition, an apparent trend of correlations was observed between 





                















































































































































Figure 21. Correlation analysis between in silico and in vitro PK parameters 
(A) Solubility versus molecular weight. (B) Solubility versus cLogP. (C) Caco-2 permeability versus molecular weight. (D) Caco-2 permeability 
versus cLogP. (E) Plasma protein binding versus molecular weight. (F) Plasma protein binding versus cLogP. The vertical lines indicate cut-off 
values as defined in Gleeson’s analysis of molecular weight and cLogP. The horizontal lines delineate the boundaries between low, moderate 
and high categories for solubility (A and B), Caco-2 permeability (C and D) and plasma protein binding (E and F). The compounds are 











permeability       
(10
-6
 cm/sec)  (n=21) 
PPB (%) (n=35) 
rs p sig
#
 rs p sig
#
 rs p sig
#
 
MW -0.17 0.364 ns -0.68 0.0006  *** 0.43 0.011  * 
cLogP -0.58 0.0007 *** -0.33 0.149  ns 0.83 <0.0001  *** 
HBD 0.08 0.667 ns -0.38 0.086  ns -0.11 0.542  ns 
HBA 0.09 0.634 ns -0.34 0.136  ns -0.04 0.816  ns 
PSA 0.15 0.429 ns -0.24 0.292  ns -0.09 0.611  ns 




rs is the Spearman’s rank correlations coefficient, p is the level of significance,  
#
significance [***, represents extremely significant (P < 0.001); **, very 
significant (P = 0.001 to 0.01); *, significant (P = 0.01 to 0.05); ns, not 
significant (P > 0.05)], n = number of compounds  
 
3.3.6 Human in vivo PK properties 
Human PK parameters were collected from the literature (Section 3.2.6) and 
are summarized in Table 9. Anti-TB compounds displayed wide range of in 
vivo PK properties with majority of them having low to moderate volume of 
distribution, total systemic clearance and moderate to high oral bioavailability. 
There was a good correlation observed between in vitro and in vivo clearance 
(Table 5 and 9). 
 
3.3.7 Correlations between in silico, in vitro and in vivo parameters 
Further, examination of clinical PK parameters retrieved from the literature 
(Table 9) revealed a moderate-to-high oral bioavailability for compounds 
which follow Lipinski’s rule of 5 and Veber’s rule (Figure 22 A-E) (Lipinski 
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et al., 2001; Veber et al., 2002), as well as compounds with a solubility of >1 
mg/mL and Caco-2 permeability of >5 X 10
-6
 cm/sec (Figure 22 F & G).  
In addition, significant positive correlation was observed between (1) 
cLogP and volume of distribution, an indicator of drug distribution into tissues 
(Figure 23A), (2) cLogP and systemic clearance of the unbound fraction 
(Figure 23B), and (3) cLogP and plasma protein binding (Figure 23C). A 
significant negative correlation was observed for cLogP and oral 
bioavailability (Figure 23D). As expected, lipophilicity emerged as an 
important parameter influencing in vitro and in vivo PK parameters. 
Interestingly, except for cLogP, none of the other physicochemical parameters 
showed any apparent trend or good correlation with in vivo PK properties 
(Table 10). 
3.4 Conclusion 
Drug discovery aims to deliver a candidate that shows efficacy, 
exposure and tolerability in a relevant animal model and in man. In silico and 
in vitro assays are employed in lead finding and optimization, attempting to 
predict these in vivo properties. In the present study, we have comprehensively 
determined and compiled physicochemical parameters, in vitro 
pharmacokinetic properties and potency values of 36 anti-mycobacterials, 
most of which are in clinical use against TB.   
TB drug discovery is challenging and complicated as Mtb is a slow 
growing pathogen, with thick lipid cell wall (Ma et al., 2010). Further, the 
biology of TB is intricate as organisms reside in multiple complex 
histopathological manifestations such as calcified granulomas, necrotic and 
caseous lesions in lungs (Barry, III et al., 2009).  
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Isoniazid 300 5.4 ± 2.0 100 0.67 ± 0.15 7.4 ± 2.0 139.0 
Rifampicin 600 14.91 70 0.97 ± 0.36 3.5 ± 1.6 72.5 
Pyrazinamide 1500 38.7 ± 5.9 70, 97 
0.57 (0.13 – 
1.04) 
1.1 (0.2 – 2.3) 3.5 
Ethambutol 1200 5 77 ± 8 1.6 ± 0.2 8.6 ± 0.8 5.8 
Streptomycin 1000 25-50 - 0.34 0.78 262 
Kanamycin 1000 22 - 0.26 1.4 28.8 






9-35 (20) 60 1.4 - 58.3 













70 - 0.56 19.1 
Moxifloxacin 400 4.3 86 ± 1 2.05 ± 1.15 2.27 ± 0.24 19.8 
Levofloxacin 500-750 6.2 (6-10) 99 ± 10 1.36 ± 0.21 2.52 ± 0.45 14.5 
Gatifloxacin 400 3.8 ± 1.0 96 
1.7 (1.5 – 
2) 
2.8 (2.7 – 3.0) 40.6 
Ciprofloxacin 250-750 2.4 60 ± 12 2.2 ± 0.4 7.6 ± 0.8 4.6 
Ofloxacin 1000 3 >95 1.8 ± 0.3 3.5 ± 0.7 4.0 
Sparfloxacin 200 1.1 - 3.9 2.7 7.3 
Capreomycin 1000 32 (20-47) - 0.25-0.4 - - 
Thioacetazone 150 - - - - - 
Linezolid 600-1200 12.9 100 0.58 1.8 17.6 
Prothionamide 250-750 3-4 - 2-3 - 8.6 
Clarithromycin 200-500 0.6 ± 0.43 55 ± 8 1.5 7.3 - 
Amoxicillin 500 8-10 93 ± 10 0.21 ± 0.03 2.6 ± 0.4 0.2 
Clavulanate 250 5-7 90 0.22 3.1 0.3 
Meropenem - - - 0.3 3.9 - 
Clofazimine 200 0.5-2 45-62 20 - 3.0 




- 21 ± 9 8.6 ± 2.9 0.6 
Mefloquine 1250 2.21 ± 0.51 - 19 ± 6 0.43 ± 0.14 0.01 
Vancomycin 1000 65.7 ± 7.9 - 0.54 1.3 4.2 
Valnemulin - - - - - - 
PNU-100480 1000 0.84 - - - 1.0 
PA-824 200 1 - - 2.14 2..8 
Bedaquiline 400 3-8 - - - 0.03 
Delamanid 200 0.23 - - - 0.03 
Range   
20 – 
100 
0.2 – 21 0.43 – 8.6  
Low
#





   30% (6) 38% (11) 20% (5)  
High
#
   
65% 
(13) 
14% (4)   
 
All clinical PK values were obtained from published literature as mentioned in 
material and methods section 3.2.6. Cmax, maximum concentration reached in plasma; 
F, oral bioavailability; Vd, volume of distribution; CL, clearance; fCmax/MIC, ratio of 
free maximum plasma concentration to minimum inhibitory concentration. Dash (-): 
data not available; 
#
compounds are grouped into various categories based on the 
following cut-offs. F: low <30, moderate 30-70, high >70%; Vd: low <1; moderate 1-
5; high >5 L/Kg; CL: low <5, moderate 5-15 mL/min/Kg; Numbers in the parenthesis 
indicate the number of compounds in each group. 
 

















































































F Grs = 0.66, p = 0.002 rs = 0.54, p = 0.046
rs = -0.48, p = 0.034
rs = -0.62, p = 0.003 rs = -0.21, p = 0.367
rs = -0.33, p = 0.161
rs = -0.42, p = 0.062
 
Figure 22. Correlation between in silico and in vitro properties and oral 
bioavailability in humans 
(A) molecular weight; (B) hydrogen bond donors; (C) hydrogen bond 
acceptors; (D) polar surface area; (E) rotatable bonds; (F) solubility; (G) Caco-
2 permeability. Vertical lines indicate the cut-off values as defined in 
Lipinski’s rule of 5 (A-C) and Veber’s rule (D and E). Horizontal lines 
delineate the boundaries between low, moderate and high categories for oral 
bioavailability. Double vertical lines delineate the boundaries between low, 
moderate and high categories for solubility (F), and Caco-2 permeability (G). 
Note the significant positive correlation observed between oral bioavailability 
and solubility, and oral bioavailability and Caco-2 permeability. The 
compounds are categorized as synthetic molecules (blue open squares) and 
natural products (red filled squares) based on their origin (Table 3). rs is the 




























































































C Drs = 0.83, p = 0.0001
rs = 0.72, p = 0.0001rs = 0.79, p = 0.0001
rs = -0.47, p = 0.037
 
Figure 23. Correlation between cLogP and volume of distribution (A), 
unbound clearance (CLu), (B) plasma protein binding (C) and oral 
bioavailability (D) 
A significant positive correlation was observed between cLogP and volume of 
distribution, cLogP and unbound clearance (ratio of clearance and unbound 
fraction (Giuliano et al., 2005)), and cLogP and plasma protein binding. A 
significant negative correlation was observed between cLogP and oral 
bioavailability. The compounds are categorized as synthetic molecules (blue 
open squares) and natural products (red filled squares) based on their origin 
(Table 3). rs is the Spearman’s rank correlations coefficient and p is the level 
of significance. 
 
Novel chemical entities have to be potent with favorable 
physicochemical properties to pass through these barriers and kill actively 
replicating and non-replicating Mtb in order to cure the disease. Anti-TB drugs 
studied displayed wide range of physicochemical properties. Acceptable 
solubility, permeability and plasma protein binding were displayed by 
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molecules with molecular weight <400 and cLogP <4. Good oral 
bioavailability observed with good solubility and permeability. 




Vd (L/kg) (n=29) 
CL (mL/min/kg)  
(n=25) 
F (%) (n=20) 
rs p sig
#
 rs p sig
#
 rs p sig
#
 
MW 0.03 0.87 ns 0.22 0.293 ns -0.48 0.034 * 
cLogP 0.79 <0.0001 *** 0.72 <0.0001 *** -0.47 0.037 * 
HBD -0.45 0.014 * -0.07 0.755 ns -0.62 0.003 ** 
HBA -0.49 0.006 ** -0.19 0.349 ns -0.21 0.367 ns 
PSA -0.56 0.001 ** -0.27 0.197 ns -0.33 0.161 ns 







-0.42 0.062 ns 
Solubili
ty 










rs is the Spearman’s rank correlations coefficient, p is the level of significance,  
#
significance [***, represents extremely significant (P < 0.001); **, very 
significant (P = 0.001 to 0.01); *, significant (P = 0.01 to 0.05); ns, not 
significant (P > 0.05)], n = number of compounds  
 
Various in vitro and in vivo PK properties were influenced by 
lipophilicity. Positive correlation was observed with volume of distribution, 
clearance and plasma protein binding and negative correlation with solubility 
and oral bioavailability. Overall, lipophilicity is one of the important 
parameter that influences various PK properties. Co-incidentally, the majority 
of the NCE’s identified and optimized recently, such as 
pyrazolocarboxamides, imidazo-pyrimidines (Pethe et al., 2013), 
indolecarboxamides (Kondreddi et al., 2013; Onajole et al., 2013; Rao et al., 
2013), adamantyl urea (Grzegorzewicz et al., 2012), spiroindoles (Remuinan 
et al., 2013), bedaquiline (Andries et al., 2005) and delamanid (Matsumoto et 
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al., 2006) have cLogP >5. Although increasing lipophilicity may help in 
gaining potency, it could be detrimental to other properties and most often 
leading to poor solubility which limits oral absorption (van de Waterbeemd et 
al., 2001), thus lowering the exposure multiples. All the above compounds 
were identified by cell-based drug discovery approaches and it is possible that 
whole cell-screening against Mtb (with highly lipid rich cell wall) may 
preferentially identify lipophilic hits. Since, higher lipophilicity poses drug 
development challenges; it is appropriate to start with small and polar 
compounds during drug discovery. This provides enough space for medicinal 
chemistry based optimization of hit during the lead optimization phase. We 
hope that this standardized data set represents a useful reference for the TB 














pharmacodynamics analysis of bicyclic 4-





PA-824 (Stover et al., 2000) and OPC-67683 (Matsumoto et al., 2006) are two 
bicyclic 4-nitroimidazoles currently in phase II clinical trials, representing a 
promising new class of therapeutics for TB (Kaneko et al., 2011). Preclinical 
testing of PA-824 showed bactericidal activity in various in vitro and in vivo 
models (Lenaerts et al., 2005; Tyagi et al., 2005). PA-824 was shown to be 
well tolerated in healthy subjects, following oral daily doses for 7 days 
(Ginsberg et al., 2009). These results, combined with the demonstrated activity 
of PA-824 against drug-sensitive and multidrug-resistant Mtb, supported the 
progression of this compound and its evaluation as a novel treatment against 
TB. An early bactericidal activity (EBA) study of PA-824 revealed a lack of 
dose-response between 200 and 1200 mg administered daily for 14 days 
(Diacon et al., 2010). Dose-fractionation PK-PD studies in mice showed the 
PK-PD driver of PA-824 to be the time during which the free drug 
concentrations in plasma were above the MIC (fT>MIC) (Ahmad et al., 2011). 
In retrospect, clinical investigators established that fT>MIC was 100% at all 
doses between 200 and 1200 mg daily. An additional phase II trial between 50 
and 200 mg was undertaken to establish the lowest efficacious dose (Diacon et 
al., 2012a). 200 mg of PA-824 was found to be efficacious and used in 
combination with other anti-TB drugs (Diacon et al., 2012b).  
Physicochemical properties, in vitro potency, in vitro and in vivo 
pharmacokinetics (PK) are critical determinants for in vivo efficacy. PA-824 is 
highly lipophilic and exhibits poor aqueous solubility. To overcome the 
limitation of its low solubility and improve its oral bioavailability, a 
cyclodextrin formulation was developed and used for in vivo animal efficacy 
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studies (Lenaerts et al., 2005; Stover et al., 2000). Extensive lead optimization 
efforts were undertaken to improve aqueous solubility, metabolic stability, in 
vitro potency and in vivo efficacy of anti-tubercular nitroimidazoles and 
various analogs were synthesized (Barry et al., 2011; Blaser et al., 2012; 
Cherian et al., 2011; Denny and Palmer, 2010; Jiricek et al., 2007; Kim et al., 
2009a; Kim et al., 2009b; Kmentova et al., 2010; Matsumoto et al., 2006; 
Palmer et al., 2010; Thompson et al., 2011). Comprehensive in vivo 
pharmacology studies are generally resource and time intensive. This is 
particularly true for TB because of the slow rate of M. tuberculosis growth, 
lengthy treatment duration and requirement of high containment facility. In 
this study, a panel of closely related potent bicyclic 4-nitroimidazoles (NI) was 
profiled both in vitro and in vivo. The data were retrospectively analyzed to 
identify the PK parameters that correlate with in vivo efficacy of a series of 
bicyclic 4-nitroimidazoles. The results of this investigation showed that PK 
properties such as volume of distribution and lung exposure predicts in vivo 
efficacy of bicyclic 4-nitroimidazoes better than other PK parameters. Thus, in 
vitro potency and lung PK could be used as surrogate to guide the 
prioritization of new pre-clinical candidates for lengthy efficacy studies, there 









4.2 Materials and Methods 
 
4.2.1 Chemicals 
Synthesis of PA-824, Amino-824, AminoEthyl-824, NI-135, NI-147 and NI-
136 have been previously reported (Cherian et al., 2011; Kim et al. 2009a). 
Other NI analogs NI-622, NI-644, NI-176, NI-269, NI-182, NI-145, NI-297 
and NI-302 have been described in two patents (Barry et al., 2011; Jiricek et 
al., 2007) and synthesis of these compounds to be described elsewhere. All 
solutions were made as 20 mM stocks in DMSO. Hydroxypropyl-β-
cyclodextrin, Lecithin, granular was purchased from Acros/Organics, New 
Jersey, and USA.  
 
4.2.2 In vitro potency 
M. tuberculosis (Mtb) (H37Rv, ATCC 27294) culture conditions have been 
described previously (Cherian et al., 2011). Minimum Inhibitory concentration 
(MIC99) against wild type Mtb H37Rv and cofactor F420 deficient (FbiC 
mutant) (Manjunatha et al., 2006) was determined by the broth dilution 
method as described earlier (Cherian et al., 2011). 
 
4.2.3 In vitro physicochemical properties 
In vitro physicochemical and PK parameters like solubility, log P, PAMPA, 
Caco-2 permeability and mouse plasma protein binding were determined in-
house in medium to high throughput format assays. Briefly, solubility was 
measured using a high throughput equilibrium-solubility assay using a novel 
miniaturized shake-flask approach and streamlined HPLC analysis (Zhou et 
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al., 2007); lipophilicity determination was carried out in 96-well micro titer 
plates and the diffusion of compounds between two aqueous compartments 
separated by a thin octanol liquid layer was measured (Wohnsland and Faller, 
2001); PAMPA permeability experiments were carried out in 96-well micro 
titer filter plates at absorption wavelengths between 260 and 290 nm (Avdeef 
et al., 2007); Caco-2 permeability assay was carried out in a 96-well format, 
and compound concentrations in each chamber were measured by LC/MS as 
described previously (Marino et al., 2005) and plasma protein binding was 
determined in mouse plasma using an ultra-filtration method (Fung et al., 
2003). 
 
4.2.4 In vivo PK studies 
All animal experimental protocols (protocol # 023/2009 and # 025/2009 for 
PK; protocol # 004/ 2010 for efficacy) involving mice were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) of 
Novartis Institute for Tropical Diseases. The animal research complied with 
Singapore Animal Veterinary Authority and global Novartis policy on the care 
and use of animals. Experimental and control animals infected with Mtb were 
euthanized at the end of the experiment. All procedures during 
pharmacokinetic experiments were performed under isoflurane anesthesia and 
all efforts were made to minimize suffering. 
Female CD-1 mice obtained from Biological Resource Center in 
Singapore were used for in vivo PK studies. Mice were acclimatized before 
initiation of pharmacokinetic (PK) experiments. Feed and water were given ad 
libitum.  The compounds were formulated at a concentration of 1, 2.5 or 5 
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mg/mL for a dose of 10 mg/kg (Amino-824, AminoEthyl-824) or 25 mg/kg 
(PA-824, NI-135, NI-147, NI-136, NI-176, NI-269, NI-182, NI-145, NI-297 
and NI-302) or 50 mg/kg (NI-622 and NI-644) given orally and at 1 or 2 
mg/mL concentration for a dose of 5 or 10 mg/kg given intravenously. For 
dose proportionality studies PA-824, NI-622 and NI-644 were administered at 
a dose of 10 and 250 mg/kg. The CM-2 formulations were prepared in 10% 
w/v hydroxypropyl-β-cyclodextrin and 10% v/v lecithin in water as described 
earlier (Lenaerts et al., 2005; Tyagi et al., 2005). The formulation was 
centrifuged and the supernatant was collected for intravenous administration. 
After oral dosing, blood and lung samples from mice were collected at various 
time points ranging from 0.08 h (but 0.02 h for i.v dosing) to 48 h. Groups of 
three mice were used for each time point.  Blood was centrifuged at 13,000 
rpm for 7 min at 4 ºC, plasma was harvested and stored at -20 ºC until 
analysis. Lung tissue samples were excised, dipped in PBS, gently blotted with 
absorbent paper, dried, weighed and stored at -20 ºC until further analysis. 
For LC/MS/MS analysis, 50 µL of plasma samples were precipitated 
using 400 µL of acetonitrile:methanol:acetic acid (90:9.8:0.2) containing 500 
ng/mL of either related compound or warfarin as internal standard. After 
vortexing and centrifuging the mixture, the supernatant was removed and 5 µL 
of sample analyzed. Whole lung tissue was homogenized in 2 mL of PBS. 50 
µL of lung homogenate was taken and processed as described above for 
plasma samples. The standard calibration curve was prepared by spiking blank 
plasma and lung tissue with different concentrations of the compound. In 
addition, quality control samples with three different concentrations were 
prepared in respective blank matrix and analyzed together with the unknown 
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samples for validation purposes. Analyte quantitation was performed by 
LC/MS/MS using optimized conditions for each compound. Liquid 
chromatography was performed using an Agilent 1100 HPLC system (Santa 
Clara, CA), with the Agilent Zorbax XDB Phenyl (3.5µ, 4.6x75 mm) column 
at an oven temperature of  35 ºC and 45 ºC, coupled with a triple quadruple 
mass spectrometer (Applied Biosystems, Foster City, CA). Instrument control 
and data acquisition were performed using Applied Biosystems software 
Analyst 1.4.2. The mobile phases used were A: water-acetic acid (99.8:0.2, 
v/v) and B either as: acetonitrile-acetic acid (99.8:0.2, v/v) or methanol-acetic 
acid (99.8:0.2, v/v), using a gradient, with a flow rate of 1.0 mL/min, and a run 
time of 6 to 8 min. Under these conditions the retention times of various 
compounds ranged between 3.2 and 6.5 minutes. Multiple reaction monitoring 
(MRM) was combined with optimized mass spectrometry parameters to 
maximize detection specificity and sensitivity (Appendix 3). Most of the 
compounds were analyzed using electrospray ionization in the positive mode. 
The recovery of the compound from both plasma and lung tissue were good 
and consistent across the concentration range studied.  The lower limit of 
quantification for different compounds ranged between 1 and 49 ng/mL in 
plasma and 1 and 132 ng/g in lungs. Calibration curve was prepared freshly 
and analyzed with every set of study samples. Intraday variability was 
established with triplicate quality control samples at three concentration levels. 
The results were accepted if relative standard deviation was less than 15%.  
Mean values of compound concentrations in plasma and lungs were 
obtained from three animals at each time point and plotted against time to 
generate concentration-time profiles. PK parameters were determined using 
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Phoenix WinNonlin, version 6.3 (Pharsight, A Certara company, USA, 
www.pharsight.com), by non-compartmental modeling using built-in model 
(200 – 202) for extravascular and intravenous bolus dosing. The oral 
bioavailability (F) was calculated as the ratio between the area under the curve 
(AUCinf) following oral administration and the AUCinf following intravenous 
administration corrected for dose (F = AUCp.o * dosei.v./AUCi.v * dosep.o). 
 
4.2.5 In vivo mouse efficacy studies  
In vivo mouse efficacy studies were determined after intranasal infection of 
Balb/c mice with 10
3 
cfu Mtb H37Rv. Treatment was initiated 4 weeks after 
infection. Compounds were orally administered at 25 mg/kg and 100 mg/kg in 
CM-2 formulation for 4 weeks daily. Bacterial loads were determined at 2 and 
4 weeks post treatment (Rao et al., 2013). Statistical analysis was done by a 
one-way analysis of variance, followed by a multiple comparison analysis of 
variance by a one-way Tukey test (GraphPad Prism, version 5.02, San Diago, 
California USA, www.graphpad.com). Differences were considered 
statistically significant at the 95% level of confidence (Lenaerts et al., 2005). 
 
4.2.6 Calculation of PK-PD parameters 
The MIC against Mtb was used to calculate PK-PD indices (Cmax/MIC, 
AUC/MIC and T>MIC). The Cmax/MIC was defined as the ratio of peak plasma 
concentration (Cmax) to the MIC, the AUC/MIC was defined as the ratio of the 
AUC0-24 to the MIC, and the time above MIC (T>MIC) was defined as 24 h 
period during which the total compound concentration exceeded the MIC. 
Cmax/MIC and AUC/MIC were calculated as ratios from PK parameter 
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obtained from non-compartmental analysis and MIC. T>MIC were derived from 
Phoenix WinNonlin software by specifying MIC as therapeutic response and 
time above therapeutic response was obtained. Using plasma protein binding, 
unbound concentrations in plasma were calculated, PK parameters were 
derived from Phoenix WinNonlin and PK-PD indices were defined as 
fCmax/MIC, fAUC/MIC and %fT>MIC where ‘f’ refers to free concentration. For 
calculation and plotting of mean concentration-time curve, concentrations 
indicated as below the lower limit of quantification (LLOQ) were replaced by 
0.5*LLOQ. Ignoring the values here would impact some of the PK-PD 
parameters. This approach has no impact on pharmacokinetic parameter 
calculations (Duijkers et al., 2002). 
 
4.2.7 PK-PD analysis  
PK-PD indices were estimated from the plasma and lung drug concentrations, 
in vitro potency and plasma protein binding.  A Spearman’s rank correlation 
(Djukic et al., 2012; Ferl et al., 2007) was run to determine the relationship 
between various PK parameters and mean log CFU reduction using Prism 





4.3.1 In vitro potency and physicochemical properties 
In an effort to improve the solubility and potency of PA-824, diverse structural 
analogs of PA-824 were synthesized and their in vitro activities reported 
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(Barry et al., 2011; Cherian et al., 2011; Jiricek et al., 2007; Kim et al., 2009a; 
Kim et al., 2009b).  A few potent bicyclic 4-nitroimidazole analogs were 
selected and characterized in detail (Figure 24). In vitro Mtb potency and 
physicochemical properties of these nitroimidazole analogs are summarized in 
Table 11. All the NI analogs studied showed Mtb specific growth inhibitory 
activity and no cytotoxicity was observed in THP1 macrophage cell lines 
(Table 11). F420 deficient (FbiC) mutants were resistant to all these bicyclic 4-
nitroimidazoles analogs (Table 11), suggesting a mechanism of action similar 
to PA-824, involving F420-dependent bio-activation (Manjunatha et al., 2006). 
Modifications on the benzyl ring (NI-135, NI-147, NI-136 and NI-176), and 
oxazine ring (NI-269, NI-182, NI-145, NI-297, NI-302 and NI-176) showed 
significant improvement of in vitro potency compared to PA-824. The 
nitroimidazole (NI) analogs tested in this study displayed a wide range of 
solubility (<2 to 127 µg/mL). Amino-nitroimidazoles showed improved 
solubility compared to their respective benzyl ether analogs (Amino-824 
versus PA-824 and NI-269 versus NI-145).  NI-297, a biphenyl derivative of 
NI-182, had very poor aqueous solubility (<2 µg/mL) due to its high 
lipophilicity (logP 6).  In general, the logP of all the other NI derivatives 
ranged between 2.4 and 3.8 and all showed high permeability except NI-644, 
which had moderate permeability in the Caco-2 assay. Overall the compounds 
exhibited moderate-to-high mouse plasma protein binding (80 to 98%), except 
for AminoEthyl-824, which showed the lowest binding (45%). 
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       A-B B-A B-A / A-B  
PA-824 0.30 > 10 > 10 13.0 2.75 -4.2, 99 27.6 20.4 0.8 90 
NI-622 0.18 > 10 > 10 28.2 2.9 -5.3, 31 9.5 12.4 1.3 97 
NI-644 0.09 > 10 > 10 14.0 2.6 -4.9, 83 2.8 13.7 4.8 90 
Amino-824 0.14 > 10 > 10 127 2.5 -4.8, 91 35.4 21.0 0.6 80 
AminoEthyl-824 0.06 > 10 > 10 104 3.6 -4.6, 85 18.6 20.7 1.1 45 
NI-135 0.03 > 10 > 10 77.0 3 -4.5, 90 23.4 15.3 0.6 91.5 
NI-147 0.03 > 10 nd 56.0 2.4 -5.2, 43 nd nd 
NI-136 0.03 > 10 > 10 43.0 2.6 -4.7, 83 15.4 12.6 0.8 82.7 
NI-176 0.03 > 10 > 10 8.0 3.5 -3.7, 99 nd nd 
NI-269 0.03 > 10 > 10 12.0 3.15 -3.7, 99 nd nd 
NI-182 0.02 > 10 > 10 32.0 3.05 -3.8, 99 18.3 13.9 0.8 91.3 
NI-145 0.06 > 10 > 10 <2.0 3.85 -3.85, 99 nd nd 
NI-297 0.02 > 10 > 10 <2.0 6 -4.1, 97 nd 98.2 
NI-302 0.03 > 10 > 10 26.0 3.2 -3.6, 99 45.1 18.7 0.4 95.7 
 
MIC99=Minimum Inhibitory Concentration required to reduce the bacterial growth by 99%, MIC against both H37Rv (wild type) and F420 
deficient (FbiC) mutants were tested. PAMPA = Parallel Artificial Membrane Permeability Assay, Caco-2 = Permeability using colon carcinoma 
cell lines, PPB= Plasma Protein Binding, Pe = effective permeability, FA = fraction absorbed, Papp = apparent permeability, A-B = Apical to 
Basolateral, B-A = Basolateral to Apical, nd = not determined, CC50 = Cytotoxicity against THP1 macrophage cell lines was determined as 
described previously (Pethe et al., 2010), with Puromycin as positive control (CC50 = 1.4 mg/L).  
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4.3.2 In vivo plasma PK properties 
Each compound was subjected to intravenous and oral mouse PK in CM-2 
formulation. The total compound concentration in mouse plasma was 
measured and free plasma concentrations were calculated using in vitro 
plasma protein binding (Table 11 and 12). NI-147 with a hydroxyl functional 
group on the benzyl ring, displayed markedly inferior PK properties (Table 12, 
Figure 25). The poor PK is likely due to glucuronidation of the hydroxyl group 
as suggested by the presence of an extra peak corresponding to + 176 Da in 
the mass spectrometry analysis. Hence NI-147 was not included in in vivo 
mouse efficacy studies. The NI analogs displayed a wide range of volume of 
distribution (Vss = 0.7 to 4.2 L/kg) corresponding to 1.1 to 7 times total body 
water. NI-135 showed higher Vss (4.2 L/kg), followed by NI-182, NI-297 and 
NI-269 (2.6 to 3 L/kg). All other analogs showed moderate Vss similar to PA-
824, except for NI-644, which showed a low volume of distribution (Vss = 0.7 
L/kg). The total systemic clearance was low to moderate (4 to 44 mL/min/kg) 
corresponding to 5 to 49% of hepatic blood flow. NI-135 and AminoEthyl-824 
showed moderate clearance (41 and 44 mL/min/kg respectively). All other 
analogs showed clearance similar to PA-824 (10 to 25 mL/min/kg), except for 
NI-297 and NI-302, which showed very low clearance (5 mL/min/kg). The 
elimination half-life ranged between 0.7 h and 6.7 h for the NI analogs 
studied. NI-297, NI-135 and NI-302 showed long half-life (3.7 to 6.7 h). All 
other analogs showed half-life similar to PA-824 (1.3 to 2.8 h), except for NI-
644 and AminoEthyl-824, which showed short half-life (<1 h). Generally, the 
NI analogs at comparable doses displayed rapid absorption (Tmax, 0.3 to 4 h), 
except for NI-297, which showed delayed absorption with a Tmax of 8 h, 
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possibly due to its higher lipophilicity and lower solubility. The peak plasma 
concentration (Cmax) ranged between 1.2 µg/mL and 12.9 µg/mL and exposure 
(AUC) ranged between 4.8 µg·h/mL and 144 µg·h/mL (Table 12). NI-135 had 
significantly lower plasma Cmax, exposure and oral bioavailability compared to 
PA-824, likely due to its three times higher in vivo clearance combined with 
higher volume of distribution. On the contrary, NI-302 and NI-297 had higher 
systemic plasma exposure mostly due to decreased in vivo clearance (Table 
12, Figure 25). At comparable dose, NI-622 and NI-644 showed similar 
plasma Cmax, exposure and oral bioavailability compared to PA-824. All other 
NI analogs showed moderate plasma exposure and oral bioavailability (64 to 
88%) except for NI-135, NI-297 and NI-302. Despite, NI analogs displayed 
varied aqueous solubility (<2 to 127 ug/mL), in CM-2 formulation all the 
analogs showed moderate to high oral bioavailability (Table 12). Interestingly, 
NI-145 and NI-297 had least solubility (<2 µg/mL), in CM-2 formulation both 
compounds showed good oral bioavailability. The use of CM-2 (lipid coated 
cyclodextrin complexation) formulation is known to improve solubility and 
bioavailability (Stella and Rajewski, 1997). At 25 mg/kg, the free plasma Cmax 
and AUC parameters ranged from 0.1 - 0.8 µg/mL and 0.4 – 5.1 µg·h/mL 
respectively. NI-644 showed similar free plasma concentration as PA-824, 
whereas all other NI analogs showed relatively lower free plasma Cmax and 
exposure (Table 18).  
89 
 























PA-824 25 6.0 50.9 2 2.7 100 10 1.6 12.1 1.6 
NI-622 50 14.8 108.4 4 2.1 100 10 1.8 14.7 1.8 
NI-644 50 16.2 89.5 1 3.6 100 10 0.7 9.5 0.9 
Amino-824 10 1.7 6.0 0.3 2.0 74 10 2.3 20.5 2.0 
AminoEthyl-
824 
10 1.0 2.9 1 1.7 76 
10 
2.0 44.0 0.7 
NI-135 25 1.2 4.8 0.5 2.9 51 5 4.2 41.0 4.0 
NI-147 25 0.04 0.02 0.1 0.2 0.3 5 0.4 70.8 0.3 
NI-136 25 2.0 10.7 0.5 2.0 64 5 1.8 25.1 1.3 
NI-176 25 2.2 13.7 1 4.3 86 5 1.8 22.2 1.0 
NI-269 25 2.8 16.0 0.3 3.8 88 5 2.6 19.7 2.1 
NI-182 25 3.5 22.5 0.5 2.0 82 5 3.0 15.2 2.8 
NI-145 25 1.8 16.2 2 4.2 68 5 1.7 17.0 2.0 
NI-297 25 6.0 99.1 8 4.9 100 5 2.6 5.0 6.7 
NI-302 25 12.9 144.1 4 4.1 100 5 1.2 4.3 3.7 
 
Cmax = maximum concentration reached in plasma, AUC24 = exposure between 0 to 24 h, Tmax = time to reach maximum concentration, t1/2 = 
half-life, F = oral bioavailability, Vss = volume of distribution at steady state, CL = total systemic clearance. 
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Figure 25. Plasma concentration time profiles of representative bicyclic 4-
nitroimidazole analogs following an oral administration at a single 25 mg/kg 
dose in mice 
 
4.3.3 In vivo lung PK properties 
The primary and the most important site of Mtb infection in patients is lung 
tissue. To understand the effect of structural changes in the NI molecules on 
lung PK parameters, we measured total compound concentration in mouse 
lungs (Table 13). The NI analogs at 25 mg/kg dose showed a wide range of 
values for lung Cmax (4.2 - 17.8 µg/g), Tmax (0.08 – 2 h) and exposure (18.6 - 
233 µg·h/g). All NI analogs displayed near parallel concentration-time profile 
in plasma and lung tissue, suggesting a rapid equilibrium between these two 
tissues. Interestingly, the lung-to-plasma partitioning varied from 0.5 to 4.6 for 
Cmax and 0.4 to 3.9 for AUCs across the series in correlation with the observed 
volume of distribution (Table 13). NI-135, NI-136, NI-182 and NI-297 
showed lung partitioning of 2.5 to 4.6 fold, and are comparable to PA-824. NI-
622, NI-644, Amino-824 and NI-302 showed lower lung partitioning (<1) 
compared to PA-824. Although, NI-135 and NI-136 showed higher lung to 
plasma ratio (L/P) of 3.6 to 4.6, their absolute lung concentrations were 2.5 to 
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7.5 fold lower than PA-824. On the contrary, NI-302 showed lower lung 
partitioning, but its absolute concentrations were comparable to PA-824 
(Table 13). 


















PA-824 25 17.8 139.9 0.3 4.8 3.0 2.7 
NI-622 50 10.2 71.1 0.5 1.8 0.7 0.7 
NI-644 50 7.5 38.1 1 2.9 0.5 0.4 
Amino-824 10 1.4 4.5 0.5 1.3 0.8 0.8 
AminoEthyl-
824 
10 1.6 5.2 0.5 1.2 1.6 1.8 
NI-135 25 5.5 18.6 0.5 3.3 4.6 3.9 
NI-147 25 0.5 2.6 0.1 - - - 
NI-136 25 7.2 39.8 0.5 2.5 3.6 3.7 
NI-176 25 4.8 30.3 0.5 4.3 2.2 2.2 
NI-269 25 5.4 27.5 0.3 2.7 1.9 1.7 
NI-182 25 11.4 73.2 0.5 1.9 3.3 3.3 
NI-145 25 4.2 34.6 2 4.1 2.3 2.1 
NI-297 25 16.3 233.4 8 4.6 2.7 2.4 
NI-302 25 9.7 100.3 2 4.1 0.8 0.7 
 
Cmax = maximum concentration reached in lungs, AUC24 = exposure between 











4.3.4 Dose proportionality PK study 
Dose range PK studies were done with three selected NI analogs (PA-824, NI-
622 and NI-644). Pharmacokinetic parameters in plasma and lungs are 
summarized in Table 14 and 15 respectively. Despite, these NI analogs 
displayed low aqueous solubility (13 to 28.2 ug/mL) (Table 11), in CM-2 
formulation, all of them showed moderate to high oral bioavailability across 
the dose range studied. Noteworthy, the calculated oral bioavailability was 
more than 100%. This might be due to nonlinear behavior of these three NI 
analogs in the dose range investigated. Interestingly, the lung-to-plasma 
partitioning was higher for PA-824 and ranged from 2.1 to 3.0 for both Cmax 
and AUCs across the dose range studied indicating preferential lung 
distribution relative to plasma. However, both NI-622 and NI-644 showed 
lower lung partitioning (<1) at all the doses studied. 
Plots of log-transformed Cmax, AUC and the regression lines are shown 
in Figure 26 (plasma) and Figure 27 (lungs). Results from the regression 
analysis of the Cmax and AUC in both plasma and lungs are summarized in 
Table 16. It was observed that the PK parameters, Cmax and AUC increased 
with doses in plasma and lungs for both PA-824 and NI-622. However, the 
increases were not strictly proportional to the doses, in the dose range 
investigated, indicating possible saturation in some of the processes. 
Interestingly, there is dose related but over proportional increase in Cmax 
(plasma only) and AUC was observed in both plasma and lungs for NI-644. 
Further, lung Cmax seems to increase linearly with dose. These observations are 
supported by the slope of the regression line (Table 16), dose normalized Cmax 
and AUC in both plasma (Table 14) and lungs (Table 15). Overall, all the NI 
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analogs showed an apparent dose related but nonlinear increase in Cmax and 
exposure in both plasma and lungs. Due to the above nonlinear observation for 
three representative NI analogs and lack of dose proportionality, data analysis 
for other NI-analogs was done only with available experimental PK data.  
Table 14. Pharmacokinetic parameters in plasma for bicyclic 4-












F* (%) Cmax/Dose AUC/Dose 
PA-824 
25 6.0 50.9 151 0.24 2.04 
50 10.3 119.9 185 0.21 2.10 
100 16.3 268.7 204 0.16 2.69 
250 22.8 336.1 156 0.09 1.34 
NI-622 
10 6.6 37.0 329 0.66 3.70 
50 14.8 108.5 192 0.30 2.17 
100 20.9 197.1 174 0.21 1.97 
250 50.7 627.4 222 0.20 2.51 
NI-644 
10 2.0 9.5 58 0.20 0.95 
50 16.2 89.5 96 0.32 1.79 
100 26.6 329.8 193 0.27 3.30 
250 79.9 986.4 231 0.32 3.95 
*F was calculated using dose normalized exposures between p.o. and i.v. routes.   
 
Table 15. Pharmacokinetic parameters in lungs for bicyclic 4-nitroimidazoles 




















25 17.8 139.9 0.71 5.60 3.0 2.6 
50 22.9 262.6 0.46 5.25 2.2 2.1 
100 35.2 564.9 0.35 5.65 2.2 2.1 
250 55.5 778.9 0.22 3.12 2.4 2.2 
NI-622 
10 3.2 22.5 0.32 2.25 0.8 0.6 
50 10.2 71.1 0.20 1.42 0.7 0.7 
100 19.5 181.5 0.19 1.81 0.9 0.9 
250 35.5 472.0 0.14 1.89 0.7 0.8 
NI-644 
10 1.3 5.6 0.13 0.56 0.6 0.6 
50 7.5 38.1 0.15 0.76 0.5 0.4 
100 14.4 124.6 0.14 1.25 0.5 0.4 

























































































































Figure 26. Dose linearity test by power regression analysis in plasma for Cmax 




















































































































Figure 27. Dose linearity test by power regression analysis in lungs for Cmax 
























PA-824 25 - 250 
Plasma 
Cmax 0.97 0.58 0.28 0.88 Nonlinear 
AUC0-24 0.92 0.83 0.05 1.62 Nonlinear 
Lungs 
Cmax 0.99 0.51 0.37 0.64 Nonlinear 
AUC0-24 0.95 0.77 0.24 1.29 Nonlinear 
NI-622 10 - 250 
Plasma 
Cmax 0.97 0.61 0.27 0.95 Nonlinear 
AUC0-24 0.97 0.86 0.42 1.30 Nonlinear 
Lungs 
Cmax 0.99 0.76 0.64 0.87 Nonlinear 
AUC0-24 0.98 0.95 0.55 1.34 Nonlinear 
NI-644 10 - 250 
Plasma 
Cmax 0.99 1.13 0.83 1.43 Inconclusive 
AUC0-24 0.99 1.47 1.18 1.75 Nonlinear 
Lungs 
Cmax 0.99 1.04 0.96 1.12 Linear 
AUC0-24 0.99 1.39 1.06 1.71 Nonlinear 
 
 
CI, confidence interval; The system was considered to be linear when R
2
 ~ 1, 
Slope CIlower > 0.8, and CIupper < 1.25 
Dose linearity tests on Cmax and AUC0-24 were carried out by the regression of 
log-transformed data (power regression model) (Hummel et al., 2009; Smith et 
al., 2000). Doses and PK parameters were log-transformed, and correlation 
coefficient (R
2
), slope, and 95% confidence intervals were calculated using the 
graphpad prism software. Inferences were made based on the R
2
 ~ 1, 
theoretical slope of 1, and confidence limits of 0.8 and 1.25. If one of CI value 
is outside the range, it is inferred as inconclusive. 
 
4.3.5 Established mouse efficacy 
Based on the in vitro potency and the in vitro and in vivo PK results, ten 
compounds were selected for in vivo mouse efficacy studies with 4 weeks of 
daily oral treatment. The mean lung CFU reductions compared to untreated 
controls are summarized in Table 17. The efficacy ranged from 0.5 to 1.56 log 
at 25 mg/kg and 0.6 to 2.3 log at 100 mg/kg compared to vehicle treated 
animals. At 25 mg/kg, NI-622 and NI-644 were significantly (P < 0.05) less 
efficacious than PA-824, however other NI analogs (NI-135, NI-136, NI-182 
and NI-297) showed comparable efficacy to PA-824. At 100 mg/kg, 
AminoEthyl-824, NI-135, NI-136 and NI-302 showed comparable efficacy to 
96 
 
PA-824, however NI-622, NI-644, Amino-824 and NI-182 were significantly 
(P < 0.05) less efficacious than PA-824. For PA-824, NI-135 and NI-136 a 
dose dependent increase in efficacy was observed, on the contrary, no dose-
dependent increase in bactericidal activity was observed for NI-622, NI-644 
and NI-182. However, none of the selected bicyclic 4-nitroimidazole analogs 
showed significantly better efficacy than PA-824 at respective 25 and 100 
mg/kg doses. 
Table 17. In vivo pharmacodynamics of bicyclic 4-nitroimidazole analogs 
studied in mice 
 
 Mean log lung CFU ± SEM 
∆ Mean log lung CFU 





25 100 25 100 
PA-824 
6.07 ± 0.12 4.67 ± 0.37 4.12 ± 0.13 1.40 ± 0.37 1.95 ± 0.13 
6.24 ± 0.02 4.67 ± 0.10 3.93 ± 0.09 1.57 ± 0.10 2.31 ± 0.09 
6.66 ± 0.14 5.20 ± 0.05 4.19 ± 0.11 1.46 ± 0.05 2.47 ± 0.11 
   1.48 ± 0.09
$
 2.30 ± 0.08
$
 
NI-622 6.66 ± 0.14 5.77 ± 0.08 5.85 ± 0.11 0.89 ± 0.08* 0.81 ± 0.11* 
NI-644 6.66 ± 0.14 6.18 ± 0.03 6.09 ± 0.07 0.48 ± 0.03* 0.57 ± 0.07* 
Amino-824 6.22 ± 0.08 nd 5.14 ± 0.08 nd 1.08 ± 0.08* 
AminoEthyl-
824 
6.22 ± 0.08 nd 4.53 ± 0.07 nd 1.69 ± 0.07
 ns
 
NI-135 6.24 ± 0.02 4.76 ± 0.07 4.36 ± 0.07 1.48 ± 0.07
ns
 1.88 ± 0.07
 ns
 
NI-136 6.24 ± 0.02 4.93 ± 0.06 4.18 ± 0.17 1.31 ± 0.06
ns
 2.06 ± 0.17
 ns
 
NI-182 6.07 ± 0.12 4.84 ± 0.14 4.81 ± 0.18 1.23 ± 0.14
ns
 1.26 ± 0.18* 
NI-297 6.07 ± 0.12 4.51 ± 0.11 nd 1.56 ± 0.11
ns
 nd 




The mean log lung CFU’s in five independent in vivo efficacy studies ranged 
between 6.07 and 6.66 in untreated infected mice. nd = not determined; ∆ 
Mean log lung CFU reduction compared to untreated controls. Each data 
represents mean value ± SEM from 5 animals. 
$
Mean value from three 
independent experiments (n=15). *Significant difference at P < 0.05 compared 
to respective PA-824 doses. 
ns
No significant difference at P < 0.05 compared 
to respective PA-824 doses. Statistical analysis was done by a one-way 
analysis of variance, followed by a multiple comparison analysis of variance 
by a one-way Tukey test (GraphPad Prism, version 5.02, San Diego, 
California, USA, www.graphpad.com).  
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4.3.6 Correlation of PK parameters with efficacy 
Further, mouse PK and efficacy data were used to understand the relationship 
of PK parameters with in vivo efficacy for a series of NI analogs. Both PK and 
efficacy data at 25 mg/kg were available for only 7 compounds. PK 
parameters were obtained after a single oral dose (Table 12), while efficacy 
studies were performed at oral daily doses of 25 and 100 mg/kg for 4 weeks 
(Table 17). The relationship between mean log CFU reduction and PK 
parameters (Cmax and AUC) was analyzed in both plasma and lungs using the 
Spearman’s rank correlation (Figure 28, Table 18). The free plasma 
concentrations were obtained by correcting for in vitro mouse plasma protein 
binding. As shown in Figure 28, with the limited set of compounds, the in vivo 
efficacy correlated well with lung PK parameters than plasma PK parameters. 
The Spearman’s rank correlation coefficient for lung Cmax and AUC were 0.76 
and 0.52 respectively. Across the NI analogs studied, compounds with higher 
lung concentration (PA-824, NI-297 and NI-182) tended to achieve higher 
efficacy (∆log CFUs ranging from 1.23 to 1.56), likewise compounds with 
lower lung concentration (NI-644 and NI-622) displayed only marginal 
efficacy (∆log CFUs ranging from 0.48 to 0.89) (Table 13 and 17). In general, 








































































































































































PA-824 NI-622 NI-644 NI-135 NI-136 NI-182 NI-297
 
Figure 28. Correlation of PK parameters (Cmax, AUC) with in vivo efficacy in mice for bicyclic 4-nitroimidazole analogs in total plasma (A), free 
plasma concentration (B) and total lung concentration (C) 
Each data point represents ∆ mean log lung CFU reduction compared to untreated controls (mean value ± SEM from 5 animals). rs is the 
Spearman’s rank correlations coefficient. 
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Cmax (µg/g) AUC (µg·h/g) 
PA-824 25 6 50.9 0.6 5.1 17.8 139.9 1.48 ± 0.09 
NI-622 25
#
 7.4 54.2 0.2 1.6 5.1 35.6 0.89 ± 0.08 
NI-644 25
#
 8.1 44.8 0.8 4.5 3.8 19 0.48 ± 0.03 
NI-135 25 1.2 4.8 0.1 0.4 5.5 18.6 1.48 ± 0.07 
NI-136 25 2 10.7 0.3 1.8 7.2 39.8 1.31 ± 0.06 
NI-182 25 3.5 22.5 0.3 2.0 11.4 73.2 1.23 ± 0.14 




 rs = -0.52 rs = 0.11 rs = -0.58 rs = -0.16 rs = 0.76 rs = 0.52  
 
PK parameters obtained from single dose PK data. Free concentrations in plasma were calculated using in vitro plasma protein binding. 
#
PK 
parameters derived from 50 mg/kg. rs = Spearman correlation coefficient. ∆ Mean log lung CFU reduction compared to untreated controls. Each 
data represents mean value ± SEM from 5 animals. 
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4.3.7 Correlation of PK-PD indices with efficacy 
In vitro activity against Mtb is one of the key determinants of in vivo efficacy, 
hence the relationship between mean log lung CFU reduction with three 
primary descriptive PK-PD indices (Cmax/MIC, AUC/MIC and T>MIC) was 
analyzed in both plasma and lungs (Figure 29, Table 19). As observed above, 
over all, the in vivo efficacy seems to have a stronger positive correlation with 
lung PK parameters than plasma. Among all the PK-PD indices, total lung 
T>MIC correlated best with in vivo efficacy (rs = 0.88) than lung Cmax/MIC (rs = 
0.63) and AUC/MIC (rs = 0.63) (Figure 29C, Table 19).  For all the 
compounds analyzed, the total lung T>MIC ranged between 64 and 100% 
resulting in 0.9 – 1.56 log lung CFU reduction. In this analysis, NI-644 was 
found to be an outlier, with T>MIC of 84% resulted in only 0.48 log CFU 
reduction. Overall, these results suggest that in vivo efficacy of bicyclic 4-
nitroimidazole analogs correlates better with the time during which the total 
lung concentrations are above in vitro potency. 
 
4.4 Discussion   
PA-824, a bicyclic 4-nitroimidazole has demonstrated bactericidal activity in 
both preclinical and clinical settings (Diacon et al., 2010; Lenaerts et al., 2005; 
Tyagi et al., 2005). Extensive medicinal chemistry efforts to improve aqueous 
solubility, metabolic stability, in vitro potency and in vivo efficacy have 
independently generated several series of NI analogs (Barry et al., 2011; 
Blaser et al., 2012; Cherian et al., 2011; Denny and Palmer, 2010; Jiricek et 
al., 2007; Kim et al., 2009a; Kim et al., 2009b; Kmentova et al., 2010; 
Matsumoto et al., 2006; Palmer et al., 2010; Thompson et al., 2011). All the 
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bicyclic 4-nitroimidazole analogs analyzed in this study showed cofactor F420 
dependent bio-activation (Table 11) suggesting the mechanism of action of 
these compounds similar to PA-824 (Manjunatha et al., 2006; Singh et al., 
2008). Comprehensive in vivo efficacy studies are generally resource / time 
intensive and are particularly true for TB. Thus, prioritizing potential lead 





























































































































































































































































PA-824 NI-622 NI-644 NI-135 NI-136 NI-182 NI-297
 
Figure 29. Correlation of PK-PD indices (Cmax/MIC, AUC/MIC and T>MIC) 
with in vivo efficacy in mice for bicyclic 4-nitroimidazole analogs in total 
plasma concentration (A), free plasma concentration (B) and total lung 
concentration (C) 
Each data point represents ∆ Mean log lung CFU reduction compared to 
untreated controls (mean value ± SEM from 5 animals). rs is the Spearman’s 













Total concentration Free concentration Total concentration 
Cmax/MIC AUC/MIC %T>MIC fCmax/MIC fAUC/MIC fT>MIC Cmax/MIC AUC/MIC %T>MIC 
PA-824 25 20 170 66 2.0 17 37 59 466 96 1.48 ± 0.09 
NI-622 25
#
 41 301 65 1.1 8.9 17 28 198 64 0.89 ± 0.08 
NI-644 25
#
 90 498 93 8.9 50 53 42 211 84 0.48 ± 0.03 
NI-135 25 40 160 66 3.3 13.3 16 183 620 95 1.48 ± 0.07 
NI-136 25 67 357 65 10 60 49 240 1327 89 1.31 ± 0.06 
NI-182 25 175 1125 66 15 100 61 570 3660 75 1.23 ± 0.14 




 rs = -0.05 rs = -0.05 rs = 0.30 rs = -0.16 rs = 0.16 rs = 0.07 rs = 0.63 rs = 0.63 rs = 0.88  
 
PK-PD indices were calculated using PK parameters obtained from single dose PK data and in vitro potency. Free concentrations in plasma were 
calculated using in vitro plasma protein binding. 
#
PK parameters derived from 50 mg/kg. rs = Spearman correlation coefficient. ∆ Mean log lung 





This study is a retrospective analysis of in vivo efficacy with PK for bicyclic 
4-nitroimidazole analogs to identify the PK parameters and PK-PD indices 
that correlate with the in vivo potency. The results of this analysis could 
potentially be exploited to prioritize new analogs for efficacy studies. 
Mtb mainly resides in lung granulomatous structures and hence it is 
important for a drug to be available at the site of the infection for it to be 
active. The volume of distribution is a primary PK parameter defined by the 
physicochemical properties of the compound that indicates the extent of 
compound distribution in the body. Azithromycin, a macrolide antibiotic, with 
very high Vss (33 L/kg) (Obach et al., 2008) is known to have higher lung 
concentration than serum (AUC lung/serum = 21) (Veber et al., 1993) and it 
correlates well with in vivo activity against respiratory pathogens. Likewise, 
moxifloxacin displays a high volume of distribution (Vss = 2 to 5 L/kg) 
resulting in pronounced penetration into tissues (AUC L/P ratio of 3.3) (Siefert 
et al., 1999a; Siefert et al., 1999b) possibly leading to its potent in vivo 
efficacy against TB (Nuermberger et al., 2004). Recently, moxifloxacin has 
been shown to penetrate and accumulate in granulomatous lesions in TB 
infected rabbit lungs (Prideaux et al., 2011). TMC207, a diarylquinoline 
analog, extensively distributes to lungs (AUC L/P ratio of 22) and is 
efficacious against Mtb (Andries et al., 2005). In this study, NI analogs having 
moderate-to-high volume of distribution (Vss = 1.6 to 4.2 L/kg) and L/P ratio 
of > 2 showed good efficacy in a murine TB model (∆log CFUs ranging from 
1.23 to 1.56) (Table 12, 13 and 17, Figure 30). Interestingly, NI-622 and NI-
644 that showed lower lung to plasma ratio displayed only a marginal efficacy 
(∆log CFUs ranging from 0.48 to 0.89). Although, NI-135 and NI-136 showed 
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higher lung to plasma ratio (3.6 to 4.6), their absolute lung concentrations 
were 2.5 to 7.5 fold lower than PA-824. However, both these compounds 
displayed 10 times better in vitro potency resulting in comparable in vivo 
efficacy to PA-824. Overall, the relationship between in vivo efficacy of 
bicyclic 4-nitroimidazoles displayed positive correlation with Vss (rs = 0.45) 
(Figure 30). Based on these observations, the Vss and lung distribution could 
give an initial indication about a compound’s potential for in vivo efficacy and 
thus these two parameters could be used for initial prioritization of compounds 
during early drug discovery.  




































Figure 30. Correlation of volume of distribution with in vivo efficacy in mice 
for bicyclic 4-nitroimidazole analogs 
Each data point represents ∆ Mean log lung CFU reduction compared to 
untreated controls (mean value ± SEM from 5 animals). rs is the Spearman’s 
rank correlations coefficient. 
 
A thorough dose fractionation study of PA-824 in a murine model 
showed that the primary PK-PD driver for in vivo efficacy is the duration 
during which the free concentration are above MIC (fT>MIC) in plasma (Ahmad 
et al., 2011). In this study lung PK parameters have not been measured. 
Further,  fT>MIC in plasma of 22%, 48% and 77% is required for it to show 
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bacteriostatic, 1-log10 and 1.59 log10 kill respectively (Ahmad et al., 2011). In 
general, the PK-PD parameter driving efficacy is conserved within a given 
class of compounds (Barbour et al., 2010), for example, the efficacy of all 
fluoroquinolone analogs are driven by AUC/MIC (Craig, 1998; Craig, 2001; 
Shandil et al., 2007), while the efficacy of β-lactams correlates with T>MIC 
(Andes and Craig, 2002; Craig, 2001; Scaglione and Paraboni, 2006). These 
studies are done with thorough dose fractionation of single compound with 
multiple doses and dosing regimen. During lead optimization program 
prioritization of promising compounds that show good in vivo efficacy is 
important to reduce the overall turnaround time. In this retrospective analysis 
with 7 different bicyclic 4-nitroimidazole analogs, we attempted to correlate in 
vivo efficacy at 25 mg/kg with PK parameters. On the contrary to what has 
been observed by Ahmad et al., in this study, with seven bicyclic 4-
nitroimidazole analogs having varied lung distribution, in vivo efficacy 
showed weak correlation with free T>MIC in plasma. However, the total T>MIC 
in lungs showed positive correlation with in vivo efficacy (rs = 0.88) likely due 
to their preferential distribution into lungs for some analogs. For all the 
compounds analyzed, the total lung T>MIC ranged between 64 - 100% resulting 
in 0.9 – 1.56 log lung CFU reduction, hence efficacy studies at lower doses 
(resulting in T>MIC less than 65%) might be necessary to see a better 
correlation. Overall, in this study a diverse set of bicyclic 4-nitroimidazoles 
with Vss ranging from 0.7 L/kg to 4.2 L/kg, lung to plasma ratio ranging from 




NI analogs (PA-824, NI-622 and NI-644) appear to exhibit dose 
related increase in pharmacokinetics (Cmax and exposure) in mice in CM-2 
formulation. Further, at comparable doses, NI-622 and NI-644 showed similar 
or higher Cmax and exposure in plasma, but had lower lung partitioning (<1) 
compared to PA-824 (Section 4.3.4). Favorable lung distribution is a desirable 
attribute for compounds developed to treat pulmonary tuberculosis. In general, 
total lung concentration and partitioning from the preliminary pharmacokinetic 
study could be used in the initial drug discovery program to quickly prioritize 
the compounds for lengthy efficacy studies. The lack of dose related increase 
in efficacy for NI-622 and NI-644 cannot be explained in spite of increase in 
the lung concentrations with the dose. The underlying mechanism for this 
behavior is yet to be understood. Further investigation like free concentration 
at the site of infection, active species and transporter mechanisms are required 
to understand the thorough PK-PD relationship for a specific compound. 
The results presented in this study must be interpreted with a couple of 
limitations in mind. First, single-dose PK parameters determined in healthy 
mice were assumed to be predictive of multiple-dose PK parameters in 
infected animals and were correlated with efficacy data. This assumption is 
supported by published preclinical data that has shown the absence of plasma 
accumulation of PA-824 in mice dosed for 2 months (Nuermberger et al., 
2006). Further, in clinical studies with PA-824, the PK parameters from a 
single dose phase I study were similar to a multiple dose phase II study in 
patients (Diacon et al., 2010; Diacon et al., 2012a; Diacon et al., 2012b; 
Ginsberg et al., 2009). Another limitation of this study is that total 
concentrations in lungs rather than the free lung concentrations were used for 
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the PK-PD analysis. It is well accepted that for a given compound unbound 
drug concentrations in plasma are equivalent to unbound tissue concentrations 
when active transport is not involved in the drug distribution (Lin, 2006; 
Smith et al., 2010). Further, it is the unbound concentration of a compound at 
its target site driving the pharmacological effect (Gonzalez et al., 2013; Liu et 
al., 2002; Mouton et al., 2008; Muller et al., 2004; Smith et al., 2010; 
Theuretzbacher, 2007). Nevertheless, whole-tissue concentrations can be of 
some value in early drug discovery providing a first assessment of partition 
into the lungs (Mouton et al., 2008). Techniques like microdialysis in lungs 
can be applied to assess unbound tissue concentration (Brunner et al., 2005; 
Chaurasia et al., 2007). In TB patients, Mtb mainly resides in diverse and 
heterogeneous lesions in lungs. In general, interpretation of PD activity of 
anti-TB compounds is complicated by differential lung pathophysiology. PK 
in intrapulmonary compartments like the epithelial lining fluid and alveolar 
macrophages have also been studied in humans for standard TB drugs like 
rifampicin (Ziglam et al., 2002), isoniazid (Conte, Jr. et al., 2002b), 
ethambutol (Conte, Jr. et al., 2001), pyrazinamide (Conte, Jr. et al., 1999), 
rifapentine (Conte, Jr. et al., 2000), moxifloxacin (Soman et al., 1999), 
ofloxacin (Chierakul et al., 2001) and linezolid (Conte, Jr. et al., 2002a). The 
concentration in these sites could be the key factor governing the efficacy of 
anti-TB drugs. However, measurement of compound concentration in lungs by 
microdialysis, epithelial lining fluid and alveolar macrophages have 
limitations in sampling, methodology and interpretation of results (Kiem and 
Schentag, 2008; Mouton et al., 2008); and such studies have not been explored 
in preclinical settings for TB. The total lung concentration may not be equal to 
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the concentration in Mtb lesions, thus warranting lesion PK analysis to 
improve the predictive power for efficacy. Recently PK in lung lesions of 
mycobacterium-infected rabbits has been investigated for isoniazid, 
rifampicin, pyrazinamide and moxifloxacin (Kjellsson et al., 2012; Prideaux et 
al., 2011). Although lesion PK can offer better insights in understanding PK-
PD relationships, it is not easily applicable to early drug discovery especially 
with mouse efficacy model as it doesn’t display spectrum of lesions observed 
in TB patients or in higher animal models. In addition, similar studies with 
bicyclic 4-nitroimidazoles may be challenging as they undergo enzymatic 
transformation in Mtb to multiple stable and unstable metabolites (Singh et al., 
2008). 
Our findings show that the efficacy of all bicyclic 4-nitroimidazole 
analogs is most likely driven by PK parameters in lungs. A simple efficacy 
surrogate would be useful during the lead optimization to prioritize candidates 
for lengthy efficacy studies. For this class, efficacy correlated better with 
concentration in lungs rather than in plasma, consistent with Vss and 
differential lung: plasma distributions. The results of this analysis potentially 
be exploited to prioritize new analogs for efficacy studies based on in vitro 
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5.1 Introduction  
During a whole cell screening campaign for P. falciparum proliferation 
inhibitors, a series of spiroindolones was identified. Lead optimization efforts 
were further undertaken to improve their pharmacokinetic properties and in 
vitro potencies against P. falciparum (Yeung et al., 2010). Spiroindolones act 
through a novel mechanism that disrupt intracellular Na
+
 homeostasis through 
the inhibition of the parasite non-sarco(endo)plasmic reticulum Ca
2+
 (non-
SERCA) P-type ATPase PfATP4 (Rottmann et al., 2010; Spillman et al., 
2013). The same parasiticidal mechanism across the series is further supported 
by the conserved enantiomer specificity (Yeung et al., 2010). KAE609 is a 
spiroindolone product of the lead optimization efforts and is currently in 
clinical development for the treatment of P. falciparum and P. vivax malaria. 
We have previously shown that the compound exhibits pharmacokinetic 
properties in rodents compatible with once-daily oral dosing in human 
(Rottmann et al., 2010). In the murine P. berghei malaria model, a single oral 
dose of 100 mg/kg of body weight of KAE609 was sufficient to cure 100% of 
the animals. Three daily oral doses of 50 mg/kg also afforded complete cure, 
while a 50% cure rate was achieved with a single dose of 30 mg/kg. In light of 
these results, it was speculated that sustained reduction in parasitemia could be 
achieved at low doses in human (Rottmann et al., 2010).  
Dose-response experiments were performed to investigate the 
relationship between dose and efficacy (i.e., reduction in parasitemia) across 
the spiroindolone series. In order to further characterize KAE609, the most 
promising of this new class of antimalarials, a classical dose fractionation 
approach was adopted to identify the PK-PD index that correlates best with a 
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reduction in parasitemia in the P. berghei malaria murine model. Once such a 
PK-PD relationship is established, we propose that it could be used to 
prioritize analogs within the same class of compounds and contribute to the 
efficacy study design, thereby facilitating early drug discovery and lead 
optimization programs.  
 
5.2 Materials and Methods 
 
5.2.1 Chemicals 
All spiroindolone analogs studied (Figure 31) were synthesized at Novartis 
Institute for Tropical Diseases, as described elsewhere (Yeung et al., 2010). 
Organic solvents (acetonitrile and methanol) were purchased from Merck, 
Darmstadt, Germany; ethanol and hydrochloric acid (HCl) were obtained from 
Fisher Scientific, Leicestershire, United Kingdom; polyethylene glycol 400 
(PEG400) was purchased from  Acros Organics, New Jersey, USA; d-α-
tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) NF grade 
from Eastman, Anglesey, United Kingdom; Solutol HS15 was obtained from 
BASF, Ludwigshafen, Germany; and acetic acid, warfarin and citrate acid 
buffer (prepared from anhydrous citric acid) were obtained from Sigma 
Aldrich, St. Louis, MO, USA. 
 
5.2.2 In vitro antimalarial activity of spiroindolone analogs 
In vitro potency against P. falciparum and P. berghei were determined as 
described in Appendix 4. All assays were repeated at least three times. The 
results were recorded and expressed as a percentage of the untreated controls. 
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The 50% inhibitory concentrations (IC50) were estimated by linear 
interpolation. In addition, for the PK-PD analysis of KAE609, a 99% 
inhibitory concentration (IC99) value was determined by transforming the data 
from scintillation counter (Anscombe transformation) to account for 
Poissonian measurement error. The inhibitory concentrations conferring 50% 
(IC50), 90% (IC90) and 99% (IC99) growth reduction were inferred from fitting 
a four parametric logistic function (equation 1) to the transformed data in 
dependence of the log-transformed concentrations.  where R is the response 
measured at any given concentration, E0 is the base line effect in the absence 
of the drug, Emax is the maximum possible effect in the presence of the drug, C 
is the concentration of the drug, IC50 is the concentration that cause 50% of the 
effect, s is the Hill slope describing the steepness of the curve. Each of the 
three replicates was performed on a distinct 96-well plate. This has been 
accounted for in the fitting procedure by means of a Bayesian hierarchical 
model. The software used for parameter inference was Stan (2014). 
                                   --------  Equation 1 
 
5.2.3 In vivo PK studies for spiroindolone analogs in CD-1 mice 
The Institutional Animal Care and Use Committee (IACUC) of the Novartis 
Institute for Tropical Diseases, registered with the Agri-Food and Veterinary 
authority (AVA), Government of Singapore, reviewed and approved all 
animal experimental protocols. For the in vivo PK studies, female CD-1 mice 
(25 to 30g) were obtained from the Biological Resource Center, Biopolis, 
Singapore, and were randomly assigned to cages.  The mice were allowed to 
acclimate before the initiation of the experiments. Feed and water were given 
ad libitum. The compounds were formulated at concentrations of 2.5 mg/mL 
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for a dose of 25 mg/kg administered orally (p.o.) and at a concentration of 1 
mg/mL for a dose of 5 mg/kg given intravenously (i.v.). The solution 
formulation for p.o. and i.v. dosing contained 10% ethanol, 30% PEG 400 and 
60% of 10% vitamin E TPGS. The blood samples from the mice were 
collected at 0.02 (for i.v. only), 0.08, 0.25, 0.5, 1, 2, 4, 8, 16 and 24 h post 
dosing. The dose proportionality studies were conducted with KAE609. 
Formulations containing 0.1, 0.5 and 10 mg/mL were prepared to support oral 
dosages of 1, 5, and 100 mg/kg, respectively. Additional samples were 
collected at 32 h and 48 h post dose for the 1- and 5-mg/kg dose groups and up 
to 72 h post dose for the 100 mg/kg dose group. Groups of three mice were 
used for each time point.  Blood was centrifuged at 13,000 rpm for 7 min at 4 
C, and plasma was harvested and stored at -20 C until analysis.  
Plasma samples were processed by protein precipitation using 
acetonitrile:methanol:acetic acid (90:9.8:0.2) to recover both analytes and 
internal standard (warfarin) using a 8 to 1 extractant to plasma ratio for all the 
analogs studied except (+)-1 (6 to 1 ratio) and (+)-6 (3.6 to 1 ratio) (Yeung et 
al., 2010). After vortexing and centrifuging the mixture, the supernatant was 
removed and 5 µL of sample analyzed. Analyte quantitation was performed by 
high-performance liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS). Liquid chromatography was performed using an 
Agilent 1100 high-performance liquid chromatography (HPLC) system (Santa 
Clara, CA), with the Agilent Zorbax XDB Phenyl (3.5 µm, 4.6x75 mm) 
column at oven temperatures of 35 °C for all the analogs studied [except (+)-5, 
(+)-6 and (-)-6 at 45 °C], coupled with a API3200 triple quadruple mass 
spectrometry (Sciex Applied Biosystems, Foster City, CA) for all the analogs 
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studied except (+)-1, (+)-5, (+)-6 and (-)-6 that were analyzed using QTRAP 
4000 triple quadruple mass spectrometer (Applied Biosystems, Foster City, 
CA). Instrument control and data acquisition were performed using Applied 
Biosystems software Analyst 1.4.2. The mobile phases used were A, water-
acetic acid (99.8:0.2, vol/vol) and B, either acetonitrile-acetic acid (99.8:0.2, 
v/v) for (+)-1, (+)-5 and (-)-6 or methanol-acetic acid (99.8:0.2 v/v) for all the 
other analogs studied, using a gradient 0 to 0.2 min (10% B), 0.2 to 1.8 min 
(10 to 80% B), 1.8 to 2.5 min (80% B), 2.5 to 2.51 min (80 to 10% B) and 
2.51 to 6 min (10% B), with flow rate of 1.0 mL/min, and run time of 6 min. 
Under these conditions, the retention time of various compounds ranged from 
3.2 to 4.1 minutes. Multiple reaction monitoring (MRM) was combined with 
optimized MS parameters to maximize detection specificity and sensitivity.  
The most intense MRM transitions [338.3/295.1 for (+)-1, 370.1/327.0 for (+)-
2, 370.0/326.9 for (+)-3, 354.1/310.8 for (+)-4, 354.1/311.2 for (+)-5, 
372.1/329.1 for (+)-6, 388.0/331.8 for (+)-7, 372.1/316.1 for (-)-6 and 388/332 
for (-)-7] were used for quantitation. Most compounds were analyzed using 
electrospray ionization in the negative mode, except (+)-1 which was analyzed 
using positive mode. The recovery of the compounds from plasma was good 
and consistent across the concentration range studied. The lower limits of 
quantification for different compounds ranged between 1.3 and 70 ng/mL in 
plasma. A calibration curve was prepared freshly and analyzed with every set 
of study samples. Intraday variability was established with triplicate quality 
control samples at three concentration levels. The results were accepted if 
relative standard deviation was less than 15%.   
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The mean values of the compound concentrations in plasma were 
obtained from three animals at each time point and plotted against time to 
generate concentration-time profiles. The pharmacokinetic parameters were 
determined using WinNonlin Professional, version 5.0.1 (Pharsight, 
California, USA), by noncompartmental modeling using software model 200 
for oral dosing and model 201 for intravenous dosing. The oral bioavailability 
(F) was calculated as the ratio between the area under the curve from 0 to 
infinity (AUCinf) following oral administration and the AUCinf following 
intravenous administration corrected for dose (F = AUCp.o. · dosei.v. / AUCi.v. · 
dosep.o.). 
 
5.2.4 In vivo antimalarial efficacy of spiroindolone analogs in NMRI mice 
All in vivo studies conducted at the Swiss Tropical and Public Health Institute 
(TPH) were adhered to local and national regulations of laboratory animal 
welfare in Switzerland (permission number 1731). For in vivo efficacy, female 
(specific pathogen free) National Medical Research Institute (NMRI) mice 
were obtained from Janvier, Le Genest-Saint-Isle, France. Only mice without 
visible signs of disease were used for the study. Standard laboratory conditions 
were adopted for husbandry.  In vivo antimalarial activity was assessed using 
groups of five female NMRI mice (20 to 22 g) intravenously infected on day 
zero with 2x10
7
 erythrocytes parasitized with P. berghei GFP ANKA malaria 
strain PbGFPCON (a donation from A. P. Waters and C. J. Janse, Leiden 
University) (Franke-Fayard et al., 2004). Upon inoculation of P. berghei 
parasites, the infection of untreated mice with P. berghei (ANKA strain) 
invariably takes a lethal course within 6 to 7 days (Rottmann et al., 2010). 
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Hence, both survival and a reduction in parasitemia can be monitored to 
evaluate (i) the ability of a drug candidate to clear all viable parasites, as 
measured by the absence of recrudescence up to 30 days post-infection (i.e., 
‘cure’), and (ii) drug-mediated reduction in parasitemia at the end of 
treatment. Untreated control mice typically died between day six and day 
seven post infection. Experimental compounds were formulated in 10% 
ethanol, 30% PEG400 and 60% of 10% vitamin E TPGS and were 
administered orally in a volume of 10 mL/kg.  Dose-response efficacy studies 
were conducted for each spiroindolone analog. Doses of 2.5, 5, 10, 30 and 100 
mg/kg were administered to groups of 5 mice as a single dose 24 h post 
infection. Parasitemia, expressed as parasitized red blood cells (pRBCs) over 
100 RBC’s, was determined 72 h post infection using standard flow cytometry 
techniques (Franke-Fayard et al., 2004).  
 
5.2.5 Dose-response relationship analysis for spiroindolone analogs  
Data analysis was done using nonlinear mixed effect modeling (NONMEM 
version VI 2.0), which analyzed the PD data from multiple dose groups 
obtained from different experiments simultaneously. Within NONMEM, first 
order conditional estimation (FOCE) was the method used (Silber et al., 2010) 
(Appendix 5).  The log-transformed dose and level of parasitemia were used 
for analysis.  For each compound a dose-response model was built and 
effective dose lowering 90% of parasitemia (ED90) was determined using the 
equation 2 (Knudsen et al., 2000),  where P is the parasitemia measured at any 
given dose, Pmax is the maximum level of parasitemia, Pmin is the minimum 
level of parasitemia, EZ50 is the dose required to produce 50% of the maximal 
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effect, s is the Hill slope describing the steepness of the curve and x is the dose 
(mg/kg). 
 --------Equation 2 
5.2.6 In vivo PK and dose fractionation studies for KAE609 in NMRI mice 
For the in vivo PK studies, female NMRI mice (specific pathogen free) were 
obtained from Janvier, Le Genest-Saint-Isle, France. To investigate the 
influence of the disease status on the pharmacokinetics, a single oral dose (5.3 
mg/kg) of KAE609 was given to both the infected and uninfected NMRI mice, 
and the PK parameters determined. The infected mice were dosed 24 h 
postinfection. The formulation, sampling times (0.25, 0.5, 1, 2, 4, 8, 24 and 48 
h post dose), extraction and analysis were similar to the method described 
above.  
The dose fractionation studies were conducted at daily oral doses of 
0.5, 1, 2, 4, and 8 mg/kg. The total daily doses were either administered as a 
single dose (24 h postinfection) or divided into two (bid) or three oral doses 
(tid) per day. Four mice were used for each regimen, with control mice 
receiving vehicle only. Parasitemia, expressed as parasitized red blood cells 
(pRBCs) over 100 RBC’s, was determined 72 h postinfection (48 h after 
initiation of treatment with KAE609) using standard flow cytometry 
techniques (Franke-Fayard et al., 2004).   
 
5.2.7 PK modeling and simulation for KAE609 
Population PK modeling of concentration-time data of KAE609 in mice was 
performed using naive pooling without intersubject variability using 
NONMEM version VI 2.0 (Appendix 6). A two-compartment 
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pharmacokinetic model with first-order absorption and nonlinear elimination 
was built to fit the time concentration-time data of KAE609 generated in 
(infected and healthy) NMRI mice at 5.3 mg/kg. In the model, clearance (CL) 
was described by the equation 3, where Cp is compound plasma concentration, 
Vmax/Km is the maximal clearance achievable when Cp << Km, and Km 
corresponds to the compound concentration at which the clearance reached 
50% of the Vmax.  The primary model parameters derived were plasma 
clearance (CL, in liter/h/kg), inter compartmental clearance (Q, in liter/h/kg), 
central and peripheral volume of distribution (Vc and Vp, respectively in 
liter/kg) and the absorption rate constant (Ka, in h
-1
). The diagnostic plots were 
analyzed for closeness to and randomness along the line of identity on the 
observed versus predicted concentration plot, as well as randomness along the 
weighted residual zero line on the predicted concentration or time. The 
estimates were accepted when plots showed no systematic pattern (Sinou et 
al., 2008). Based on the estimated primary model parameters (Vmax, Km, Vc, 
Vp, Q, and Ka), plasma concentration-time profiles and secondary 
pharmacokinetic parameters, such as Cmax, AUC at different doses and dosing 
regimens, were simulated using Berkeley Madonna software (version 8.0.1) 
(Berkeley Madonna
TM
, University of California, Berkeley, CA). 
                                                      -------Equation 3
 
 
5.2.8 PK-PD relationship analysis of KAE609 (dose fractionation study) 
Preliminary analysis was done using IC50 values against P. falciparum and P. 
berghei parasite as threshold (not shown). However, IC50 refers to the 
concentration of compound inhibiting only 50% of the parasites. In order to 
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completely eliminate the parasites, 2*IC99 values are required. Further, mouse 
was infected with P. berghei parasite, hence 2*IC99 value against P. berghei 
was used for final PK-PD analysis.  Initially, % activity (compared to vehicle 
treated animals) was used as efficacy read out. However, parasitemia was 
obtained for different compounds from different experiments. In order to 
evaluate dose-response relationship for a single compound from multiple 
experiments, the data points were pooled from different experiments; hence 
parasitemia was used as efficacy readout for final analysis.  
The concentration of compounds which inhibited 99% of P. berghei 
growth (IC99) was used to calculate the threshold (TRE = 2*IC99) and the PK-
PD indices. The Cmax/TRE was defined as the ratio of peak plasma 
concentration (Cmax) to the threshold (2*IC99), the AUC0-48/TRE was defined 
as the ratio of area under the concentration-time curve from 0 to 48 h (AUC0-
48) to  the threshold (ratio without dimensions), and the percent time over 
threshold (%T>TRE) was defined as the percentage of the 48 h period during 
which the compound concentration exceeded the threshold (Mouton et al., 
2005). The Cmax/TRE, AUC0-48/TRE and %T>TRE at different doses and dosing 
regimen were calculated using Berkeley Madonna Software (version 8.0.1) 
(Berkeley Madonna
TM
, University of California, Berkeley, CA).  
The relationship between PK-PD indices (log transformed Cmax/TRE, 
log transformed AUC0-48/TRE, %T>TRE) and log transformed parasitemia were 
analyzed by nonlinear regression analysis.  An exploratory analysis of PK-PD 
data was done using various models such as maximum effect (Emax), sigmoid 
Emax, and with and without slope. A sigmoidal dose-response (variable slope) 
model without constants was fitted to the data. GraphPad Prism version 5.02 
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for windows (GraphPad software, San Diego, California, USA) was the 
software used for this analysis. The model choice was guided initially by a 
visual inspection of the y-by-x plots and then by correlation analysis and by 
evaluating the standard error of the estimate. The parasitemia (P) measures at 
any value of each different PK-PD index is expressed in equation 2,  where 
Pmax is the maximum parasitemia, Pmin is the minimum parasitemia, EZ50 
(otherwise referred to as EC50) is the value of the specific PK-PD index 
(Cmax/TRE, AUC0-48/TRE and %T>TRE, respectively) required to produce 50% 
of the maximal effect, s is the Hill slope describing the steepness of the curve 
and x is any of the PK-PD indices.  The values of ‘x’ corresponding to the 





5.3.1 In vitro potency of the spiroindolone analogs  
A series of chiral spiroindolone analogs were synthesized as part of a lead 
optimization campaign against P. falciparum (Yeung et al., 2010)  (Figure 31). 
These compounds were profiled in vitro against the human parasite P. 
falciparum and the rodent parasite P. berghei (Table 20). In vitro biological 
activity was mainly associated with the (+)-enantiomer across the class 
suggesting the inhibition of or interaction with a discrete molecular target. 
Interestingly, the compounds were consistently more potent against P. 
falciparum than P. berghei, with a 13- to 27-fold shift in the IC50.  This 
finding may be explained by some species selectivity against the ATP4 target 
 121 
 
and/or differences in life cycle stage susceptibilities between the two parasites. 
It is important to mention that although the inactive enantiomers of our most 
potent analogs [(-)-6 and (-)-7] displayed submicromolar in vitro activities 
against P. falciparum, both compounds showed no efficacy in the P. berghei 
mouse model.  This apparent discrepancy could be explained by the 
enantiopurity of (-)-6 and (-)-7, which despite having an enantiomer excess 
(e.e.) of >98%, still contained low amounts of the active (more potent) 
enantiomer as contaminant.  
   
Figure 31. Structure of spiroindolone analogs 
Active spiroindolones have the 1R, 3S configuration while inactive 













































(+)-1 13 ± 2.2 242 ± 124 194 97 7.19 770 98.4 1.04 
(+)-2 5.6 ± 0.9 75 ±  32 22 98 n.t 92 99.8 0.77 
(+)-3 5.6 ± 0.7 140 ± 54 8 98 41.7 35 99.7 0.93 
(+)-4 5.9 ± 0.9 104 ± 53 137 97 7.66 330 98.8 0.62 
(+)-5 4.3 ± 0.4 88 ±  26 131 98 4.33 26 98.5 1.18 
(+)-6 0.33 ± 0.06 7.5 ± 2.5 169 99 5.55 41 99.5 1.12 
(+)-7 
(KAE609) 
1.2 ± 0.2 26 ±  14 39 98 1.69 28 99.8 0.85 
(-)-6 105 ± 20 2851 ± 897 112 97 4.8 36 99.6 0.81 
(-)-7 210 ± 19 4908 ± 1445 35 98 1.73 21 99.4 0.52 
 
*
IC50s were determined at least three times in independent assays (16 h + 8 h incubation periods, as indicated Appendix 4. 
§
P. berghei GFP 
ANKA malaria strain PbGFPCON (n=3, Mean ± SD). The data in parentheses indicates whether the compound is the (+) or (-) optical isomer. In 
vitro PK parameters like solubility, PAMPA, Caco-2 permeability, hepatic clearance, mouse plasma protein binding and RBC to plasma 
partitioning were determined in a medium to high through put format using in-house standard assay protocols that are described in the literature. 
(a)
HT-Equilibrium solubility at pH 6.8 (Zhou et al., 2007); 
(b)
Parallel Artificial Membrane Permeability Assay expressed in % fraction absorbed 
(FA) (Avdeef, 2005; Avdeef et al., 2007); 
(c)
Apparent permeability from apical to basolateral in Caco-2 cells expressed as Papp (A-B) 10
-6
 cm/sec 
(Balimane and Chong, 2005; Marino et al., 2005),  n.t, not tested;  
(d)
intrinsic clearance in mouse liver microsomes expressed as µL/min/mg 
protein,  in the presence of liver enzymes (Obach, 1999); 
(e)
Mouse plasma protein binding using rapid equilibrium dialysis method (Banker et al., 
2003; Kariv et al., 2001), 
(f)




5.3.2 In vivo pharmacokinetics of the spiroindolone analogs 
A complete set of in vitro PK parameters of all spiorindolone analogs can be 
found in Table 20.  The in vivo PK parameters obtained following intravenous 
and oral administration of each compound in CD-1 mice are presented in 
Table 21. The results reflected a wide range of exposure, with Cmax values 
from 0.7 µg/mL to 8.3 µg/mL and AUC0-24 (area under the concentration- time 
curve from 0 to 24 h) from 1.3 µg·h/mL to 107.3 µg·h/mL. The volume of 
distribution at steady state (Vss) was moderate to high (0.9 to 13.7 liters/kg). 
The elimination half-life and systemic clearance varied widely and were 
consistent with the intrinsic clearance measured in vitro in liver microsomes. 
Most analogs showed moderate to high oral bioavailability (26 to 100%), in 
agreement with good solubility and permeability observed in vitro (Table 20 
and 21).  
 
5.3.3 Dose-response relationship of the spiroindolone analogs in the 
murine malaria model: 
 
Dose-response experiments were conducted with spiroindolone analogs in the 
P. berghei mouse model at single oral doses of 2.5, 5, 10, 30 and 100 mg/kg, 
monitoring parasitemia as primary efficacy readout.  Consistent with its poor 
ex vivo potency against P. berghei, (-)-6 and (-)-7 showed poor efficacy 
regardless of dose; hence, these two compounds were not included in the 
current evaluation. Additionally, for several compounds, parasitemia seemed 
not to change between 30 mg/kg and 100 mg/kg, approaching detection limit 




Table 21. Summary of in vivo pharmacokinetic parameters of spiroindolone analogs following single oral dosing at 25 mg/kg and intravenous 
(i.v.) dosing at 5 mg/kg to female CD-1 mice 
 
Compound 
Oral PK parameters IV PK parameters 
Cmax (µg/mL) Tmax (h) AUC0-24 (µg·h/mL) t1/2 (h) F   (%) Vss (L/kg) CL (mL/min/kg) t1/2 (h) 
(+)-1 1.2 0.25 1.3 0.7 13 0.9 49.7 0.4 
(+)-2 0.6 1 2.9 4.3 62 9.9 92.6 4.6 
(+)-3 0.7 2 5.8 6.2 91 13.7 60.1 4.3 
(+)-4 1.0 0.25 3.9 5.6 26 1.9 24.0 4.7 
(+)-5 3.1 0.25 17.7 4.0 47 1.6 11.8 3.8 




 1 1.0 8.7 44 
2.1 9.7 3.4 
0.25
b
 2 2.6 7.5 32 
3.6 1 43.3 10.0 100 
10.8
c
 24 186.9 9.4 100 
(-)-6 5 2 68.2 7.9 78 2.8 4.2 13.2 
(-)-7 8.3 1 107.3 9.1 92 1.3 2.6 5.6 
 
a, b, c 
Dose proportionality PK for KAE609 at 1.5, 5.6 and 105 mg/kg, respectively using the formulation, 1.1 equimolar 1N HCl, 5% Solutol 
HS15 in 50mM pH3 citrate acid buffer. Cmax, maximum concentration of drug in plasma; Tmax, time to Cmax; AUC0-24, area under the 
concentration-time curve from 0 to 24 h; t1/2, elimination half-life; F, oral bioavailability; Vss, volume of distribution at steady state; CL, total 
systemic clearance.  
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The relationship between parasitemia and doses was described by a sigmoid 
dose-response model (Figure 32). The model parameters such as Pmax, Pmin, 
ED90 and Hill slope were derived and are reported in Table 22.  A goodness-
of-fit profile for a representative compound [(+)-6] is shown in Figure 33. All 
the compounds studied displayed a maximum reduction in parasitemia, with 
ED90 ranging between 5.6 (KAE609) and 38.1 [(+)-5] mg/kg. KAE609 was 
identified as the most potent spiroindolone in the series. Interestingly, 
treatments with none of the spiroindolones except KAE609 resulted in 
complete cure (>30 days survival, data not shown).   
 
5.3.4 KAE609 displays higher exposure in NMRI mice as compared to 
CD-1 mice  
The oral PK properties of KAE609 were determined in infected and 
uninfected NMRI mice at 5.3 mg/kg (Table 23). No significant difference was 
observed in the PK profiles between the two groups, indicating that the disease 
status does not affect the PK properties of KAE609. However, at comparable 
dose (5 mg/kg), the Cmax and exposure were significantly higher (4-fold) in the 
NMRI mice than those in the CD-1 mice (Table 21 and 23). Based on this 
finding, the concentration-time data in NMRI mice were used for modeling 
purposes and further PK-PD analysis. 
 126 
 
                     
Figure 32. Relationship between dose and parasitemia for spiroindolone analogs 
 
The plot shows the log10 parasitemia at day 4 versus log10 dose administered in mg/kg for a set of spiroindolone analogs in a P. berghei murine 
malaria model. A minimum of five dose levels for each compound were used for dose-response relationship (total doses of 2.5, 5, 10, 30 and 100 
mg/kg were administered as single oral dose at 24 h postinfection). For (+)-7 (KAE609), additional doses ranging between 0.5 and 200 mg/kg 
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were studied. Each data point is from individual animal, and various symbols correspond to different studies. The solid line represents the 
predicted profile from the model. 
 
         
 
 
Figure 33. Goodness-of-fit plots for dose-response relationship 
 
Goodness-of-fit plots for a representative compound [(+)-6] (A) observed data (DV) versus populations predictions (PRED) (B) weighted 




Table 22. Dose-response relationship of spiroindolone analogs in the P. 








 Hill Slope  
(+)-1 33.11 0.03 15.3 -3.1 
(+)-2 30.90 0.03 17.4 -3.36 
(+)-3 24.55 0.12 17.9 -6.4 
(+)-4 30.90 0.03 16.7 -2.87 
(+)-5 25.70 0.05 38.1 -2.99 
(+)-6 32.36 0.09 17.3 -2.03 
(+)-7 (KAE609) 33.88 0.29 5.6 -2.73 
 
a
Pmax, maximum parasitemia; 
b
Pmin, minimum parasitemia ; 
c
ED90, effective 




5.3.5 Pharmacokinetic modeling  
Nonlinear mixed-effect modeling of the oral PK data led to the estimation of 
model parameters that might describe the PK behavior of KAE609 in NMRI 
mice. For the purpose of modeling, a two-compartment PK model with first-
order absorption and nonlinear elimination was built in NONMEM.  The 
estimated PK parameters, such as Vmax, Km, Vc, Vp, Q and Ka, are summarized 
in Table 23. The linear and semi-logarithmic plots of the observed and 
modeled KAE609 plasma concentrations versus time are shown in Figure 34 















Table 23. Pharmacokinetic parameters following oral administration of 






Mouse infection status 
Uninfected Infected 
Cmax (µg/mL) 1.01 0.96 
AUCinf (µg·h/mL) 13.21 12.64 
Vmax (µg/hr/kg) 143 
Km (µg/liter) 34.1 
Vc (liters/kg) 4.4 
Vp (liters/kg) 5.1 
Q (liters/h/kg) 0.61 
Ka (1/h) 1.78 
 
a
Cmax, maximum concentration of drug reached in plasma; AUCinf, area under 
the curve from 0 to infinity;  CL = Vmax / (Km+Cp), where Cp is compound 
plasma concentration, Km is the compound concentration to have 50% of 
clearance saturation, and Vmax/Km is the maximal clearance which can be 
approximated when Cp << Km. The primary model parameters were, CL, 
plasma clearance; Vc, central volume of distribution; Vp, peripheral volume of 
distribution Q, inter compartmental clearance; Ka absorption rate constant. 
 
5.3.6 KAE609 exhibiting time dependent killing in the P. berghei malaria 
mouse model 
 
In the P. berghei malaria mouse model, KAE609 showed 50%, 90% and 99% 
reductions in parasitemia after single oral dose of 1.2, 2.7 and 5.3 mg/kg, 
respectively (Rottmann et al., 2010). In order to expand the dynamic range of 
the pharmacological response, doses ranging from 0.5 to 8 mg/kg were 
selected for a dose fractionation study. The PK model parameters derived as 
described above were used to simulate oral plasma concentration time profiles 
at different doses and dosing regimens, and the corresponding PK parameters 
(Cmax and AUC) were calculated using the Berkley Madonna software. 
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Figure 34. Pharmacokinetics of KAE609 in NMRI mice 
Plot of linear (A) and semilog (B) concentration-time data for KAE609 in infected (0) and uninfected (1) NMRI mice following a single oral 





           
 
Figure 35. Goodness-of-fit plots for pharmacokinetic modeling of KAE609. (A) observed data (DV) versus populations predictions (PRED), (B) 
weighted residuals (WRES) versus PRED, (C) WRES versus Time. 
PRED aligns well with the observations (DV) and did not show either any substantial or systematic deviations from the line of identity. 
Additionally, weighted residual plots are evenly distributed around zero when plotted against PRED or TIME, indicating the model did not show 
any pattern and is not biased either against concentration or time. 
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The IC99 obtained in the ex vivo P. berghei maturation assay was estimated 
(Section 5.2.2) to be 61.6 nM. The 2*IC99 values (123 nM or 48 ng/mL) was 
used as threshold (TRE). The PK-PD indices (Cmax/TRE, AUC0-48/TRE and 
%T>TRE) at different doses and dosing regimens, were calculated (Section 
5.2.8) and are summarized in Table 24. The results showed that Cmax/TRE 
ranged between 0.4 and 30, AUC0-48/TRE ranged between 3 and 514, and 
finally, the T>TRE was approximately 0 to 100% (Table 24).   
A sigmoid dose-response model was chosen to describe the data.  The 
relationship between parasitemia and various PK-PD indices is described by 
equation 2. The derived model parameters such as Pmax, Pmin, EC50 and Hill 
slope, for various PK-PD indices (Cmax/TRE, AUC0-48/TRE and %T>TRE) are 
summarized in Table 25. These results suggest a strong correlation of the 
efficacy of KAE609 with all three PK-PD indices over a wide range of 
exposures as a consequence of parameter interdependency. Among the three 
indices, the percentage of the time that the KAE609 plasma concentration 
remained above 2*IC99 (%T>TRE) and the AUC0-48/TRE correlated best (R
2 
= 
0.97 and 0.95, respectively) with a reduction in parasitemia, followed by the 
Cmax/TRE (R
2 
= 0.88) (Figure 36). Further, %T>TRE displayed the lowest 
magnitude for the standard error of the estimate (standard deviation of the 
regression (Sy.x), 0.17) followed by AUC0-48/TRE (0.22) and Cmax/TRE 
(0.34). Residual plots of the three nonlinear regressions are shown in Figure 
37. Collectively, our data indicate a trend favoring time over threshold and 
exposure over threshold as most important determinant of efficacy for 
KAE609 rather than the concentration over threshold. 
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Table 24. Dose fractionation and corresponding PK-PD indices and level of 






















Mean ± SD 
8 
8 1 29.95 513.68 99.9 0.15 ± 0.03 
4 2 19.4 414.93 99.8 0.18 ± 0.04 
2.67 3 16.44 383.23 99.8 0.16 ± 0.02 
4 
4 1 14.56 148.45 54.5 0.63 ± 0.57 
2 2 7.92 106.02 56.1 0.43 ± 0.38 
1.33 3 6.00 92.12 57.3 0.55 ± 0.28 
2 
2 1 6.93 45.07 23.0 5.64 ± 1.69 
1 2 3.37 30.66 22.7 6.48 ± 3.94 
0.67 3 2.24 25.18 22.3 10.83 ± 4.67 
1 
1 1 3.21 14.57 10.7 17.82 ± 3.05 
0.5 2 1.49 10.16 8.8 18.19 ± 6.81 
0.33 3 0.96 8.55 0 20.31 ± 5.71 
0.5 
0.5 1 1.45 4.98 4.3 28.82 ± 4.49 
0.25 2 0.67 3.75 0 38.28 ± 2.95 
0.17 3 0.43 3.34 0 35.37 ± 5.32 
Vehicle - - - - - 35.51 ± 3.86 
a
The total daily dose was given as one, two (once every 12 h), or three (once 
every 8 h) equally divided doses over 24 h. 
b
Parasitemia expressed as 
parasitized red blood cells (pRBCs) over 100 RBC’s (determined 48 h post 
treatment). Cmax/TRE, ratio of peak plasma concentration (Cmax) to the 
threshold (TRE = 2*IC99); AUC0-48/TRE, ratio of area under the curve from 0 
to 48 h (AUC0-48) to the threshold and %T>TRE, percentage of the 48-h period 
during which the total compound concentration exceeded the threshold. 
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 Cmax/TRE AUC0-48/TRE %T>TRE 
Pmin 0.12 (0.05 – 0.29) 0.13 (0.09 – 0.20) 0.15 (0.12 – 0.20) 
Pmax 
34.51 (21.78 – 
54.58) 
32.66 (25.06 – 42.56) 53.09 (32.28 – 87.50) 
EC50 5.43 (4.2 – 7.0) 52.72 (44.16 – 62.95) 32.06 (28.04 – 36.07) 
Hill Slope -1.87 (-2.69 – -1.05) -1.63 (-2.04 – -1.22) 




 0.88 0.95 0.97 
 
a
Pmax, maximum parasitemia; Pmin, minimum parasitemia, EC50, value required 
to produce 50% of the maximal effect. Cmax/TRE, ratio of peak plasma 
concentration (Cmax) to the threshold (TRE = 2*IC99); AUC0-48/TRE, ratio of 
area under the curve from 0 to 48 h (AUC0-48) to the threshold and %T>TRE, 
percentage of the 48- h period during which the total compound concentration 









      






































































Figure 36. PK-PD relationship for KAE609 
 
The relationships between Cmax/TRE (A), AUC0-48/TRE (B) and %T>TRE (C) of KAE609 and parasitemia, when the total daily dose was 
administered as a single dose or fractionated in two or three equally divided doses over 24 h, are shown. The line represents the predicted profile 






















































     
Figure 37. Residual plots (A) Residual versus Cmax/TRE (B) Residual versus AUC/TRE and (C) Residual versus %T>TRE 
 
Scatterplot of residuals against independent variables – residuals were randomly distributed around zero and spread of the residuals is same 




5.4 Discussion                  
In the field of anti-infectives, doses and regimens selected in clinical trials are 
increasingly informed by dose fractionation studies in animals (Craig, 1998; 
Craig, 2001). This approach was not traditionally adopted for antimalarial 
drugs, as most agents were developed when therapeutic strategies were largely 
based on empirical clinical evidence. Recently, PK-PD relationships have 
been established for chloroquine (time-dependent killing) and artesunate 
(concentration-dependent killing) (Bakshi et al., 2013). This study is an 
attempt to understand the dose- response relationship for a class of 
spiroindolone analogs and to identify the PK-PD driver of the reduction in 
parasitemia resulting from treatment with KAE609. The results presented in 
this study must be interpreted with a few limitations in mind. First, the single-
dose PK parameters determined in NMRI mice were assumed to be similar to 
multiple-dose PK parameters and were correlated with the efficacy data for 
KAE609. Second, the PK data used for PK-PD analysis at different doses and 
regimens were simulated based on model parameters from single-dose PK 
under the assumption of nonlinearity observed in both NMRI and CD-1 mice. 
The third limitation of this study is that in the absence of supporting 
intravenous PK data in NMRI mice, oral bioavailability was assumed to be 
100%.  
A class of spiroindolones was identified in a whole-cell screening 
against the human malaria parasite P. falciparum. In order to support the 
selection of compounds to progress in the murine malaria model, the in vitro 
potency was also assessed against P. berghei (rodent parasite).  A systematic 
13- to 27-fold shift in IC50 was observed between P. falciparum and P. 
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berghei for all study compounds (Table 20).  The likely explanations for the 
differential sensitivity to the spiroindolones could be either species 
susceptibility differences (P. falciparum versus P. berghei) or stage 
selectivity. It should indeed be noted that the P. falciparum assay covers 
intracellular parasite growth and reinfection of new blood cells, with growth 
inhibition measured after 24 h. In contrast, the P. berghei in vitro (ex vivo) 
assay is a schizont maturation assay over a single life cycle without reinvasion 
of new red blood cells over a 24-h period.   
The dose-response experiments were performed in mice with a series 
of potent spiroindolones. Parasitemia was used as primary pharmacodynamic 
(PD) readout for multiple reasons. It provides a wide dynamic range and is a 
fast, easy, and reproducible measurement. Unfortunately, in this P. berghei 
model, a real-time measurement of parasitemia over time that could be used to 
determine the more clinically relevant parasitemia reduction ratio (PRR) was 
not feasible. For each compound, the data derived from all experiments (i.e., 
doses) were fitted simultaneously using nonlinear mixed-effect modeling 
(using NONMEM VI). A good correlation was observed between the doses 
and a reduction in parasitemia across the spiroindolone class (Figure 32, Table 
22) with ED90s ranging from 6 to 38 mg/kg. These results are in line with 
those available for the currently used antimalarials in the P. berghei ED90-
normalized assay (Jimenez-Diaz et al., 2013). Generally, the investigated 
compounds displayed a rather steep Hill slope (≥2). Specifically, for 
compounds (+)-3 and (+)-5, due the limited data points covering the middle 
portion of the dose-response curves, our confidence in the derived Hill slopes 
is rather moderate. Interestingly, all the spiroindolone analogs tested achieved 
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complete reduction in parasitemia (below the detection limit, < 0.1%), but 
only KAE609 showed complete cure (i.e., survival > 30 days). The reason 
underlying this observation is yet to be elucidated. 
The most promising spiroindolone, KAE609, which is currently in 
clinical development, was selected for more extensive dose fractionation 
studies in the P. berghei murine model. The objective of such an 
investigation was to identify the PK-PD driver of efficacy and determine 
whether this compound exhibits time or concentration dependent killing. 
The results suggested that the time during which plasma concentrations 
remained above the 2*IC99 (%T>TRE) and the AUC0-48/TRE correlated 
slightly better (although not statistically significantly) with reduction in 
parasitemia than did Cmax/TRE. In our study, all three PK-PD indices 
(Cmax/TRE, AUC0-48/TRE and %T>TRE) correlated well with a reduction in 
parasitemia as a consequence of their significant interdependency 
(Spearman correlation coefficient of > 0.97; P value <0.0001). The PK 
properties of KAE609 (i.e., long half-life) and the almost complete 
reduction in parasitemia reached in a narrow dose range do not allow us at 
this stage to clearly distinguish between concentration and time dependent 
killing for KAE609 in the investigated model. A definitive conclusion could 
be achieved by a more extensive dose fractionation study up to 48 h with 
several different dosing regimens to break the colinearity (Ambrose et al., 
2007; Drusano, 2004; Scaglione et al., 2003).  Based on the correlation 
analysis and the standard error of the estimate, collectively, our data 
indicate a trend favoring time over threshold and exposure over threshold as 
most important determinant of efficacy. This would suggest time-dependent 
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rather than concentration-dependent killing for KAE609. In addition, a 
conservative interpretation of the results is the prediction that a dosing 
regimen covering a Cmax/TRE of 30, AUC0-48/TRE of 587 and T>TRE of 
100% for an observation period of 48 h is likely to yield maximum 
reduction in parasitemia (parasitemia, <0.1%) in the malaria mouse model. 
Interestingly, the concentration of KAE609 needed to inhibit 50% of 
parasite (P. berghei) in vitro (IC50 = 26 nM or 10 ng /mL, Table 20) is 
significantly lower than the one needed to reduce parasitemia by 50% in 
vivo (Cmax = 260 ng/mL) as derived from Cmax/TRE (Table 25). The 
difference could be due to the limitations of the in vitro experimental 
setting, which does not capture reinvasion. Also, parasites are exposed to a 
constant concentration of the compound over time in vitro (static system), 
whereas in vivo (dynamic system) the exposure varies with time, according 
to the pharmacokinetics of the compound. In addition, the protein binding 
might differ in the two systems (Zeitlinger et al., 2011). KAE609 and other 
spiroindolone analogs showed very high plasma protein binding in mice ( 
99%) (Table 20). It is challenging to accurately measure free fraction 
accurately for highly protein bound compounds (Weiss and Gatlik, 2014). 
For our analysis, we used total plasma concentrations when analyzing the 
PK-PD relationship, similarly to what was reported for other drug 
candidates such as bedaquiline (Rouan et al., 2012). Considering the 
relationship between in vitro potency and concentration achieved in mice, 
compounds with a Cmax/TRE ≥ 30, AUC0-48/TRE ≥ 587 and T>TRE of 100% 
would likely be efficacious and would be prioritized for further studies.  
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The use of murine models in drug discovery for both PK and PD 
assessment of antimalarial test compounds is widespread (Charman et al., 
2011; Jimenez-Diaz et al., 2013; Patel et al., 2013; Rottmann et al., 2010). 
These models can generate robust PK-PD data that can be used for dose 
optimization. This has been reported for dihydroartemisinin (DHA) (Gibbons 
et al., 2007), piperaquine (Moore et al., 2008) and chloroquine (Moore et al., 
2011). The data reported in this thesis were generated in either uninfected CD-
1 mice (PK) or NMRI mice (PD). Surprisingly, for KAE609 significant strain 
differences were observed, yielding to a 4-fold higher exposure in NMRI mice 
compared to that in CD-1 mice.  No significant difference between infected 
and uninfected NMRI mice was observed; these results are consistent with 
published reports showing no impact of malaria infection on the PK of 
antimalarial agents (Batty et al., 2008; Moore et al., 2008; Moore et al., 2011). 
The reasons for the observed strain difference are yet to be understood. A two-
compartment pharmacokinetic model with nonlinear elimination was chosen 
to fit to the plasma concentration versus time data of KAE609 generated in 
NMRI mice (infected and uninfected) at 5.3 mg/kg. Preliminary analysis of i.v 
PK data for KAE609 in CD-1 mice showed that a two compartment model 
better describes the data than a one compartment model. The parameters and 
diagnostic plots are given in the below Table 26, Figure 38 and Figure 39. The 
nonlinear behavior for KAE609 was previously observed in the dose 
proportionality studies in CD-1 mice (Table 21, Figure 40).  The nonlinear 
mixed-effects modeling provides a good solution for modeling sparse datasets 
and has been well established in preclinical and clinical situation (Bouzom et 
al., 2000). The concentration time data obtained from different population 
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(infected and uninfected NMRI mice) were fitted simultaneously using this 
method. The estimated model parameters were used to simulate the PK 
profiles of KAE609 at any of the doses and regimens administered in the dose 
fractionation study.  
In conclusion, all spiroindolone analogs studied displayed good dose-
response relationship in the P. berghei murine model. KAE609 exhibits a 
trend favoring time or exposure over threshold as most important determinant 
of reduction in parasitemia. Furthermore, our results suggest that for KAE609 
and, supposedly, for its analogs, dosing regimens covering T>TRE of 100%, 
AUC0-48/TRE of 587 and Cmax/TRE of 30 are likely to result in maximum 
reduction in parasitemia (<0.1%) in the P. berghei mouse model of malaria. 
Based on the present results, the optimization campaign of leads belonging to 
the same chemical class could be guided by a PK-PD driven strategy. 
Compounds could be characterized in terms of their potency and in vivo 
pharmacokinetics. PK-PD indices could be estimated and compared to those 
derived here for KAE609. Compounds showing promising properties (i.e., 
matching the indices of KAE609) could be prioritized and efficacy studies 
designed in an informed manner in order to maximize the reduction in 








1 compartment estimate      
(% CV) 
2 compartment estimate     
(% CV) 
V 1063 (33%) 485 (26%) 
CL 347 (26%) 608 (9%) 
V2 - 1832 (14%) 
CLD2 - 2048 (29%) 
Correlation 0.69 1.00 
AIC 13.5 -3.8 
       
V, central volume of distribution; CL, clearance; V2, peripheral volume of 
distribution, CLD2, intercompartmental clearance; AIC, Akaike information 
criterion 
 






















































































Figure 38. One-compartment analysis after i.v. administration of KAE609 in 
CD-1 mice 
(A) Observed and predicted concentration versus time; (B) Predicted versus 
observed concentration; (C) Weighted residuals versus predicted 
concentration; (D) Weighed residuals versus time. Poor fit of observed and 
predicted concentrations; bias in predictions, as observed data points are 




























































































Figure 39. Two-compartment analysis after i.v. administration of KAE609 in 
CD-1 mice 
(A) Observed and predicted concentration versus time; (B) Predicted versus 
observed concentration; (C) Weighted residuals versus predicted 
concentration; (D) Weighed residuals versus time. Good fit of observed and 
predicted concentrations; unbiased predictions, as observed & predicted data 
points are close to line of identity. 
 
 
Assuming similar PK-PD relationships, regardless of the parasite species, the 
PK-PD indices (as TRE the human relevant 2* P. falciparum IC99 is to be 
considered) derived in the present study could be applied to the clinical 
situation. Our results support a recent clinical phase II study with KAE609 
demonstrating positive results with a 3-day dosing regimen of 30 mg daily 
clearing parasitemia in P. vivax and P. falciparum malaria patients (White et 
al., 2014). The average PK parameters from the two cohorts were Cmax of 855 
ng/mL, AUC of 14300 ng·h/mL and % T>TRE of 100% of the treatment period 
(2* P. falciparum IC99 = 1 ng/mL = TRE). 
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Figure 40. Dose proportionality for KAE609 in CD-1 mouse 
 
Dose linearity tests on Cmax and AUC0-24 were carried out by the regression of 
log-transformed data (power regression model) (Hummel et al. 2009; Smith et 
al. 2000). Doses (1.5 – 105 mg/kg) and PK parameters (Cmax and AUC0-24) 
were log-transformed, and correlation coefficient (R
2
), slope, and 95% 
confidence intervals of slope were calculated using the GraphPad Prism 
version 5.02 for windows (GraphPad software, San Diego, California USA). 
The system was considered to be linear when R
2
 ~ 1, Slope 95% CIlower > 0.8, 
and CIupper < 1.25 (Hummel et al. 2009; Smith et al. 2000). (A) Dose vs Cmax 
(R
2
 = 0.97, Slope = 1.18, 95% CIlower = 0.52 and CIupper = 1.83); (B) Dose vs 
AUC0-24 (R
2
 = 0.97, Slope = 1.30, 95% CIlower = 0.65 and CIupper = 1.96). 
Based on the above observations, KAE609 shows nonlinear behavior in CD-1 
mouse between the doses studied. 
 
Such parameters are comparable to the ones derived for KAE609 in the 
P. berghei murine malaria (Cmax of 1440 ng/mL, AUC of 28176 ng·h/mL and 
% T>TRE of 100% (2* P. berghei IC99 = 48 ng/mL = TRE). This demonstrates 
that PK-PD indices required for reduction in parasitemia were similar between 
mouse and human models. Overall, our results could be used to prioritize 
analogs within the same class of compounds and contribute to the design of 



















It is vital to select the most promising drug candidates to progress into 
development. This will help minimizing late-stage failures and thus reduce the 
overall cost, time and resources involved. Moreover, the animal pharmacology 
studies are lengthy and resource intensive, hence there is a need to have a 
prioritization process in place to limit the number of compounds selected. For 
this purpose, it would be of interest to investigate early on in the drug 
discovery cycle the in silico – in vitro – in vivo correlations and understand the 
pharmacokinetic-pharmacodynamics relationships to guide lead optimization 
programs.  
Chapter 1 gives an overview of literatures on the drug discovery of the 
two therapeutic areas (tuberculosis and malaria), with discussion on the 
desirable properties of the ideal drug candidates, current drug discovery 
pipeline, efficacy of combination therapy and challenges encountered in the 
development of each of these therapeutic agents. In addition, various strategies 
adopted in drug discovery are highlighted. Drug discovery aims to deliver a 
candidate that shows efficacy, exposure and tolerability in a relevant animal 
model and in man. In silico and in vitro assays are employed in lead finding 
and optimization, attempting to predict the in vivo properties. Empirical rules 
have been established for diverse set of compounds from different therapeutic 
areas.  Further, in the antibacterial field, PK-PD relationship and drivers are 
known for specific classes and individual compounds, but not for all. There is 
a lack of systematic in silico – in vitro – in vivo correlation analysis and 
concentration – effect (PK-PD) relationship analysis for anti-mycobacterial 
and anti-malarial compounds.  
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Chapter 2 describes the rationale, hypotheses and objectives of the 
work. We formulated two hypotheses and the main objective of the first study 
was to establish the relationship between physicochemical and 
pharmacokinetic properties by studying in silico – in vitro – in vivo 
correlations for standard anti-TB compounds. In the second study, we 
attempted to understand the PK-PD relationship for nitroimidazole and 
spiroindolone analogs with the aim to extend it to new compounds of the same 
class. To our knowledge such analysis is novel and has never been reported 
before. The outcome will be used to prioritize new drug candidates, thereby 
facilitating the lead optimization and possibly expedite the drug discovery 
process. 
The currently used first line anti-mycobacterial drugs in the market 
were discovered during 1950s and 1960s. Noteworthy, TB drug development 
has met limited success with only two new drugs approved over the last 40 
years. In chapter 3, we have comprehensively determined and compiled 
physicochemical parameters, in vitro and in vivo pharmacokinetic properties 
of 36 anti-mycobacterials, most of which are in clinical use against TB. 
Analysis of physicochemical properties, in vitro PK and in vivo PK has been 
undertaken to identify the relationship that could potentially serve as guide for 
medicinal chemists and pharmacologists to select new promising candidates in 
discovery phase. Anti-TB drugs displayed a wide range of physicochemical 
properties. However, majority of the anti-TB compounds followed empirical 
rules (Lipinski, Veber, Egan and Gleeson) with few exceptions (natural 
products). Acceptable solubility, permeability and plasma protein binding are 
displayed by molecules with molecular weight < 400 and cLogP <4. Good 
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solubility, permeability and metabolic stability were found to be important 
prerequisites for high oral bioavailability. Further, lipophilicity appeared to be 
one of the most important physicochemical parameter that will not only 
influence various PK properties but also contribute to developability 
challenges. This finding agrees with previous studies in different therapeutic 
area. The novelty of this work is that, to our knowledge, it is the first 
comprehensive summary and analysis of physicochemical properties, in vitro 
PK and in vivo PK for standard anti-mycobacterial drugs. Our hope is that this 
standardized data set represents a useful reference for the TB drug discovery 
community. The understanding of the impact of such individual properties and 
their interplay on the PK of the drug candidates is key for lead optimization in 
TB drug discovery programs.  
In chapter 4, a panel of closely related potent bicyclic 4-
nitroimidazoles was profiled in both in vivo PK and efficacy studies. Lung PK 
parameters correlated well with in vivo efficacy than plasma PK parameters. 
Total lung T>MIC correlated better than Cmax/MIC or AUC/MIC. Interestingly, 
Vss also showed positive correlation with in vivo efficacy. Over all, our 
findings show that the efficacy of all bicyclic 4-nitroimidazole analogs is most 
likely driven by lung PK. Generally, tuberculosis efficacy studies are lengthy. 
It takes approximately 10 to 12 weeks to obtain single PD readout. 
Alternatively, Vss and lung distribution can be generated from single dose 
pharmacokinetic studies. A simple surrogate would be useful during the lead 
optimization to prioritize candidates for resource intensive efficacy studies. 
For bicyclic 4-nitroimidazoles, efficacy correlated better with concentration in 
lungs, consistent with Vss and differential lung to plasma distributions. The 
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results of this analysis could potentially be exploited to prioritize new analogs 
for efficacy studies based on in vitro potency, volume of distribution and lung 
concentration. This process will reduce the overall turnaround time and 
expedite drug discovery programs. 
Spiroindolones, a new class of compounds, were found to be active 
against malarial parasites. KAE609 is a compound of the spiroindolone class 
currently in clinical development for the treatment of P. falciparum and P. 
vivax malaria. This compound exhibited promising therapeutic effects in 
preclinical studies. Understanding the PK-PD relationship of KAE609 will be 
valuable for the lead optimization and the selection of back-up compounds 
belonging to the same chemical class. In chapter 5, we report the PK-PD 
analysis done for spiroindolones. All analogs studied displayed good dose-
response relationship in the P. berghei murine model. KAE609 was identified 
as the most potent analog exhibiting a trend that favors percentage of the time 
the concentration of KAE609 over threshold or exposure over threshold as 
most important determinant of reduction in parasitemia. Furthermore, the 
results suggest that for KAE609, and supposedly for its analogs, dosing 
regimens covering T>TRE of 100%, AUC0-48/TRE of 587 and Cmax/TRE of 30 
are likely to result in maximum reduction in parasitemia (<0.1%) in the P. 
berghei mouse model of malaria. We propose that this information could be 
used to prioritize back-up compounds and to design efficacy studies, thereby 
facilitating early drug discovery and lead optimization programs. 
Assuming a conserved mechanism of action across a compound class, 
the PK-PD correlations can be extended from one compound to new members 
of the same class. We suggest here to prioritize potential back-up compounds 
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based on in vitro potency and in vivo PK, before conducting labor-intensive in 
vivo efficacy studies. Such approach would be very useful to reduce attrition 
rate and increase the chance of success during drug discovery and preclinical 
development specifically in the anti-mycobacterial and anti-malarial fields. 
The work presented in this thesis evaluated ISIVIVC and PK-PD 
relationships. The findings indicate that new lead compounds foreseen as 
chemotherapy against tuberculosis must not only show good in vitro activity 
but also have good physicochemical and pharmacokinetic properties. Most 
importantly, our investigations showed that volume of distribution and lung 
PK could be used as surrogate markers for progression of promising 
compounds into lengthy efficacy studies that are critical for lead optimization 
in TB drug discovery programs. Further, PK-PD analysis done for KAE609 
led to the identification of indices related to the compound’s efficacy in a 
mouse malaria model. The same PK-PD indices could be used to identify 
promising back-up candidates belonging to the same chemical class. To the 
best of our knowledge, this is the first comprehensive report about ISIVIVC 
for anti-mycobacterial compounds; PK-PD analysis for a compound class 
(nitroimidazole and spiroindolone analogs) and further dose fractionation 
analysis of a novel anti-malarial compound (KAE609).  
The work reported in this thesis represents the attempt to develop an 
understanding of ISIVIVC and PK-PD correlations in early drug discovery 
programs to avoid late stage failures. In conclusion, our results could 
contribute to drug discovery programs in the field of tuberculosis and malaria. 
Furthermore, the same strategy could be extended broadly beyond specific 
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compound classes and therapeutic areas aiding successful lead optimization 
and drug discovery programs. 
 
6.2 Future directions 
The in vivo efficacy of bicyclic 4-nitroimidazols correlated with total lung 
T>MIC. Our results differ from the ones reported for PA-824 where in vivo 
efficacy correlated well with the time during which the free drug 
concentrations in plasma were above the MIC (fT>MIC) (Ahmad et al., 2011).  
In their study, PA-824 results were obtained from extensive dose fractionation 
experiment, whereas the analysis reported here are from single dosing regimen 
with multiple bicyclic 4-nitroimidazole analogs. Hence, further investigations 
are warranted to confirm the hypothesis of similar PK-PD driver existing 
across the compound class by conducting dose fractionation studies for 
additional nitroimidazole analogs. In addition, total concentrations in lungs 
were used for PK-PD analysis of bicyclic 4-nitroimidazoles. Additional work 
is necessary to assess their free concentration in lungs and consider it for PK-
PD analysis.   
Classical dose fractionation study was done only for KAE609. The 
other compounds were characterized in dose-response studies. Additional 
investigations would be recommended to confirm the hypothesis that a similar 
PK-PD driver exists across the compound class. In addition, NMRI mouse PK 
data was available only for KAE609. PK in NMRI mice for other 
spiroindolone analogs would be useful to establish the relationship between in 
vitro potency and PK. Moreover, the PK-PD relationship for KAE609 was 
analyzed considering parasitemia reduction as pharmacodynamic readout. The 
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relationship with cure as alternative pharmacodynamic readout is not yet 
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Appendix 1. Determination of in vitro anti-TB activity  
Mtb H37Rv (ATCC #27294) was maintained in Middlebrook 7H9 broth 
supplemented with 0.05% Tween 80 and 10% ADS (5% Albumin, 2% 
Dextrose and 0.81% Sodium chloride) supplement. The compounds dissolved 
in 90% DMSO were two-fold serially diluted in duplicates and spotted by 
mosquito HTS liquid handler (TTP LabTech, Hertfordshire, UK) to 384-well 
clear plates, resulting in 10 dilutions of each compound. A volume of 50 μL of 
Mtb culture (final OD600 of 0.02) was added to each well, and the plates were 
incubated at 37 °C for 5 days. OD600 values were recorded using a Spectramax 







































1 Isoniazid 137.059 137.08 
138.08 > 
121.34 
25 15 ESP+ 256 
2 Rifampicin 822.405 822.52 
823.52 > 
791.25 
25 15 ESP+ 313 
3 Pyrazinamide 123.043 122.99 
123.99 > 
80.94 
25 15 ESP+ 259 
4 Ethambutol 204.184 204.43 
205.43 > 
116.32 
25 15 ESP+ 300 
5 Streptomcin 581.26 581.69 
582.69 > 
263.75 
50 35 ESP+ 309 
6 Kanamycin 484.238 484.69 
485.69 > 
162.45 
30 25 ESP+ 305 
7 Amikacin 585.286 585.75 
586.75 > 
163.35 
30 35 ESP+ 330 
8 PAS 153.043 153.09 
152.09 > 
107.26 
25 15 ESP- 265 
9 Cycloserine 102.043 101.9 
102.90 > 
74.91 
15 5 ESP+ 308 
10 Ethionamide 166.056 166.18 
167.18 > 
107.26 
35 25 ESP+ 267 
11 Rifabutin 846.442 846.61 
847.61 > 
815.33 
40 25 ESP+ 264 
12 Rifapentine 876.452 876.61 
877.61 > 
845.32 
30 25 ESP+ 310 
13 Moxifloxacin 401.175 401.56 
402.56 > 
110.24 
40 25 ESP+ 233 
14 Levofloxacin 361.144 361.56 
362.56 > 
261.57 
30 25 ESP+ 267 
15 Gatifloxacin 375.159 375.56 
376.56 > 
261.61 
35 25 ESP+ 249 
17 Ofloxacin 361.144 361.56 
362.56 > 
261.61 
35 25 ESP+ 308 
18 Sparfloxacin 392.166 392.62 
393.62 > 
292.63 
30 25 ESP+ 279 
19 Capreomycin 654.331 652.33 
653.33 > 
491.08 
40 35 ESP+ 269 
20 Thioacetazone 236.073 236.37 
237.37 > 
120.29 
25 25 ESP+ 268 
21 Linezolid 337.144 337.5 
338.50 > 
296.69 
35 15 ESP+ 243 
22 Prothionamide 180.072 180.26 
181.26 > 
121.33 
35 25 ESP+ 231 




24 Amoxicillin 365.105 365.02 
366.02 > 
113.87 
20 15 ESP+ 226 
25 Clavulanate 237.004 196.13 
197.13 > 
149.01 
30 25 ESP+ 266 
26 Meropenem 383.151 330.06 
331.06 > 
220.14 
25 15 ESP+ 272 
27 Clofazimine 472.122 472.62 
473.62 > 
431.58 
50 35 ESP+ 268 
28 Metronidazole 171.064 171.24 
172.24 > 
82.28 
25 25 ESP+ 301 
29 Thioridazine 370.154 370.62 
371.62 > 
126.43 
35 25 ESP+ 258 
30 Mefloquine 378.117 378.62 
379.62 > 
82.35 
45 45 ESP+ 269 
31 Vancomycin 1447.43 724.33 
725.33 > 
143.92 
25 15 ESP+ 269 
34 PA-824 359.073 359.43 
360.43 > 
175.42 
35 25 ESP+ 311 
35 TMC-207 554.157 556.62 
557.62 > 
58.01 




Appendix 3. MRM transitions for bicyclic 4-nitroimidazole analogs 
 





1 PA-824 359.26 360.2 > 175.1 
2 NI-622 471.4 472.3 > 245.1 
3 NI-644 459.36 457.2 > 230.2 
4 Amino-824 358.28 359.2  > 175.1 
5 AminoEthyl-824 372.31 373.3 > 244.2 
6 NI-135 392.05 393  > 209.1 
7 NI-147 374.08 375  > 191 
8 NI-136 376.08 377  > 193.1 
9 NI-176 404.11 405.1 > 193.2 
10 NI-269 386.12 387.1 > 175.1 
11 NI-182 386.12 387.1 > 175.1 
12 NI-145 387.1 388.4 > 175.1 
13 NI-297 462.42 463.5 > 251.1 
14 NI-302 386.12 386.3 > 227.3 
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Appendix 4. Determination of in vitro antimalarial activity 
Isolates of P. falciparum were maintained using standard methods (Trager and 
Jensen, 1976) in an atmosphere of 93% N2, 4% CO2, 3% O2 at 37 °C in 
complete medium (CM) (10.44 g/liter RPMI 1640, 5.94 g/liter Hepes, 5 g/liter 
Albumax II, 50 mg/liter hypoxanthine, 2.1 g/liter sodium bicarbonate and 100 
mg/liter neomycin). Human erythrocytes served as host cells. In vitro 
antimalarial activity was measured using the [
3
H]-hypoxanthine incorporation 
assay (Desjardins et al., 1979) with strain NF54 of P. falciparum (obtained 
from Hoffmann-LaRoche Ltd). The compounds were dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 10 mM, diluted in hypoxanthine-free 
culture medium and titrated in duplicates over a 64 fold range in 96-well 
plates. Infected erythrocytes (0.3% final parasitemia and 1.25% final 
hematocrit) were added to the wells. After 16 h incubation, 0.25 μCi of [3H]-
hypoxanthine was added per well, and plates were incubated for an additional 
8 h (in contrast to the conventional 48-h plus 24-h assay) to enable direct 
comparison with the in vitro (ex vivo) P. berghei assay (see below). The 
parasites were harvested onto glass fiber filters, and radioactivity was counted 
using a Betaplate liquid scintillation counter (Wallac, Zurich, Switzerland). 
 For in vitro (ex vivo) P. berghei maturation assays (Brunner et al., 
2012), heparinized blood from infected mice (P. berghei GFP ANKA malaria 
strain PbGFPCON, a donation from A. P. Waters and C. J. Janse, Leiden 
University, Leiden, the Netherlands) (Franke-Fayard et al. 2004) was washed 
with 9 mL of hypoxanthine-free culture medium and diluted with 
hypoxanthine-free culture medium and red blood cells (RBCs) from 
uninfected mice to a hematocrit of 5% and a parasitemia of 0.3%. Serial 
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compound dilutions were prepared in DMSO and distributed as described 
above. The infected erythrocytes (0.3% final parasitemia and 2.5% final 
hematocrit) were added into the wells. After the plates were incubated for 16 
h, 0.25 μCi of [3H]-hypoxanthine was added per well, and plates were 
incubated for an additional 8 h. The parasites were harvested, and the in vitro 




Appendix 5. NONMEM code for dose-response relationship 
$PROB Dose-response spiroindolones, all single dose [mg/kg] 
 
; PRBC = parasitized RBCs [%] (P.RBC.100) 
; DOSE = Dose [mg/kg]  (DOSE) 
; CMPD = compound  (CPD) 
; ID   = individual study (STDY) 
; UID  = unique identifier, compound and study (CMPD.STDY) 
; LOGD = IDV Log10 Dose (mg/kg) (LOG DOSE) 
; DV   = LOG10 parasitemia (log% parasitemia) 
; Equation from graphpad prism help (dose finding) 
; Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50)*HillSlope)) 
 
$DATA  Spiroindolones.NMRI.Mice.Dose.Response.csv IGNORE=@ 
$PRED 
  TVTP = THETA(1) 
  BASE = TVTP*EXP(ETA(1)) 
   
  TVBT = THETA(2) 
  MIN = TVBT*EXP(ETA(2)) 
   
  TVI9 = THETA(3) 
  ID90 = TVI9*EXP(ETA(3)) 
 
  TVHS = THETA(4) 
  SLP = TVHS*EXP(ETA(4)) 
 
TRF90 = (1/0.90-1)**(1/SLP) 
TRF95 = (1/0.95-1)**(1/SLP) 





IPRED =MIN + (BASE-MIN)/((1+10**((LOGD-
LOG10(ID50))*SLP)))**TRT 
; TRT yields exact baseline estimation (0, 1 switch) 
 
Y = IPRED + EPS(1) 
 
  IRES  = DV-IPRED 
  IWRES = IRES   ; for xpose 
 
$THETA 
(0, 1.5)   ; BASE 
(-2,-1,0)   ; MIN 
(0,40)   ; ID90 





0.1 ; BASE 
0 FIX  ; MIN 
0 FIX ; ID90 
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Appendix 6. NONMEM code for PK modeling 
 
$PROB 2-cmt model - KAE609_Mouse_PPK.nmctl 
 
; COMPOUND 1: KAE609 
; TRT=0 healthy, TRT=1 Malaria 
 







TVVM = THETA(1)*EXP(ETA(1))  
TVKM = THETA(2)*EXP(ETA(2))  
TVVC = THETA(3)*EXP(ETA(3))  
TVVP = THETA(4)*EXP(ETA(4))  
TVQ  = THETA(5)*EXP(ETA(5))  
TVKA = THETA(6)*EXP(ETA(6))  
 
VMAX=TVVM  
KM = TVKM  
VC = TVVC  
VP = TVVP  
Q =  TVQ   
KA = TVKA  
 
S2 = VC/1000 
 
$DES 
CP = A(2)/S2 
CL = VMAX/(KM+CP) 
K10 = CL/VC 
K12 = Q/VC 
K21 = Q/VP 
 
DADT(1) = -KA*A(1) 
DADT(2) = KA*A(1)-K10*A(2)-K12*A(2)+K21*A(3) 
DADT(3) = K12*A(2)-K21*A(3) 
 
;################################################# 
; Karlsson parameterization (THETAs for $ERROR) 
;################################################# 
$ERROR 
IPRED=F          ;  individual-specific prediction 
IRES=DV-IPRED    ;  individual-specific residual 
DEL=0 
IF (IPRED.EQ.0) DEL=1  




Y = IPRED*(1+EPS(1))+EPS(2) 
 
;################################################## 
$SIGMA 0.1 10 ;(1 is BLOQ) 
;################################################## 
; starting values for NPD fits 
; TH8: RACE on F1 
$THETA (0,200) (0,1000) (0,2) (0,2) (0,1) (0,0.6) 
$OMEGA 0 FIX 0 FIX 0 FIX 0 FIX 0 FIX 0 FIX 
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MINIMUM VALUE OF OBJECTIVE FUNCTION   : 489.256      
 
